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To investigate the yield, and cost effectiveness of testing for TB in a contem-
porary, HIV-infected population.
Methods:
1. Economic modelling of three LTBI testing strategies of testing HIV clinic 
attendees using data from two successive periods from the Royal Free Hospital, 
using univariate, multivariate and probabilistic sensitivity (Monte Carlo) analyses. 
2. A prospective cross-sectional study of extensive TB testing in HIV clinic 
attendees and economic modelling of 30 different strategies using similar methods. 
Results:
1. From 2000-2010, testing people living with HIV for latent TB infection became 
progressively less cost-effective. 
2. From the prospective study, 219 HIV-infected individuals were recruited 
between June 2013 and September 2014. No cases of active TB, two cases of 
subclinical TB and 14 cases of latent TB infection were detected. Modelling 30 
differing strategies based on this data, strategies based on UK guidelines were no 
longer cost effective. Testing with a tuberculin skin test (TST) or single interferon 
gamma release assay (IGRA) in black Africans, or testing both black Africans and 
those from middle TB incidence countries with TST were the only cost-effective 
strategies at under £30,000/QALY. Probabilistic sensitivity analysis results found 
no testing to be most probably cost-effective up to a threshold of £30,000. 
5Conclusion:
TB testing has become increasingly less cost-effective over the past decade 
possibly due to increasing antiretroviral use and changing demographics. Even 
testing the most high-risk groups is now only marginally cost-effective at the 
NICE threshold.
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1.1.1 Tuberculosis and HIV
Tuberculosis disease (TB) and human immunodeficiency virus (HIV) infec-
tion vie as the biggest infectious causes of death worldwide. [1] After a fall in 
global incidence of TB for 100 years, it began to rise in the 1980s. This was pre-
dominantly due to the HIV epidemic, especially in the most southerly nations 
of Africa – where more than one in four adults are infected with HIV – leading 
to a lifetime risk of TB of more than 50% in some areas. [1] Unlike other parts 
of Europe, the incidence of TB disease in the United Kingdom (UK), and most 
notably in London, had been increasing up until 2011, and is only just starting 
to fall. HIV co-infection may have contributed to this. [2] 
1.1.2 Natural history of HIV infection
The acquired immune deficiency syndrome (AIDS) was first described in 
1981. [3] The HIV virus was discovered in 1983 and may have started infecting 
humans as early as in the first half of the twentieth century. [4-6]  
HIV is usually acquired through sexual contact, infected blood through shared 
needles or blood products, or vertically from mother to child. [7] The natural 
history of infection in humans is an initial, usually temporary, fall in blood 
CD4+ T lymphocytes, which then somewhat recover in number, plateau (with 
sustained cell death and replication in near balance), until a fall (often years 
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later) leading to AIDS and then death. [8,9]  HIV increases the risk and sever-
ity of several infections that are regulated by innate immunity (such as certain 
viruses, mycobacteria and fungi), and also malignancies, frequently associated 
with a viral co-factor, such as Kaposi’s sarcoma (KS), lymphoma and cervical 
cancer. [10] The increased, sustained, systemic inflammatory response associated 
with HIV has also been implicated in an increase in coronary artery disease and, 
possibly in combination with recurrent infection due to the immunosuppression, 
certain respiratory illnesses such as chronic obstructive lung disease (COPD) 
and bronchiectasis. [11] 
1.1.3 Natural history of tuberculosis infection
TB disease in humans is caused by Mycobacterium tuberculosis (M. tuberculosis) 
complex, which also includes species such as Mycobacterium bovis, Mycobacterium 
canetti and Mycobacterium africanum. The most frequent method of transmission in 
humans is via an aerosol route and usually person to person, where the bacillus 
is inhaled in 5-10 micrometre droplets and ingested by alveolar macrophages 
where it can evade killing. Whether the bacteria causes disease depends on 
factors in both the microbe and the host. [12] If not eliminated by the body, it 
can proliferate, then spread via dendritic cells to the pulmonary lymphatics and 
throughout the body via the bloodstream. [13,14] Locally, it can cause pulmonary 
disease and induces cytokines, attracting monocytes, macrophages and neutro-
phils to form a granuloma (although the histopathology of tissue infective with 
M. tuberculosis can vary depending on the organ involved and immune status of 
the person infected). [15-18]  In up to a half of cases, there are extra pulmonary 
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manifestations (with or without pulmonary involvement), most frequently in 
lymph nodes, the central nervous system, abdomen or disseminated widely 
throughout the body. [19]
After 2-10 weeks a cell-mediated immune response occurs in most people 
and contains the infection. This relies on CD4+ and CD8+ T-cells that protect 
against intracellular pathogens, producing interferon-gamma in order to acti-
vate macrophages (mediated by tumour necrosis factor, TNF) to generate nitric 
oxide leading to cell death. [10,13,14]  HIV infection impairs this mechanism 
as well as possibly affecting the interferon gamma-interleukin 2 axis (involved 
in T-cell proliferation), interleukin 27 production, and suppression of cytokine 
signalling 1 (SOCS1). These inhibit bacterial clearance and increase susceptibility 
to TB reactivation. [18]
CD4+ T-cells and TNF are important in granuloma formation, and therefore 
HIV can affect how granulomata are formed or survive. [20] This could account 
for the atypical findings (fewer cavities on chest radiographs, lack of necrosis 
in pathological specimens) seen in patients with lower blood CD4 counts. [21]
TB has also been found to exacerbate HIV infection in humans by up-regulat-
ing replication in infected T-cells or macrophages, facilitating the late replication 
pathways of HIV, and help HIV evade type I interferon anti-viral signalling or 
upregulating SOCS1. [22-24] 
1.1.4 Control of TB infection
The immune response to M. tuberculosis in humans can lead to various states 
of elimination or infection. Despite close contact with people infectious with TB 
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disease – the risk of developing TB disease varies depending on the infectiousness 
of patients and susceptibility of contacts – approximately 70% of adults exposed 
either are not infected with M. tuberculosis or clear the infection after exposure. 
[25,26]  (Figure 1.1.4) Of the remaining 30%, approximately 5% develop primary 
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disease, perhaps associated with a fever, sometimes with chest pain, weight 
loss, sweats or cough, [17] whilst around 25% develop latent infection – where 
there is immune evidence of sensitisation, but individuals are asymptomatic 
and the bacillus cannot be isolated or cultured. At this point, the bacillus is 
thought to be contained in a granuloma, possibly in a dormant state or with 
low metabolic activity, [27] and preventing TB disease requires a balance of a 
healthy immune system with functioning CD4 T-cells. [28,29] In the general 
population, approximately 5-10% of people with latent infection will go on 
to reactivate and develop TB disease. This is often at a time associated with a 
decrease in cell-mediated immunity, for example, HIV infection, chronic renal 
impairment, immunosuppressive medications, malnutrition, chemotherapy, 
diabetes or age (immunosenescence). [18,30] This ‘post-primary’ TB tends to 
localise to a particular organ – in the case of pulmonary disease with chest radi-
ographic changes (consolidation or cavitation) in the predominantly the lower 
segments of the upper lobe or upper segments of the lower lobes. There can be 
“atypical” changes, however – coexistent adenopathy, lower zone infiltrates, or 
disseminated disease – if there is weakened immunity. [15] 
1.1.5 Clinical consequences of HIV and TB interaction
HIV infection increases both the risk of primary disease and of reactivation 
of latent infection, especially in those with a detectable HIV viral load or with a 
lower blood CD4 lymphocyte cell count (referred to as CD4) of <200 cells/µL. 
[16,31]  In early studies, this was up to forty times higher in tuberculin skin test 
(TST) positive, HIV-infected individuals than HIV-negative controls. [32]
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Active TB disease can have a more indolent onset, affect other organ systems 
more frequently, and have more associated morbidity and mortality in those 
co-infected with HIV, plus there are often more adverse events related to TB 
treatment. [33] In TB endemic areas, such as subSaharan Africa, TB is the most 
common cause of death in people infected with HIV, even though the burden 
of TB in this group could still be underestimated. [1] Postmortem studies have 
shown evidence of TB in HIV patients – including in 46% of those thought to have 
died of other causes. [34,35] TB disease can also be ‘unmasked’ as the immune 
system reactivates after starting HIV (antiretroviral) medications (ART). This 
occured in 17% of those with TB just after starting ART in one London study 
– most notably in subjects with a low blood CD4 cell count and high plasma 
HIV viral load. [36] Explanations may be a sustained Th1 response, cytokine 
dysregulation and T-cell migration. [36-38] TB disease can also worsen during 
effective treatment. These paradoxical reactions can occur in individuals without 
HIV infection, but seem more common in HIV-infected patients just after start-
ing antiretroviral therapy (ART). [36,39]  There are also numerous interactions 
between antiretrovirals (ARV) and antituberculous medications. [33] Given that in 
low TB incidence areas, most TB is thought to be due to reactivation, preventing 
this by testing for and treating latent TB infection is attractive as a strategy, and 
has been recommended in HIV treatment guidelines since the late 1980s. [40-45] 
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1.2 HIV epidemiology in the UK
In 2015 there were estimated to be approximately 101,000 people living with 
HIV in the UK, although around 13% would not be aware of their infection. In 
all, 47% of diagnoses are made in men who have sex with men (MSM), 28% in 
African-born men and women and approximately 2% in people with a history 
of injecting drug use (IDU). [46,47]  The number of new HIV diagnoses in black 
Africans has fallen from around 5,000 in 2005 to 1000 in 2015, likely reflecting a 
change in migrant demographics, whilst the number in MSM have increased from 
2,500 to around 3,000. [48] Effective combination antiretroviral therapy (ART) has 
been available from 1995 and led to a large fall in the number of people dying 
directly from HIV or AIDS-defining illnesses. There has been a debate as to when 
to start ART – toxicity has improved and studies suggest that early initiation of 
ART leads to preserved life and prevents HIV transmission. [49] Consequently, 
national and international guidelines have suggested treating HIV infection at 
higher CD4 thresholds, or even at HIV diagnosis. [44,49-51]  This has led to an 
increase in the use of ART in people with known HIV infection, from 68% in 
2003 to 95% in the UK in 2015. [46,47] 
1.2.2 Epidemiology of HIV/TB co-infection in the UK
TB was the second most common AIDS-defining illness in the UK between 
2010 and 2015. There were 205 diagnoses in 2014 (incidence rate of 203/100,00 
compared to 10.5/100,000 in the general population), although the incidence 
of HIV/TB coinfection has fallen after a rise in the early 2000s. [47,52] In 2002 

























































































by 2011 this had fallen to 400 per 100,000. TB disease occurred most commonly 
in black African heterosexuals (incidence of 10.9/1000 compared to 3.1/1000 in 
white heterosexuals). [46] This fall coincided with a reduction in HIV diagnoses 
in the number of black African migrants from subSaharan Africa (sSA),[2,52] 
although increasingly widespread use of ART may also have decreased the 
number of people that develop active TB. [53,54] 
As a proportion of all TB cases, HIV coinfected patients rose to 9% between 2000 
and 2004, a level that plateaued and then fell to 4% by 2011 (Figure 1.2.2). [2,55] 
Similar trends were seen in Belgium and other parts of Western Europe. [56,57] 
However, the majority of HIV/TB diagnoses were made in people not yet aware 
of their HIV status – between 2002-2010, 60% of HIV/TB co-infected adults were 
diagnosed with HIV and TB simultaneously. Most of these had blood CD4 cell 
counts of under 350 cells/µL. [52,54]  This late presentation of HIV was reflected 
in an increased short and long-term mortality. [52] 
1.3 Case definitions of active, subclinical, latent TB infection
The spectrum of TB disease seen in people with HIV has challenged the par-
adigm of two dichotomous states of active TB or latent infection. Instead, there 
appears to be a range from disseminated disease to full M. tuberculosis elimination 
with no immunological sensitisation, and include active disease, subclinical and 
latent infection (see Figure 1.3).
Active disease is characterised by symptoms such as fever, night sweats, and 
weight loss associated with localising symptoms such as cough or back pain, 
with consistent radiology and in many cases, the ability to culture sputum or 
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tissue infected with M. tuberculosis (the gold standard). Subclinical infection is 
most commonly defined as a positive sputum culture, without symptoms, with 
or without X-ray changes consistent with TB disease. [12,60-62]  To clarify the 
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pathophysiology between these states, ‘incipient tuberculosis’ has been used to 
describe a state in a subject with a strong immune response, where there are CXR 
changes (e.g. nodules), features of latent infection and high risk of reactivation. 
‘Subclinical tuberculosis’ more describes active disease but without symptoms, 
most commonly in the immunocompromised. [12] In most cases, subclinical TB 
with HIV co-infection seems to be a temporary state, and left untreated, active 
disease frequently develops soon afterwards (75% between five days to two 
months in one South African study). [61]  Latent TB infection (LTBI) is defined 
as an asymptomatic state with no consolidation or cavitation on CXR, an ina-
bility to culture sputum (or other tissue), but with a positive immune response 
(measured with an immunological test such as a tuberculin skin test, TST or 
Interferon-gamma release assay, IGRA) and described further below. [63]
These states may not be so well defined – some patients have no symptoms, no 
radiological changes on CXR and negative sputum microbiology (thereby fitting 
criteria for latent infection), but may have increased lymph node metabolism on 
fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, and/
or blood transcriptional upregulation similar to those with active disease. [64-66]
1.4 Treatment of active tuberculosis disease
 Minimum standard treatment for drug-sensitive active TB disease consists of 
four antituberculous medications given for two months (rifampicin R, isoniazid H, 
ethambutol E, pyrazinamide Z, 2RHZE), followed by two drugs for four months 
(4RH). This regimen is associated with relapse rates of about 3% in people without 
HIV infection. [67]  In HIV co-infected patients, the same short course (6 month) 
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TB treatment often need not be changed or prolonged, unless there is reduced 
absorption, drug interactions preclude it, or disseminated disease such as central 
nervous system involvement, and provided sputum becomes culture negative 
at two months. Adverse events, however, do seem to be more frequent in the 
HIV co-infected group. [33,43,68]  In drug-resistant cases the treatment is more 
prolonged and regimens based on microbiological in-vitro sensitivities.  [69,70] 
1.4.2 Duration of latent TB chemoprophylaxis
Treatment with one or two anti-tuberculosis drugs in patients with evidence of 
LTBI (by TST) has been shown to reduce the risk of active TB disease in HIV-in-
fected individuals by 62% in randomised controlled trials in high TB incidence 
countries. [71] TST seems to be a good predictor of effect – efficacy is 33% if TST 
is not used, and there is no significant benefit in those with a negative TST result. 
[71] The use of isoniazid alone has advantages as it has fewer drug interactions 
with ART and similar efficacy to other drug combinations. [71] Nine months 
treatment with isoniazid preventive therapy (IPT) has been recommended by the 
United States (US) Centers for Disease Control (CDC), but the optimal length of 
therapy probably depends on immune status and local tuberculosis prevalence. 
[41] In a South African study, six months was found to be as good as continu-
ous treatment in those with CD4 >500 cells/µL, whilst in a Botswanan study, 
36 months had more prolonged efficacy.  [72-74]  In lower TB incidence areas, 
and in individuals without HIV, the effect of IPT seems to last much longer – 
possibly due to the lower risk of person-to-person transmission. Six months has 
been suggested as a compromise between tolerability and efficacy. [75] There 
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have been very few cases of active TB in HIV-infected individuals who have 
completed LTBI prophylaxis in low TB incidence countries. [76-80] 
Rifampicin alone (for four months), rifampicin and isoniazid in combination 
for three months, or rifapentin weekly with isoniazid for three months have been 
used successfully, although there are more drug interactions between ART and 
rifamycins. [81-83]  
1.4.3 Protective effect of ART
Increasingly widespread ART use has had an effect on the incidence of TB 
in both high and low TB incidence areas. World Health Organisation (WHO) 
guidelines increased the threshold for initiation of ART from 200 to 350 cells/µL, 
and now suggest treating all infected individuals. [51,84,85]
A retrospective review in South Africa showed that the TB incidence rate 
fell significantly in people after starting ART, from 175/1000 person years (PY) 
without ART to 34, even in those with a blood CD4 count of <200 cells/µL. TB 
incidence also fell from 1995 onwards in those who acquired HIV by sexual 
transmission, IDU and in haemophiliacs. [86,87] Extrapolated data from South 
Africa showed a risk of TB up to 40x background in those with very low CD4 
counts, but estimated a 1-5x increase in those with a CD4 >200 cells/µL. [88] In 
the UK, pooled epidemiological data showed a fall in TB incidence rate from 
13.3/1000 PY to 1.8/1000 PY in individuals two years after starting ART. [31] 
In a national cohort between 2007-2011, black Africans treated with ART had a 
similar incidence of active TB to the background HIV negative population [59] 
In a meta-analysis of ART use in predominantly high TB incidence areas, the 
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risk of TB fell by around 65% in all CD4 strata, and even more benefit was seen 
in those with CD4 <200 cells/µL with a reduction to one-sixth. [89] In the Tem-
perano study (also in Africa), early initiation of ART led to a 60% reduction in 
those developing tuberculosis. [90]
1.5 Testing and screening methods for TB infection in patients with HIV
1.5.1 Testing in low resourced, high TB-HIV settings
TB control has long-relied on individuals presenting with symptoms and being 
investigated and then treated for TB. Two studies in India found that, despite 
regional chest radiograph (CXR) screening taking place, two-thirds of patients 
were aware of symptoms before TB was detected by screening. [91,92]  This led 
to passive case detection becoming the norm for decades. TB transmission can 
occur between symptom onset (although possibly before) and starting treatment. 
In areas of high incidence of TB transmission and HIV, such as parts of subSa-
haran Africa, active case detection has been used, and is now recommended, as 
a public health measure. [1]
Country guidelines have varied, and given the costs required, routine radiol-
ogy and sputum microscopy were not always available outside of large cities. 
Studies from the late 1990s tried to optimise symptom combinations to detect or 
rule out active TB in people with HIV before LTBI prophylactic treatment. [93-
95]  In the early 2000s, an increase in TB incidence was noted in individuals just 
after starting ART, and this was associated with a higher mortality. This made 
screening for TB even more crucial in ART clinics. [38,96-100]      
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Whether symptoms alone are useful for testing is questionable. Study results 
have been mixed – even in the highest TB incidence areas. In a study in Cape 
Town in patients with advanced HIV, two of: cough, night sweats, fever plus 
documented weight had a sensitivity of 100% and specificity of 88.1% for active 
tuberculosis. An absence of symptoms was able to rule out active TB in this 
group (with a negative predictive value of 100%). When added to the screening 
questionnaire, CXR did not improve its sensitivity (CXR was abnormal in only 
a third of subjects), although the study was criticised for not having microbio-
logical outcomes in all subjects. [93] 
In gold miners in South Africa worsening cough, night sweats and >5% weight 
loss had the highest sensitivity for active TB (75%). This increased further in indi-
viduals with a low blood CD4 cell count or abnormal CXR. [101] Many cases were 
still missed, however, if CXR screening was not used in combination. Another, 
more comprehensive, case-finding study in Cape Town, found that symptoms 
were not a useful screen for active TB disease, and that induced sputum for 
microscopy and culture, even in the absence of symptoms, was most effective, 
especially before starting IPT. [102] 
In Ethiopia, cough lasting over two weeks only detected a third of patients 
with active TB, although 75% had both cough and fever. [103] In a South-East 
Asian study investigating the optimal combination of symptoms in ART-naive 
HIV clinic attendees, high negative predictive values (96–98%) but fairly poor 
positive predictive values (21–24%) were found using combinations of two or 
more symptoms including: cough, fever, drenching night sweats, loss of appetite 
and lymphadenopathy. [94] Sensitivity improved with CXR screening. In 2011, 
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in a strategy designed to increase the uptake of IPT, a presence of any of: current 
cough, fever, night sweat or weight loss (with CXR in higher TB prevalence areas) 
was adopted by the WHO as a screening algorithm. This had a sensitivity of 
79% and negative predictive value of 97.7%. [104] All HIV-infected individuals 
in high TB incidence areas with no symptoms were recommended to start IPT. 
A review by Rangaka in South Africa soon after found a lower sensitivity than 
published associated with this strategy, and consequently a high number of 
people with active TB were started, possibly incorrectly, on IPT. [104,105] Despite 
its widespread use, testing using symptoms plus sputum smear microscopy 
only also seems inadequate for detection of active TB. [106] One reason why 
symptoms may not be reliable is because of the surprising number of patients 
(between 4-40%) with otherwise undiscovered asymptomatic (subclinical) TB 
in ART clinics throughout high TB incidence countries. [60-62,97,107,108] Some 
patients with subclinical infection are also sputum mycobacteria-smear positive 
(more so in those with low blood CD4 cell counts). If TB transmission occurs 
in this state of infection, earlier detection from active case finding might also 
prevent transmission. [109] 
1.5.2 Role of chest radiographs
Although radiographic changes in TB-HIV confection can be characteristic 
for TB, especially at higher CD4 cell counts, atypical appearances or multiple 
abnormalities can occur in those with poorer immunity. For example, individu-
als with ≤200 blood CD4+ cells/µL were more likely to have lymphadenopathy, 
pleural effusion or infiltrates, compared to those with ≥200 blood CD4+ cells/µL 
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who were more likely to have cavitation. [21,110] Chest radiographs in HIV-TB 
co-infection can be normal in smear-negative TB disease. One study in Malawi 
(70% HIV seroprevalence in the cohort) showed 21% of those with normal/min-
imally abnormal CXR developed culture-positive pulmonary TB. [111] Another, 
investigating Ugandan HIV inpatients (with a median blood CD4 of 64 cells/
µL) rather than screening asymptomatic clinic attendees, showed that CXR often 
missed smear-negative disease. [112] When used in isolation as a screening 
tool in South Africa, CXR had a positive predictive value of 22% and negative 
predictive value of 90% for active disease. [113] Ten patients in one study (with 
median blood CD4 70 cells/µL) in New York had normal CXR, four of whom 
were sputum smear positive. [21] Similar results were seen in San Francisco. [114]
1.5.3 Role of microscopy and culture
Sputum microscopy (Auramine or Ziel-Nielsen, ZN) is used routinely in parts 
of the world for fast detection of mycobacteria. Microscopy alone has reported 
in a systematic review to miss up to a third of TB cases, [115] although a more 
recent study based in an ART clinic in Durban (median CD4 100 cells/µL) showed 
only 9% of culture-positive TB cases were smear-positive. [113] Microscopy also 
requires significant resource to be performed safely, such as a Category 3 lab in 
order to protect laboratory staff. 
Despite being the gold standard for diagnosis, microbiological culture is often 
too expensive to be routine in many countries with high TB prevalence. Culture is 
usually performed using solid (Lowenstein-Jensen, LJ) or liquid media – the latter 
has reduced the time to positive culture from six to three weeks. Approximately 
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one to ten colony forming units (cfu) of M. tuberculosis are required for sputum 
positivity on liquid culture, compared to around 100 with polymerase chain 
reaction (PCR – such as the XpertTB.RIF), 1000 for auramine and 10,000 for ZN 
staining. The sensitivity of each test is affected by this. Positive sputum culture 
has also been reported in children recently exposed to TB and thought to be 
excreting bacilli, although with no later evidence of infection. [116,117]  Sputum 
culture may be negative for M. tuberculosis despite a positive smear for acid-fast 
bacilli (AFB) in non-tuberculous mycobacterial infection or when there has been 
aggressive sputum decontamination. 
Sputum analysis usually requires patients to be productive. Diagnostic yield 
improves with a larger volume of sputum (up to 5ml) as does testing two samples 
for culture, even in asymptomatic patients where it increased sensitivity by 22% 
in one study from South Africa and by 17% in SE Asia. [118-121]  
In individuals that cannot spontaneously produce sputum, sputum induction 
has been shown to be safe and almost as effective as bronchoscopy, although it 
still requires strict infection control measures to prevent transmission to staff 
and other patients. [122,123]
1.5.4 Role of Xpert MTB.RIF
Xpert MTB.RIF (Cepheid, USA) is a semi-automated, nucleic-acid amplifica-
tion test (NAAT) in a cartridge-based system (that can also be used for other 
microbiological PCR assays). It uses a molecular beacon assay with fluorescent 
markers to detect five regions in the rpo-gene (specific for M. tuberculosis and 
very few other mycobacteria) which will also show variations consistent with 
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rifampicin resistance. [124] Rifampicin resistance is nearly always associated 
with isoniazid resistance. As it takes as little as two hours, the Xpert MTB.RIF 
is marketed as a fast and reliable test for drug sensitive and multidrug resist-
ant tuberculosis. Standard liquid culture takes around 12 days. [125] In studies 
from Peru, Azerbaijan, South Africa and India, a single sputum PCR diagnosed 
98.2% of smear-positive cases, 72.5% of smear-negative cases with a specificity 
of 99.2%. [124,126]  It has been shown to be cost-effective as a diagnostic test 
in many high and medium TB incidence countries, and in the USA. [127,128] 
It has been assessed as part of a screening strategy in HIV-infected patients in 
Durban, South Africa (median blood CD4 100 cells/µL in the cohort), where its 
positive predictive value (PPV) when screening for active TB in an ART clinic 
was 29% and negative predictive value (NPV) 86%, more accurate than the 
combination of cough and acid fast bacillus (AFB) smear (the previous national 
recommended strategy for excluding active TB). However, it missed half of the 
cases of smear negative, culture positive TB disease, which would most likely 
be subclinical. [113,129] 
1.5.5 Testing for active and latent TB in the UK and low TB incidence countries
The UK and other low TB incidence countries use active case finding amongst 
other high TB incidence groups, most notably with homeless people, where 
screening with chest radiographs has been the most popular initial test. [130,131] 
CXR has also been used to screen new arrivals, but surprisingly little active TB 
was detected (0% in one recent multicentre study). [132] Almost three-quarters 
of cases of TB disease in the UK are in people born abroad, but only 15% are in 
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recent migrants making reactivation of latent infection a more likely cause than 
importing active disease. [19] Preventive strategies in low TB incidence countries 
are therefore increasingly focused on the detection of latent infection with an 
aim to prevent subsequent reactivation. Given people with HIV are at higher 
risk of TB reactivation, and those who know their status tend to be in engaged 
in long-term care, to test for and treat LTBI seems even more attractive in this 
group. [31,76] There are also reports of subclinical TB in HIV clinics in the UK 
and Western Europe. [77] 
1.5.6 TB testing strategies in HIV infected individuals
Two sets of UK guidelines for TB testing in people living with HIV were 
published in 2011, although they have differing testing algorithms. [42,43] The 
National Institute for Health and Care (then Clinical) Excellence (NICE) guide-
lines (for England and Wales) from 2011 suggests only testing those with blood 
CD4 cell count of under 500/µL - with a single IGRA with or without TST if 
blood CD4 is 201-499, and both TST and IGRA in those with a blood CD4 <200 
cells/µL. LTBI treatment should be considered in those with either positive 
test. [43,133] This guideline was updated in 2016 and suggested IGRA and TST 
in those with blood CD4 <200 cells/µL and IGRA with or without TST in all 
others, with the intention to treat with preventive therapy in all those with one 
positive test. [134]
   The British HIV Association (BHIVA) guidelines advise only testing if intend-
ing to treat, and only target the highest risk patients (depending on the place 
of birth, blood CD4 cell count and time on ART). This guideline was based 
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predominantly on the Swiss and CHIC data sets. [31,42,76] The United States 
Centre for Disease Control (CDC) advise the most comprehensive strategy with 
testing for LTBI in all HIV infected individuals at HIV diagnosis, plus retesting 
in certain groups. [41] Other strategies are listed in Table 1.5.6. WHO have sug-
gested that systematic testing and treatment for LTBI should be performed in 
people living with HIV in low TB burden countries. [45]
1.5.7 TB elimination
An ambitious target of TB elimination (<1 case per million per year) has been 
set by the WHO for 2050. [1] Modelling has suggested that in the absence of a 
new vaccine or shorter treatment for active TB, mass latent TB chemoprophylaxis 
may be the only way to reduce TB burden. [139] 
Some US states already have declining notification rates and are on target for 
elimination. Many European countries have elimination plans where this is felt 
to be achievable, although TB incidence is too high to be thought to be achievable 
in many, including the UK. [140,141]
1.6 Diagnosis of LTBI
Latent TB infection is defined by a lack of symptoms and persistent immune 
response to and inability to culture M. tuberculosis. Its presence has to be inferred 
using surrogate markers, predominantly immunological tests of sensitisation. 
Both the TST and IGRA rely on cell-mediated immunity to recognise a myco-
bacterial antigen and then invoke a reaction (either in vivo or in vitro). The tests 
cannot distinguish between active disease from latent infection, the time of TB 
49
exposure or predict risk of reactivation. [142] There is no gold standard with 
which to compare the two tests – TST do not have optimal sensitivity (there can 
be an anergic response, increasing in frequency as cell-based immunity deterio-
rates) nor specificity (cross-reaction with environmental mycobacteria and BCG 
vaccine). IGRA have a positive control, which helps to distinguish true from false 
negatives, but there is still a false positive rate, and each IGRA can (and often) 
give discordant results to each other and the TST. [143-146] TB infection seems 
to behave in a dynamic rather than dichotomous state. A more pragmatically 
useful screening test for LTBI would identify those at highest risk of progres-
sion to active disease, or specifically those with active disease or subclinical TB 
requiring four-drug treatment and where less drug for less time may risk drug 
resistance and treatment failure. Findings from transcriptomics studies or PET 
scanning look promising, but they are not yet in a convenient or commercially 
available form. [64,65]
1.6.2 Use of TST
The tuberculin skin test (TST) relies on a delayed (type IV) hypersensitivity 
reaction to an intradermal injection of tuberculin protein (most commonly purified 
protein derivative  – PPD), extracted from killed Mycobacterium tuberculosis. It 
has been in use for over 100 years, initially as an attempted vaccine and then as 
a test to sensitisation to M. tuberculosis. It requires interpretation between 48-72 
hours and any raised induration be marked and measured. The interpretation is 
subjective. Trained health care professionals are usually responsible for recording 
the result, although some studies show a relatively good correlation between 
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patients and clinicians interpretation. [147,148] 
The TST can react to previous BCG (Bacille Calmette et Guerin) vaccination 
also to other, environmental mycobacteria. A phenomenon called ‘boosting’ also 
occurs when a repeat TST is performed (especially within four weeks) and lead 
to a false positive result. Various formulations of PPD are available globally, 
although the Danish Staten Serum Institute preparation has widely been used 
in the UK. 
In non-HIV-infected adults and children, regardless of previous BCG vaccina-
tion in the UK, a reaction of ≥5mm is used as a cut-off to maximise sensitivity. 
[134,149] 
A lower TST sensitivity and anergy (no reaction) are associated with HIV 
infection, especially in those with lower blood CD4 cell counts. [150] Studies just 
after the discovery of HIV showed a higher incidence of active TB in individuals 
with anergy to PPD when compared to HIV patients with a 1-4mm response. 
[151,152]  Anergy testing was often performed simultaneously on the other fore-
arm, usually using candida or mumps antigen. This regimen was abandoned 
by 1997 as the strategy was found to be flawed as anergy to mumps or candida 
did not correlate with anergy to PPD. The interpretation may also have been 
affected by boosting. [78,153,154]  In vitro testing since then has also shown that 
interferon-gamma secretion from HIV-infected CD4 cells is lower than from 
non-HIV infected cells, despite the improvements in blood CD4 counts seen in 
patients after starting ART. [155]
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1.6.3 Use of IGRA
IGRA were developed around twenty years ago to detect a T-cell immune 
response to tuberculosis antigens in vitro, which is quantified by measuring 
interferon-gamma (INF-gamma) release. [156] The response was initially to two 
TB mitogens - CFP (culture filtrate protein) 10 and ESAT (early secretory antigenic 
target) 6. These are still used in commercial tests – the Quantiferon-TB Gold test 
(QFT, Qiagen) uses an enzyme-linked immunoassay (ELISA) to detect the IFN-
gamma, whereas the TSpot.TB (Oxford Immunotec) assay uses enzyme-linked 
immunospots (ELISPOTS). [157] Other mycobacteria that express these antigens 
are M. kansasii, M. szulgai, M. marinum, M. riyadhense and virulent strains of M. 
bovis. Its advantages over the TST are that it requires one visit, there is no boosting 
phenomenon, and there is less confounding with BCG cross-reactivity. The tests 
require at least 24 hours incubation, and the QFT requires three tubes of blood 
(one nil control, one for TB antigens, one for mitogen). Like TST, IGRA can be 
negative in those with active TB. [158,159] The sensitivity in low/middle-income 
countries for active TB was 61% for QFT and 72% for TSpot. [159]
1.6.4 IGRA indeterminate responses
An IGRA is reported as indeterminate when there is a failure of the control 
(i.e. QFT nil tube result is >8 IU/ml or positive control <0.5 IU/ml more than the 
nil tube; there is excess spot production in the nil TSpot control or inadequate in 
the positive control). Often this is caused by technical reasons (e.g. insufficient 
mixing in the bottles when the blood is added), preexisting interferon gamma in 
the sample, or immunosuppression. [160,161]  In a meta-analysis of IGRA use in 
HIV-infected subjects, TSpot were indeterminate in 2% (range 0-10%) on average 
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in studies from low/middle-income countries and 5% (1-9%) in high-income 
countries. QFT were indeterminate in 4% in high-income countries, and more 
likely in those with blood CD4 < 200 cells/µL [162] 
1.6.5 IGRA concordance
As there is no gold-standard comparator, IGRA have been compared to known 
risk of previous TB exposure, to TST results, and to the risk of progression to 
active disease. Although TST and TSpot were concordant in a meta-analysis in 
89% cases (with significant heterogeneity) in high-income countries and between 
TST and QFT in 94%, the concordance was much lower in those with positive 
results. In multiple studies, poor concordance has been shown between TST 
and either IGRA – slightly more frequently leading to IGRA+, TST- results. 
[146,163-167]  In one US study, only 1 in 27 patients (median CD4 334 cells/µL) 
with a positive test had agreement in all three. [163] Results from Quantiferon 
GOLD In-Tube and Quantiferon GOLD have even differed, despite using similar 
methods and the same mitogens. [162,168]  
1.6.6 IGRA variability
More recent studies show that IGRA results can vary on serial testing.  Causes 
are speculated to be possible dynamic immunological processes, random with-
in-person variation or problems with test reproducibility. [169] In a Norwegian 
study, despite no known interim TB exposure, 7% of negative QFTs became 
positive at one year, and half of these then reverted to negative by two years, 
whilst six of 17 positive results became negative. None of these subjects had had 
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LTBI prophylaxis. [80]  In a US study, 80% of positive QFT in non-TB exposed 
HIV patients reverted to negative, as did a quarter of the results in patients from 
high-risk countries. [170] The phenomenon has also been seen in HIV-uninfected 
healthcare workers. [169]
1.6.7 Positive progression rates for IGRA and TST
In a meta-analysis comparing IGRA to TSTs for risk of progression to active 
TB (in HIV-negative and positive groups combined), IGRA had an NPV of 99.8% 
(QFT) and 97.8% (TSpot). TST, in one available study, had an NPV of 99.7%, 
making any of the three tests useful for ruling out LTBI in the majority of patients. 
The positive progression rate (risk of developing active TB) at 19-24 months for 
immigrants or contacts with a positive IGRA in European studies was 2.8-14.3% 
in those with a positive QFT, 3.30-10% with positive TSpot and 2.3-3.3% with 
positive TST. [145] 
There have been five studies from Europe specifically in patients with HIV, 
where those with a positive IGRA and not treated with chemoprophylaxis were 
followed up for subsequent TB. These showed a progression rate of between 
0 and 10% in those with a positive IGRA. The NPV with IGRA was 98.2-100%. 
A Norwegian study (in a population with high ART uptake) had no cases of 
subsequent TB – even in those with a positive IGRA (positive and negative pre-
dictive values of 0%). [80] A pan-European study, however, showed an NPV of 
99.48% with TSpot. [171] A large Swiss study between 1996-2006 used TST. They 
calculated a progression rate of 6.5% (16/246) in those with a positive TST over 
a median 4.6 years. This equated to an incidence rate of 15.9 per 1000 person 
years. In those with a negative TST, the progression rate was 0.26% over five 
Table 1.6.7: Progression rates for IGRA in European studies (includes 
HIV and non-HIV for comparison) 
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years (incidence rate of 0.5 per 1000 person years). [76] Table 1.6.7 summarises 
studies in HIV-infected subjects from Europe.
1.7 Cost-effectiveness of screening
Despite the caveat that ‘All models are wrong, but some are useful’ (attributed 
to George Box, British Statistician in 1976), economic models have been used to 
influence public health policy over recent years. Cost-effectiveness analysis (CEA), 
specifically, can aid decisions between alternatives in medical care – especially 
if one treatment is already routine practice. Methods have been standardised 
and criteria set: analyses should estimate costs to society, show costs and benefit 
over a lifetime (if empirical data cannot be calculated during a study period) 
and statistical significance should be indicated. [177] The cost-effectiveness is 
expressed as the ratio of cost to benefit, and this is then discounted (usually by 
around 3% per year) to recognise the decreased value of a delayed expense or 
benefit. [177]  
Benefits can be expressed in clinical outcome units (for example heart attacks 
prevented or cases of TB averted), or in a metric such as the Quality Adjusted 
Life Year (QALY), which is then comparable between different health states and 
treatments. A QALY (or health utility) score is the product of any life years gained 
and the quality of life in that health year. There are different ways to calculate 
this, based on validated quality of life scores such as the EQ5D, which is the 
questionnaire preferred by NICE in England and Wales. The Euro-QOL group 
derived this as a five-dimension questionnaire with either three (3L) or five (5L) 
































































































































































































































































making repeated assessments easy. Alternative methods include the standard 
gamble, comparing years of life gained with risk of death (often used to assess 
major surgery), or trading off years lived versus higher quality of life. [177]  
To compare interventions, and judge if these are cost-effective, cost/outcome 
(usually QALY) is compared. NICE (England and Wales) use a threshold of £20-
30,000 per QALY, which has not changed over the past decade, whilst the US 
has been noted to use $50,000. [178-180]
If one intervention has less benefit (i.e. fewer QALYs gained) than another but 
costs the same or more, it is said to be ‘dominated’. When it has more QALYs, 
but these extra QALYs each cost more than the threshold allowed (e.g. £30,000) 
this is called ‘extended dominance’. 
Given assumptions are often necessary to construct the model, sensitivity 
testing is used to assess confidence in the outcomes.  Changing one parame-
ter (univariate analysis) gives an idea about which factors influence models 
the most. Best and worst case (multivariate) scenarios can also be calculated. 
Uncertainty can be assessed using ‘bootstrapping’ or a probability sensitivity 
analysis (PSA) such as the Monte Carlo simulation, which uses a large number 
of estimates (often 10,000-100,000) based on random numbers and applies them 
to distributions around each assumption.
1.7.2 Costs of TB care and treatment
Costs of active TB have published and used in health economic models. White 
et al. suggested £6040 to treat a case of active TB in a London Hospital in 2000, 






































































































































































































































































































































* Adjusted to 2012 prices; Exchange rate €1.2=£1 
EU-15: First 15 European Union member states; 6H: 6 months isoniazid therapy; 3RH: 3 months rifampicin and  
isoniazid






Latent TB medication 
(3RH)
£86 NICE Assumption [185]
Latent TB case (6H) £524.59 Pooran 2010 2008 [186]
Active TB case £5,000 Department of Health 2009 2009 [182]
£6,040 White 2000 1996-1998 [181]
£7,619 Pooran 2010 2008 [186]
£4,742-£7,820 
(€5,691-€9,384*) 





Diel (EU15 - European 
average)
2014 2008-2012 [184]
MDR TB case £47,677 
(€57,213*) 
Diel 2012 2008-2012 [184]
































































































































































































































































































































































estimated £5000 as the cost of a drug sensitive case. [181,182]  Pooran et al. sug-
gested £7,619 in 2010, similar to published Western European ranges, collated 
in 2014 (Table 1.7.2). [183,184] 
NICE, in their 2011 guidelines, have used estimates of: £500 for chemoprophy-
laxis treatment per patient, £5100 for the treatment of active disease, IGRA £22 
(updated to £50) and clinic appointments after a positive IGRA result at £250. [185]
1.7.3 Quality of life in TB
One of the most difficult assumptions for TB cost-effectiveness modelling has 
been an assessment of the quality of life (QoL) in TB. This has been measured 
using various generic tools, albeit with little consensus on which method is 
optimal. The EQ5D has been criticised for not being sensitive enough for use in 
TB, and there is no TB related data set using this yet, but the questionnaire does 
provide a fast and straightforward assessment, especially when used repeatedly. 
[187-189]  
There are only two QoL data sets from high-income countries in order to 
calculate the loss of quality of life due to active TB disease. Both of these (one 
British, the other Canadian) have used the San Francisco-36 questionnaire (SF36). 
[188,190] There are even fewer data to quantify the quality of life lost due to pre-
ventive treatment for LTBI. This utility is often an assumption, and some papers 
have counted it as one (i.e. no loss of quality of life) unless there is associated 
hepatotoxicity. [191-193]
All the studies in HIV-uninfected individuals have shown lower QoL in those 
with active TB compared to LTBI or no TB, although in active disease the QoL 
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tends to improve at the end of treatment. [188,190,194,195] Two studies, however, 
show quite significant, prolonged lung impairment and disability after active 
disease. [195,196] Some QoL loss has also been attributed to the anxiety and 
stigmatisation around the diagnosis of TB. [197]
HIV/TB coinfection studies have tended to come from low resource settings. 
A South African and an Ethiopian study both showed lower QoL in those with 
HIV coinfection compared those without HIV, whereas a Thai and Brazilian 
study demonstrated little difference between HIV-infected and uninfected TB 
patients. [109,198-200]
1.8 Rationale for a study in cost-effectiveness of TB testing in HIV
There is no agreed consensus, either nationally or internationally on testing 
for TB in HIV-infected patients. Most rely on historical studies conducted when 
fewer patients were taking ART. In the UK clinicians were not consistent in their 
approach to testing and only a third adhered to national guidelines. [201] We 
felt it was important to assess how feasible and cost-effective it would be to test 
patients with HIV for active, latent and subclinical disease.  
It still has not been established that IGRA are superior to TST, and although 
they do not require a return trip for interpretation, they require more technology 
and therefore cost significantly more, there is variability in their results, and 
neither test has optimal sensitivity or predictive value. There is still a paucity of 
data from large studies that treating IGRA positive patients with IPT (especially 
if TST negative) prevents active TB.
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1.8.2 Existing evidence for LTBI testing
The very increased risk of TB reactivation has been known since 1987, ini-
tially in studies comparing HIV-infected and non-infected injecting drug users. 
[32,88,202,203]  Isoniazid prophylaxis has been used since then and shown to 
reduce the risk of active TB. [71] As ART was introduced in the late 1990s, the 
risk of TB began to fall in all groups. [86] In 2004, the Swiss study showed that 
treatment for LTBI was effective, but it failed as it was poorly implemented by 
physicians. [76] UK epidemiological studies showed a higher risk of TB disease 
predominantly in black Africans, those with low blood CD4 cell counts and 
individuals just starting ART. [31] However, studies over the past decade in 
Europe and the US, using IGRAs rather than the TST, have shown that very 
little active TB develops in people who have a negative IGRA result or have had 
LTBI preventive treatment. As ART increases, the risk of developing TB (even 
in those that are IGRA positive) is even lower. [172,174,175] Despite national 
guidelines, testing in clinics in the UK has been patchy and inconsistent. Many 
HIV physicians feel there is little risk of active TB or that LTBI testing strategies 
in HIV clinics have not been justified as cost-effective. [201]
In order to improve this, both NICE and BHIVA released guidelines for the 
UK in 2011. NICE modelled the cost-effectiveness of targeted testing based on 
blood CD4 cell count, using assumptions from a school based analysis reviewing 
BCG. [43]
The British HIV Association (BHIVA) guideline was not assessed for cost-ef-
fectiveness but was based on UK epidemiological data and results from the 
Swiss study in order to prevent active TB disease in those at the highest risk of 
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reactivation. [31,42,76] IGRA was used as a single test and given the lack of data 
available at the time, further research in the area encouraged. Since the CHIC 
and Swiss data sets were published, HIV demographics in the have UK changed, 
there were fewer immigrants from subSaharan Africa and ART use became more 
widespread. TB/HIV notifications have also decreased. [46,48] 
There has not been a study to assess how feasible and cost-effective testing 
for TB infection would be, or what may be the most effective strategy, in people 
living with HIV in a Western European city where there is a high uptake of ART. 
As a response to the high incidence of active TB seen in sub-Saharan African 
ART clinics, studies were conducted screening asymptomatic HIV patients for 
active tuberculosis. These demonstrated high numbers of patients with microbi-
ological or radiological evidence of active TB, but with no symptoms (described 
as subclinical tuberculosis). Some of these patients also had a negative IGRA or 
TST. [62] Subclinical TB had been described in an HIV clinic in London, but only 
in the context of a TB testing study that cultured sputum from patients with a 
positive IGRA or TST. [77] The prevalence of subclinical TB in asymptomatic 
HIV infected individuals in London (irrespective of IGRA status) is unknown.
1.9 Study hypothesis, aims and objectives
The aim of the study was to determine the feasibility of extensive testing for TB 
infection in a contemporary HIV population with widespread use of ART, and to 
assess its cost-effectiveness. This could be established by a cross-sectional study 
to show the prevalence of active TB disease, subclinical and latent TB infection 
and modelling the effects of various testing strategies to prevent active TB. By 
performing a comprehensive array of tests, limitations of symptoms, radiology 
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or immunological tests could be shown. The same patients could then provide 
a cohort to assess the prognostic value of TST/IGRA against the risk of TB over 
the next 5-20 years. 
1.9.2 Hypotheses
1. There is a significant difference in the prevalence of TB infection between 
black Africans and those from low TB incidence countries attending a UK HIV 
clinic.  
2. Systematic testing for M. tuberculosis infection (with IGRA) is feasible and 
cost-effective in a UK HIV population. 
3. TST provides no further information compared to a single step, blood IGRA 
in the detection of M. tuberculosis infection in a contemporary UK HIV-infected 
clinic population.
4. Within the Royal Free clinic population, asymptomatic HIV-infected indi-
viduals with normal chest radiographs have negative mycobacterial sputum 
microscopy and culture, despite originating from high TB incidence areas. 
1.9.3 Primary objectives
To determine the feasibility, yield and cost-effectiveness of systematic testing 
for M. tuberculosis infection in UK HIV-infected individuals.
1.9.4 Secondary objectives
For all subjects:
1. To determine the prevalence of subclinical and active TB in a UK HIV-in-
fected clinic
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2. To determine the sensitivity and specificity of systematic screening ques-
tionnaires for detecting cases of active TB outside of high TB prevalence settings
3. To determine concordance between TST and blood TSpot.TB in latent TB 
infection
4. To identify risk factors for latent TB infection in the clinic population
5. To determine the sensitivity and specificity of Xpert MTB/RIF PCR testing 
of sputum and induced sputum compared to mycobacterial microscopy and 
culture for M. tuberculosis infection
6. To determine quality of life scores (EQ-5D) for those with HIV infection, 
with and without latent TB infection and/or undergoing treatment
7. To determine the underlying frequency of airways disease (using spirom-
etry) and of respiratory symptoms
In those with evidence of LTBI:
8. To determine uptake of latent TB therapy (6 months isoniazid treatment)
9. To determine cost of latent TB treatment (including screening costs, clinic 
time)
10. To determine quality of life, and rate and severity of adverse events on 
latent TB treatment
11. To determine rate and time until active TB in those with LTBI on or off ART 
and/or LTBI preventive treatment
In all patients (over a 20-year follow-up):
12. To determine the rate of incident active TB
13. To determine the risk and time until progression to active TB in patients 
with abnormal radiographic changes consistent with old tuberculosis exposure 
or disease
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1.9.5 Contributions of experimental and analytic procedures
For the analysis and cost-effectiveness calculations of the retrospective data, I 
performed the: statistical analysis of retrospective data, initial cost-effectiveness 
calculations giving point estimates, building of the cost-effectiveness model (with 
Colette Smith and Stephen Morris), calculation of the probabilistic sensitivity 
analysis including tables and graphs and wrote the critical analysis. 
For the prospective study, I designed the study protocol (with Marc Lipman), 
wrote and submitted the ethics and research and development forms and attended 
the ethics board meeting. I recruited the subjects (along with Janey Sewell, 
Research Nurse, UCL Department of Infection and Population Health), admin-
istered tuberculin skin tests (with Janey Sewell), performed phlebotomy (with 
Janey Sewell and staff of the Ian Charleson Centre if other bloods were taken), 
performed spirometry (with Janey Sewell) and sputum induction (with Janey 
Sewell). I organised and posted T.Spot tests to an external laboratory, centrifuged 
and pipetted blood for storage, reviewed the initial chest X rays, collected and 
analysed results, performed the statistical analysis (with some confirmation from 
Colette Smith), built the cost-effectiveness model and calculated the probabilistic 
sensitivity analysis, along with tables and graphs (with some methodological help 
from Professor Steve Morris from the Department of Applied Health Research).
Colette Smith (from the UCL Department of Infection and Population Health) 
collected data for the retrospective chapter, along with the Royal Free Database 
team (Robert Tsintas) and helped build the initial cost-effectiveness model. She 
also confirmed the power calculation and some other statistical analyses in the 
thesis, including odds ratios.
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Chest X ray reporting was performed by Consultant Radiologists, Royal Free 
Hospital; sputum mycobacterial culture by the Laboratory staff, Royal Free 
Hospital, Department of Clinical Microbiology; extra sputum disinfection and 
freezing  by Dr Isobella Honeybourne, UCL Department for Clinical Microbi-
ology and the qPCR analysis by Dr Camus Nimmo and Sarah Thurston, UCL 




The studies were performed at the Ian Charleson HIV ambulatory care clinic 
at the Royal Free Hospital, London, which provides care for a large, stable pop-
ulation of HIV infected individuals of over 2,500 people. Approximately a third 
of patients treated here originate from sub-Saharan Africa. At the time of the 
analyses, the background prevalence of HIV in London was 525/100,000 adults 
aged 16-59 and the incidence of active TB local to the hospital was 36.8/100,000. 
[204,205]
There was no routine testing for latent TB infection (LTBI) in individuals 
attending the Ian Charleson Centre at this time. 
2.2 Modelling LTBI Testing from 2000-2010
We used clinical and demographic data from the Royal Free HIV clinic cohort 
to model systematic LTBI testing in this group between 2000 and 2005 and then 
between 2005 and 2010.
2.2.2 Data source
Retrospective data were obtained from the Royal Free HIV database. This is 
a prospective database containing demographic, clinical, virological and immu-
nological information for all patients receiving care at the Royal Free Hospital 
and updated yearly. 
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2.2.3 Ethics
Patients consent either at HIV diagnosis or when transferring care to the Royal 
Free Hospital. Ethical approval has been granted previously for prospective 
data extraction. 
2.2.4 Model structure
Place of birth, serial blood CD4 cell counts and a diagnosis of active tuber-
culosis disease was extracted from the database for all patients attending the 
clinic between 2000-2010. Each blood CD4 cell count was used as a surrogate for 
an HIV clinic appointment. This was used to calculate how many individuals 
would be eligible for LTBI testing using BHIVA 2011 or NICE 2011 guidance. 
The model structure, assumptions and details of the sensitivity analyses are 
described further in the methods section of that chapter.
The results of the economic analysis were measured in terms of the incremen-
tal cost per case averted (ICCA) and incremental cost per QALY gained. The 
cost-effectiveness evaluations are described more below.
2.3 Prospective study
2.3.1 Ethics
The study was sponsored by University College London, approved for R&D 
by Royal Free/UCL Joint Research Office and Ethics approval was granted by 
the City and East Ethics Committee on the 16th November 2012. REC reference 
12/LO/1516; UCL protocol number 12/0212; ‘Study of systematic TB testing 
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for active, sub-clinical and latent tuberculosis infection in a UK HIV-infected 
cohort’. Clinicaltrials.gov number was NCT02712671. There was no outside 
funding provided for the study.
The study was performed at the Royal Free Hospital, London.
All patient assessments were conducted on the hospital site.
2.3.2 Storage of information
Patient consent, questionnaires and checklists were filed and kept in a locked 
office in the Centre for Clinical Microbiology, in the UCL Department for Popu-
lation Studies or in the Ian Charleston Centre. Subjects were issued with subject 
numbers at recruitment, which were used to pseudoanonymise data for analysis. 
All computer files about the study were stored with password protection on 
encrypted hard drives. Any email correspondence within the centre was sent 
using an encrypted system.
No personal details were sent by email outside of UCL or the Royal Free Hos-
pital. TSpot.TB tests were ordered and identified using the pseudoanonymised 
research number only and results received on password protected files using 
encrypted email.
2.3.3 Recruitment and assessments
2.3.3.1 Selection
 All subjects were recruited from the Ian Charleson Centre. 
Selection criteria were:
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1. All patients with a new diagnosis of HIV
2. Patients attending routine ambulatory HIV care clinics, using stratified selec-
tion. We approached the 1st, 4th and 7th patients on each clinic list on Mondays, 
Tuesdays, Wednesdays and Fridays 
Recruitment was not possible on Thursdays as the tuberculin skin test (TST) 
had to be interpreted at 48-72 hours.
We aimed to enrol 180 patients from subSaharan Africa and 120 from lower TB 
incidence areas. This was to demonstrate a difference of 10% in the prevalence 
of TB infection between black Africans (13% prevalence) and those from low TB 
incidence countries (3% prevalence), based on data by Kall et al. [77] The power 
calculation suggested these numbers to show a difference with a power of 80% 
and a 5% chance of a Type I error, allowing for a 20% drop out rate. 
Patients were approached in the waiting area and taken to a quiet part of the 
centre to have the study explained. They were given as long as necessary to con-
sent, but to minimise travel costs and inconvenience to subjects, where possible, 
TB testing occurred on the same day as a routine clinical appointment. Travel 
costs were met for subjects to re-attend for clinical investigations, radiology and 
sputum induction related to the study. There was no financial incentive offered 
for taking part.  
Full written consent was taken. All subjects were asked specifically as part of 
the consent process if they wanted to be told the results of all their tests plus any 
action recommended, and the outcome of the entire study if interested. Specific 
consent was also requested to inform the GPs of the subjects’ involvement in 
the study and results (Appendix 1). 
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2.3.3.2 Inclusion and exclusion criteria
Inclusion Criteria:
• Able to give informed consent
• Over the age of 18
• HIV infection, with confirmed positive HIV antibody status
• Under the care of the Royal Free Ian Charleson Day Ambulatory Unit
Exclusion Criteria:
• Diagnosis of active TB or undergoing treatment for active or latent TB
• Inability to produce sputum by coughing (e.g. recent rib fracture, chest 
pain, pneumothorax)
• Pregnancy
• Use of steroids (equivalent to 15mg prednisolone for ≥4 weeks) or any other 
immunosuppressive drugs (e.g. azathioprine) (relative contraindication)
• Active solid organ or haematological malignancy (excluding Kaposi’s 
sarcoma) or undergoing chemotherapy
• Previous hypersensitivity to purified protein derivative (PPD) 
• Extensive eczema
2.3.3.3 Diagnosis
All subjects recruited had a previous positive HIV 1 or 2 serum antibody test 
and blood HIV viral load confirmed on the Royal Free pathology database.
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Figure 2.3.4: Flowchart of Procedures 
Consent
Questionnaire
Blood tests: 3 Li Hep 
(2 for T-Spot + 1 store) 
+ 2 EDTA
Spontaneous sputum (if possible)
Sputum Induction (including 
spirometry at t=10 mins)
Tuberculin skin test (reading)
Initial spirometry at t=0
48-72 hours later
















Tuberculin skin test (administration)
Chest Radiograph
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2.3.3.4 Demographic and symptom questionnaire
Subjects were asked to self-complete a questionnaire including 
• Age  
• Place of birth
• Previous time living abroad 
• History of TB contact or previous TB disease 
• History of time in prison or immigration camps 
•  Respiratory or infective symptoms (including cough, haemoptysis, fever, 
weight loss, lymphadenopathy) – see appendix 
• Smoking history
• History of injecting drug use
• Previous BCG vaccination
• History of respiratory, renal and rheumatological conditions (including 
history of asthma, COPD and bronchiectasis) plus inhaler or immuno-
suppression usage
Recent blood test results were collected from the pathology database including:
•  Blood CD4+ lymphocyte cell count and percentage (most recent and six 
months previously) 
•  HIV viral load (including most recent and six months previously)
•  Serum creatinine
•  Blood glucose
•  Nadir blood CD4 lymphocyte count and percentage when available
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A limited examination for BCG scar and cervical lymphadenopathy was 
performed.
2.3.3.5 Information extracted from the Royal Free database
Clinical and medication data were taken from subjects’ medical records 
including: 
• Suspected route of infection with HIV 
• Time of diagnosis with HIV
• Previous antiretroviral treatments 
• Most recent and nadir blood cell CD4 counts where available
• HIV viral load and previous chest radiograph reports
2.3.3.6 Quality of life and costs of investigation
Quality of life was measured by EQ5D-5L questionnaire at the time of recruit-
ment. This was used (with UK value sets) to estimate quality of life loss for 
subjects with latent and subclinical TB. In those with active, subclinical or latent 
TB infection detected, further quality of life scores and adverse events were 
recorded at each clinic appointment and also after 1-2 years in those without. 
Adverse events were recorded systematically using a standardised questionnaire, 
based on those used in cancer chemotherapy.  The number of clinic appointments 
and time spent with health professionals related to TB care were estimated using 
the Cerner computer appointments system. Further blood tests or investigations 
were recorded and costs estimated using NHS or local tariffs.
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2.3.4 Study investigations
Subjects were asked to undergo a series of tests for TB infection that included 
a symptom questionnaire, blood interferon gamma release assay (IGRA, in this 
study a TSpot.TB), tuberculin skin testing (TST), a frontal chest radiograph (CXR), 
spontaneous sputum if possible, sputum induction. 
2.3.4.1 Symptom questionnaire
TB symptoms were based on WHO and Cain symptom questionnaires. [104,206]
Four respiratory symptoms, based on the symptoms used in the NICE COPD 
guidelines and screening questions used for the diagnosis of COPD in General 
Practice were also asked to identify those at risk of airways disease. These were: 
history of tight chest, history of wheeze, breathlessness walking up one flight of 
stairs, productive cough most winters. [207-209] 
2.3.4.2 TSpot.TB
Two x 6ml lithium heparin tubes of whole blood, drawn at the time of recruit-
ment (preferably at the same time as routine clinic blood testing), were sent to 
Oxford Diagnostic Laboratories for TSpot.TB testing using the DX same-day 
courier service. Samples were identified by study number only. 
TSpot.TB results were reported as positive, borderline (positive or negative), 
negative or indeterminate/invalid. The result is interpreted by subtracting the 
number of spots in the test wells (with mitogens CFP10 or ESAT6) from the 
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number of spots in the negative control well. A positive result is defined as 
difference of greater or equal to eight spots. Four spots or fewer is a negative 
result. Where the difference between the higher of both test wells and the nil 
control is five, six or seven spots, the result is expressed as borderline. If there 
are fewer than 20 spots in the positive control or greater than ten spots in a neg-
ative control, the test is expressed as indeterminate or invalid. [160] Borderline 
and indeterminate results were recorded and a blood sample retested at the next 
available clinic appointment or convenient time.
2.3.4.3 Tuberculin skin tests (TST)
TST was administered using an intradermal injection of 2 tuberculin units 
(TU)=0.1ml purified protein derivative (Statens Serum Institute, Denmark) with 
a 28 gauge insulin needle on the volar aspect of the upper third of the forearm to 
form a wheal 6-10mm in diameter. The time and date of injection, lot number of 
solution and location of injection site were documented and the subject advised 
to avoid pressure or bandage at the injection site. The diameter of the lesion was 
measured at follow-up 48-72 hours later by the investigators, or failing that, 
by the subject. Instructions to measure the indentation with a pen were given, 
plus a ruler issued if they felt they would not be able to return. In these cases, 
subjects were also asked to provide a photograph of the forearm if possible. An 
induration measuring 5mm or above was considered a positive result.
2.3.4.4 Chest Radiograph
Subjects were asked to have a departmental posterior-anterior frontal chest 
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radiograph (unless one had been performed in last four weeks). This was reported 
by a respiratory radiologist at the Royal Free Hospital within 72 hours. If found to 
be abnormal (e.g. parenchymal lesion or pleural effusion), further testing (includ-
ing CT scan as appropriate) was conducted as necessary, as part of routine care.
Women aged under 50 had a urinary beta-hCG measured before undertaking 
a chest radiograph.
2.3.4.5 Spirometry
Spirometry was performed routinely before sputum induction and at five min-
utes of inhaling 3.5% hypertonic saline. The best of three attempts was recording 
including peak flow measurement at each time point (detailed further below).
2.3.4.6 Sputum induction
Sputum induction was performed in a negative pressure closed unit within a 
side room for infection control purposes. This consisted of a transparent polypro-
pylene tent around a 2.2m x 1.5m frame with reinforced Nyplax floor. This used 
a single HEPA filtered inlet and double HEPA filtered outlet. A motor maintained 
15 air exchanges per hour within the chamber. Bacterial/viral filters were used 
on the spirometer to prevent cross infection.
The procedure was explained to the participants before sputum induction. 
Spirometric (FEV1, FVC) and peak flow measurements were performed using a 
hand held spirometer (MicroPlus, MicroMedical, UK) as a precaution to identify 
airways disease before starting the procedure and again 5 minutes after com-
mencing the saline nebuliser. Forty millilitres of 3.5% hypertonic saline were 
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nebulised over 20 minutes using an ultrasonic nebuliser (DeVilbis Ultraneb 
3000), with active cycle of breathing and huffing to augment airway clearance. 
The procedure was stopped if the subject complained of nausea, chest tightness 
or breathlessness, or if the FEV1 fell below 15% of the pre-induction value. Sal-
butamol 100mcg 2 puffs via a spacer was also given if this occurred. Oxygen, 
inhaled and nebulised salbutamol were available if necessary for treatment of 
bronchospasm. Sputum was expectorated into three pots in rotation and anal-
ysed for mycobacterial microscopy and culture and Xpert MTB/RIF, stored for 
possible further testing or, if required clinically, for routine sputum culture.
Sputum samples were tested in the Department for Clinical Microbiology, Royal 
Free Hospital. If sputum volume was low, samples were sent preferentially for 
acid-fast bacillus (AFB) smear and mycobacterial culture. Any residual sputum 
was stored at -80ºC in the Department for Clinical Microbiology and identifi-
able by study number only. Following each procedure, the entire chamber and 
equipment were cleaned using freshly made Tristel 2% solution (Tristel Solutions 
Ltd, Cambridgeshire, UK). Filters for the ultrasonic nebuliser, spirometer, plus 
mouthpiece and tubing were all single use and disposed of in hazardous waste. 
2.3.4.7 AFB smear and mycobacterial culture
Induced sputum received was decontaminated and examined using auramine 
stain for the presence of acid-fast bacilli in a Category III laboratory for respiratory 
samples. It was then cultured using Bactec-MIGIT liquid culture (Becton, Dick-
inson, New Jersey, USA) for the presence of mycobacteria for up to 42 days. This 
was performed by staff at the Royal Free Department of Clinical Microbiology. 
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2.3.4.8 Xpert MTB.RIF
Induced sputum was routinely tested using Xpert MTB.RIF (Cepheid, Sunny-
vale, California, USA) within 48 hours in the Department of Clinical Microbiology, 
Royal Free Hospital by microbiology staff.
2.3.4.9 Other sputum - use and processing
Any unused sputum was used for further research purposes and collected in 
a universal container which was identified by date and study number only. This 
was sealed in the sputum induction tent and frozen at -80ºC within four hours 
with no additives. Samples were stored at the Centre for Clinical Microbiology, 
UCL Royal Free Hospital Campus.
DNA extraction and multiplex quantitative polymerase chain reaction (qPCR) 
processing was performed on sputum for airway bacteria (namely Streptococcus 
pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophilia, 
Chlamydophila pneumoniae and Mycoplasma pneumonia). This was performed by 
Dr Camus Nimmo and Sarah Thurston in the research department of the UCL 
Centre for Clinical Microbiology.
2.3.4.10 Other blood tests
Two EDTA and one Lithium heparin blood samples were drawn at the same 
time as TSpot.TB testing and stored for other tests of immune function (includ-
ing for the detection of biomarkers, cytokines or microRNA associated with 
active and latent TB). Written consent was obtained for these blood samples 
and only for use in ethically approved future studies. These were centrifuged 
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at 2500g for 10 minutes at 4ºC, plasma was removed using disposable pipettes 
and stored in screw-top tubes (Fisher Scientific, UK) at -80ºC in the Centre for 
Clinical Microbiology, UCL Royal Free Hospital Campus, identified by study 
number, date and preservative only.
2.3.4.11 Abnormal test results
Those who have abnormal chest radiograph results as a consequence of testing 
were investigated as per normal clinical care and offered follow up in respiratory 
clinic as appropriate.
2.4 Economic modelling
Retrospective and prospective data were used to model the uptake, yield and 
cost-effectiveness of TB testing. This was performed using Excel for Mac 2011 
and Excel for Windows 2010.
Cost effectiveness was measured in terms of the incremental cost per case 
averted (ICCA) and incremental cost per quality associated life year (QALY). 
Utilities and costs were taken from published sources, and local and national 
NHS tariffs. [43, 183, 85, 210]
Cost-effectiveness ratios were calculated as the difference in costs divided by 
the difference in outcomes (active TB cases or QALYs). 
2.4.1 Prospective data for cost-effectiveness modelling
A cost-effectiveness model was derived using the results of the prospective 
study. The study gave real-world variables to be used for uptake and cases of 
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active, latent and subclinical TB. To calculate the baseline risk of TB (number of 
new cases of active TB that may arise without testing), a progression rate was 
estimated using previous prospective studies. [173-5, 211] Numbers of cases 
prevented was then subtracted from this and cost-effectiveness calculated.   
 
2.4.2 Sensitivity analysis
Univariate and multivariate sensitivity analyses were performed with costs 
varied for tests, treatment of TB infection (active, subclinical or latent). Uptake, 
test sensitivity, effectiveness of LTBI chemoprophylaxis were all varied, as were 
quality of life scores. Multivariate most-costly and least costly scenarios were 
also estimated.
A probabilistic sensitivity analysis with 10,000 Monte Carlo simulations was 
used to calculate: 1. uncertainty ranges for each of the point estimates and 2. a 
cost-effectiveness acceptability curve, showing the probability of cost-effective-
ness for each strategy at each threshold. 
2.4.3 Costings and utilities
For those with active, subclinical or latent TB, we estimated:
• The monetary cost to the NHS of diagnosis, treatment and ongoing care 
due to a new diagnosis of TB infection (calculated as the product of blood 
tests, further investigations, new clinic appointments, plus time with TB 
nurses, ad hoc attendances to the Emergency Department and Ian Charleson 
centre and NHS national tariffs)
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• Adverse events due to latent and active TB treatment
• Quality of life scores on those with and without LTBI or active/subclini-
cal TB and those on treatment for LTBI and active/subclinical TB (using 
Euro-QoL/EQ-5D)
2.4.4 Progression rates and efficacy of testing
We estimated the progression rate of those with positive TST and IGRA based 
on the number who progress to active TB and time after testing.
We also calculated the efficacy of testing by comparing those enrolled in the 
study with LTBI and who took LTBI preventive treatment, compared to those who 
did not begin or complete treatment and those who attended the Ian Charleson 
Centre but did not take part in the study.
2.5 Statistical methods
Data were analysed using SPSS version 20 (IBM SPSS Statistics, USA) for Mac, 
or Excel 10 for Windows and Excel 2011 for Mac (Microsoft, Seattle, USA). Data 
were expressed using mean and standard deviation for parametric data and 
median and interquartile range for non-parametric data. Data were assessed for 
normality using histograms.
Non-parametric data were compared with the Mann-Whitney U test and 
proportions compared with the Pearson Chi-Squared test.
Economic modelling was performed in Excel 10 for Windows or Excel 2011 
for Mac. 
Statistical analyses were reviewed by Dr Colette Smith (Lecturer in Biostatistics, 
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Department of Infection and Population Health, University College London) and 
economic analyses by Professor Stephen Morris (Professor of Health Economics, 
Department of Applied Health Research, University College London).
2.6 Funding
Funding was provided by the Royal Free Department of HIV and Thoracic 
Medicine. 
TSpot.TB tests were paid for by the Royal Free Department of HIV and Tho-
racic Medicine at a negotiated price. There was no other transfer of funds to 
external sites.
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CHAPTER 3: COST EFFECTIVENESS OF TESTING FOR 
LATENT TB INFECTION 2000-2010
3.1 Introduction
Testing and treatment for latent TB infection (LTBI) in HIV infected individuals 
is recommended by national guideline bodies in Europe and North America. In 
2011, the National Health Institute for Health and Care Excellence (NICE) and 
the British HIV Association (BHIVA) published advice, although their strategies 
differed. [42,43]   
In previous retrospective studies, Black African ethnicity and low blood CD4 
count (<500 cells/µL) were found to be the greatest risk factors for the develop-
ment of active TB disease. [31,76] In the UK, BHIVA guidance (2011) advises very 
targeted testing with an IGRA alone, depending on country of origin, blood CD4 
count and duration of ART) (Figure 3.2.3a) [31,42,76] NICE 2011 recommended 
targeted testing in any HIV infected individuals with a blood CD4 count <500 
cells/µL irrespective of ethnicity of place of birth. [43] In 2016, this was updated 
to include at least an IGRA in all those with HIV plus TST in at least those with 
blood CD4 <200 cells/µL. Other national guidelines (including European) sug-
gest testing all attendees at HIV clinics with either a tuberculin skin test (TST) 
or a blood interferon gamma release assays (IGRA). The strategies had not been 
compared previously for cost-effectiveness. 
Sustained anti-retroviral therapy (ART) appears to reduce progression to active 
TB by up to two-thirds. [59,212] Over the past decade, the demographics of the 
UK HIV population have changed, with fewer new HIV diagnoses in migrants 
from high HIV and TB prevalence areas. [213]
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We sought to compare the utility and cost-effectiveness of testing: all HIV 
clinic attendees with a single IGRA, NICE 2011 and BHIVA 2011 latent TB testing 
strategies using HIV clinic data obtained during two consecutive time periods: 
2000-2005 and 2005-2010. Five-year ranges were selected as ART usage became 
increasingly widespread and national HIV demographics were changing in the 
UK. We expressed the outcomes in incremental cost per case averted (ICCA - 
the extra cost required by one strategy compared to another to avert one case 
of active tuberculosis) and incremental cost per QALY gained. The predictive 
accuracy of health economic models depend on their ability to model factors 
that contribute to future need, and these may change over time.
3.2 Methods
3.2.1 Setting and selection
Demographic and clinic data were obtained from the Royal Free HIV Database.
All patients attending the Ian Charleson Centre and the Royal Free HIV inpa-
tient service from 2000 to 2010 were included, other than those who had been 
given a diagnosis of active TB disease before, or within 3 months of their HIV 
diagnosis. Three months was used in the model to ensure that all subjects under 
follow up would have had time to be assessed for LTBI prior to a subsequent 
diagnosis of active TB.
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3.2.2 Data source
The Royal Free Hospital HIV Database contains information prospectively 
gathered from all patients receiving care. Routine testing for latent TB infection 
between 2000 and 2010 was not performed in people with HIV infection in this 
centre. Using clinical and demographic data between 2000 and 2005, and then 
2005 to 2010, we modeled: a) no testing, b) NICE 2011, c) BHIVA 2011 strategies 
and d) testing all patients with a single IGRA to assess the costs and benefits 
of testing for LTBI. Costs of testing the clinic for LTBI, for preventive treatment 
and treating active TB cases were calculated. Benefits were measured in terms 
of active TB cases prevented and quality-adjusted life years (QALYs). The incre-
mental cost per case averted (ICCA) and incremental cost per QALY gained 
were calculated for each strategy. For the 2000–2005 model, all patients eligible 
for testing under BHIVA or NICE guidance were tested based on their first CD4 
count in 2000. We used each subsequent CD4 count as a surrogate for an HIV 
clinic appointment – usually every 3-6 months, and those not initially eligible 
would be tested as soon as they satisfied the requirement for testing using the 
relevant guideline criteria (Figure 3.2.3a). The CD4 follow up continued until 
the end of December 2004 and cases of active TB disease recorded. The same 
analysis was performed using 2005–2010 data.
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3.2.3 Model structure and assumptions
We assumed:
• All HIV infected patients would be eligible except those with an active TB 
diagnosis in before or within 3 months of their HIV diagnosis
• Initial testing would occur in 87% of those eligible [77]
• Subjects were only tested once, but assuming 3% had an indeterminate 
IGRA result and would require a repeat test [172]
• 13% of subjects from subSaharan Africa, 10% from middle TB incidence 
countries and 3% from low TB incidence countries would have a positive 
IGRA/TST [77]
• Sensitivity of IGRA was 91% [175]
• Uptake of LTBI preventive treatment with 6 months isoniazid was 87% 
with effectiveness 62% [71]
• QALY reductions for active and latent TB were 0.676 and 0.007 respectively 
using estimates generated in the NICE guidelines (See table 3.2.3c) [214]
Costs were measured using an English National Health Service perspective in 
2011/12 £ sterling. We measured the costs of IGRA, TST, six months treatment 
with isoniazid, and treatment for active TB using costs from the British National 
Formulary and published estimates. [43,215] The additional cost of antiretroviral 
therapy in any in subjects with TB/HIV coinfection who had no other indication 
for starting ART was not included. Unit costs were based on published sources 
and local hospital charges (Table 3.2.3c). The time horizon was lifelong, although 
TB follow up data were available for 5 years. Costs and benefits were discounted 
at 3.5% per year. [178]
Num
bers m
arked in italics represent the num
ber of subjects at each stage using hospital cohort data between 2000-2005.
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Cost IGRA (based on 
T.Spot.TB test) £60  £23-£90 Gamma 10.10 5.94
[43], [133] 
local charges
Cost TST £16.14 £8.08-£32.28 Gamma 15.35 1.05 [43]
Cost 6 months isoniazid £786.5  £374.50-£1316.50 Gamma 13.99 56.18
[43],[215], 
local charges
Cost treatment for active TB £7619.67 £3809.93-£15239.30 Gamma 15.37 495.86 [183]
QALY reduction for active 
TB 0.676
0.271 to 
6.72 Gamma 16.72 0.0404 [[43][195]
QALY reduction for latent TB 0.007 0.001 to 0.1 Gamma 7.530 0.0009 [43]
Sensitivity of IGRA 91% 70%-100% Beta 710.8 71.16 [175]
Uptake testing 87% 87%-100% Beta 519.1 79.87 [77]
Uptake LTBI treatment 87% 60%-100% Beta 39.13 5.870 [77]
Efﬁcacy LTBI treatment 62% 40%-100% Beta 1474 903.3 [71]
Indeterminate IGRA rate 3% 0%-10% Beta 20.03 569.0 [172]
Proportion of black Africans 
with positive IGRA 13% Beta 16.9 113.1 [77]
Proportion of subjects from 
middle TB incidence 
countries with positive IGRA
10% Beta 7.8 70.2 [77]
Proportion of subjects from 
low TB incidence countries 
with positive IGRA
3% Beta 7.23 233.8 [77]
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3.2.4 Cost-effectiveness
Cost-effectiveness was measured in terms of the ICCA and the incremental cost 
per QALY gained over each five-year period; and calculated separately for each 
of the time periods (2000-2005, 2005-2010). Incremental analyses of the BHIVA 
strategy versus no testing, NICE versus BHIVA strategies, and testing all attend-
ees versus NICE were performed.  Cost-effectiveness ratios were calculated as 
the difference in costs between the two strategies being compared, divided by 
the difference in outcomes (cases of active TB disease, QALYs).
3.2.5 Sensitivity analysis
3.2.5.1 Univariate and multivariate analyses
Costs for IGRA, TST, treatment of latent and active TB were varied to reflect 
the additional expense of increased TB-related morbidity, isoniazid-induced 
hepatotoxicity or TB drug resistance. The uptake of testing, sensitivity of IGRA, 
uptake and effectiveness of isoniazid preventive therapy (IPT) were varied using 
published data. The effectiveness varied between 40% (an estimate, given non-op-
timal adherence) and 100% (a figure approached in a study in East London in 
2014). [76,77] Quality of life utility was also varied for LTBI preventive treatment 
and active TB treatment. Most-costly and least-costly multivariate scenarios were 
considered (Table 3.2.3c). 
A probabilistic sensitivity analysis (PSA) with 10,000 Monte Carlo simulations 
of the model was also performed and uncertainty ranges for each point estimates 
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of cost-effectiveness and cost-effectiveness acceptability curves were calculated, 
showing the probability that each option was cost-effective for different cost-ef-
fectiveness thresholds. This analysis accounted simultaneously for uncertainty 
in uptake, IGRA sensitivity, incidence of TB, detection rate of each strategy, costs 
and quality of life years lost for TB infection. The distributions and parameter 
values used are given in Table 3.2.3c.
3.3 Results
The Royal Free HIV clinic cohort consisted of 1136 individuals in 2000, 2025 
in 2005 and 2461 in 2010. 689 (61%) were on ART consisting of three drugs in 
2000, 1505 (74%) in 2005 and 2119 (86%) in 2010.
3.3.2 Cases of active tuberculosis with HIV infection
Between 2000–2010, there were 256 cases of tuberculosis with HIV co-infec-
tion at this centre. Seventy-two (28%) had a TB diagnosis ≥ 3 months after their 
HIV diagnosis. Of these, 38 (53%) had culture confirmed TB, sensitive to all first 
line anti-tuberculosis drugs, one of isoniazid resistant TB and one of multidrug 
resistant TB.
3.3.3 Cases not prevented by testing guidelines
Had either BHIVA or NICE strategies been used, neither would have tested all 
people that would later develop active tuberculosis. When compared to BHIVA, 
NICE’s broader criteria predicted more cases consistently (Figure 3.2.3a and 
Table 3.3.4a), although the costs associated with testing were higher. Five of the 
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six cases that would not have been tested by NICE were already taking ART or 
had interrupted ART. Two of the six were UK born. Twenty-two of the 31 cases 
not eligible for testing using BHIVA criteria were born in the UK, whilst 28 were 
using ART or had interrupted ART when diagnosed with active TB.
3.3.4 Comparative cost effectiveness 2000–2005 and 2005-2010
Between 2000–2005, 37 patients known to be HIV positive and undergoing 
care at the Royal Free Hospital developed active tuberculosis. Over five years, 
using BHIVA criteria, 1147 subjects would be tested and 12 of 37 (32.4%, 95% 
confidence intervals, CI 18.0, 49.8%), who later developed tuberculosis would not 
have been tested. Using the NICE testing model, 1752 subjects would have been 
tested, including 34 of the 37 patients with TB disease (8.1% not tested, 95% CI 
1.7, 21.9%). Allowing for an uptake of testing of 87%, testing all eligible subjects 
over five years, plus treating those with latent tuberculosis as well as the active 
TB cases missed by testing, would cost  £315,594, £329,854 and £349,940 using 
BHIVA and NICE guidance and testing all clinic attendees respectively (Table 
3.3.4a). These equate to an extra £143 (BHIVA), £149 (NICE), £158 (all) in costs for 
each person attending the HIV clinic. Compared to no testing, 6.4 QALYs would 
be gained with BHIVA guidance, 8.9 with NICE and 9.6 testing all. Comparing 
BHIVA to no testing, NICE to BHIVA, and all to NICE, the incremental cost-effec-
tiveness ratios were £ 5,225 (95% uncertainty ranges, UR £2,902 to £6,553), £5,832 
(£3,442 to £15,678) and £27,894 (£5,746 to £137,099) respectively (Table 3.3.4b). 
Using 2005–2010 data, 35 patients developed tuberculosis. Using BHIVA crite-
ria, 1,240 subjects would be tested and 11/35 (31.4%, 95% CI 17.4, 49.4) who later 
developed TB would not have been tested. Using NICE guidance, 2,228 subjects 
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would have been tested including 30/35 subjects with subsequent TB (14.3% not 
tested, 95% CI 5.4, 31.1%). Discounted QALYs gained by testing were 6.4 with 
BHIVA, 8.2 with NICE and 8.8 testing all and the incremental costs per QALY 
gained (95% UR) were £7,777 (£4,497 to £9,965), £27,137 (£20,888 to £55,209) and 
£61,723 (£16,354 to £554,778) (Table 3.3.4b).
3.3.5 Sensitivity analysis
LTBI testing became more cost effective as the cost of an IGRA fell, the uptake 
or effectiveness of LTBI preventive treatment increased, or the cost of treatment 
for active tuberculosis rose. The IGRA indeterminate rate made little difference. 
If an IGRA cost £25, LTBI preventive treatment was 98% effective, or treatment 
of one case of active TB increased to £11,600, testing for LTBI between 2000–2005 
using any strategy became cost-saving compared to no testing (see Tables 3.3.5c 
and d, Figure 3.3.5e). 
The cost effectiveness acceptability curves, derived from the probabilistic sen-
sitivity analysis, are shown in Figures 3.3.5a and b for the time periods 2000-2005 
and 2005-2010 respectively. These indicate that if a health service were willing 
to pay an extra £20,000 for an additional QALY,[178] the NICE strategy would 
most probably be best value between 2000 and 2005, and the BHIVA strategy 
between 2005-2010 (Figures 3.3.5a and b).
Table 3.3.4a Cases and costs of no testing, testing using BHIVA and 
NICE strategies and testing all attendees 
Data from 2000–05 (n=2,209) and 2005–2010 (n=2,902)

















Total cases of 
active TB under 
testing strategy
37 35 26 24 23 21 21 20
Total cost for of 
testing for LTBI £0 £0 £61,672 £66,673 £101,028 £124,440 £118,773 £156,035
Average cost/
patient of testing 
for LTBI
£0 £0 £28 £23 £46 £43 £54 £54
Total cost of 
preventive 
treatment





£0 £0 £24 £22 £26 £27 £31 £33
Total cost of 
remaining active 
cases





£128 £92 £91 £64 £78 £56 £73 £53
Total cost £281,928 £266,688 £315,594 £316,180 £329,854 £364,983 £349,940 £405,813
Average cost/
patient of entire 
strategy
£128 £92 £143 £109 £149 £126 £158 £140
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Table 3.3.4b Comparative testing comparing BHIVA strategy to No testing, 
NICE strategy to BHIVA strategy and testing all attendees to NICE
BHIVA vs No 
testing















testing £61,672 £66,673 £39,357 £34,863 £17,745 £31,595
Cost of 
preventive 





































£15.24 £17.06 £6.46 £16.82 £9.09 £14.07































Cost effectiveness, discounted at 3.5%/year  
(95% uncertainty ranges) 
Increment























































































































































































































































































































































































































































































































































































































































































Table 3.3.5c Univariate sensitivity analysis (Cost/case averted)
Variable BHIVA to No testing NICE to BHIVA All to NICE
2000-2005 2005-2010 2000-2005 2005-2010 2000-2005 2005-2010
Middle inputs £3,331 £4,896 £3,792 £16,573 £16,503 £33,534
TST £8.06 £3,331 £4,896 £2,884 £15,784 £19,308 £35,442
TST £32.28 £3,331 £4,896 £5,608 £18,151 £10,893 £29,719
IGRA £23 Cost saving £828 Cost saving £5,448 £4,053 £15,179
IGRA £90 £6,381 £8,194 £8,118 £25,593 £26,595 £48,416
LTBI £374.50 £589 £1,593 £3,231 £14,138 £11,316 £25,383
LTBI £1316.50 £6,858 £9,144 £4,514 £19,706 £23,173 £44,018
Active £3809.93 £7,333 £8,898 £7,665 £20,420 £20,490 £37,521
Active £15239.33 Cost saving Cost saving Cost saving £8,880 £8,525 £25,560
LTBI efficacy 0·4 £9,564 £11,991 £10,138 £29,920 £29,964 £56,363
LTBI efficacy 1 Cost saving Cost saving Cost saving £7,352 £7,200 £17,761
Uptake of testing 60% £3,331 £4,896 £3,792 £16,573 £16,503 £33,534
Uptake of testing 100% £3,331 £4,896 £3,792 £16,573 £16,503 £33,534
Uptake of LTBI treatment 
60% £8,423 £10,692 £2,173 £15,664 £23,052 £45,193
Uptake of LTBI treatment 
100% £1,853 £3,213 £4,262 £16,838 £14,600 £30,149
Sensitivity of IGRA 70% £6,715 £8,748 £7,237 £23,818 £23,810 £45,927
Sensitivity of IGRA 100% £2,299 £3,723 £2,742 £14,365 £14,274 £29,757
Indeterminate rate 10% £3,720 £5,317 £4,344 £17,725 £17,791 £35,434
Indeterminate rate 0% £3,130 £4,679 £3,508 £15,980 £15,838 £32,556
Least expensive testing, 
most expensive costs Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving
Most expensive testing, 
least expensive costs £49,952 £57,483 £29,302 £72,237 £90,613 £164,726
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Table 3.3.5d Univariate sensitivity analysis (Cost/QALY gained)
Variable BHIVA to No testing NICE to BHIVA All to NICE
2000-2005 2005-2010 2000-2005 2005-2010 2000-2005 2005-2010
Middle inputs £5,225 £7,777 £5,832 £27,137 £27,894 £61,723
TST £8.06 £5,225 £7,777 £4,435 £25,845 £32,637 £65,235
TST £32.28 £5,225 £7,777 £8,623 £29,720 £18,413 £54,702
IGRA £23 Cost saving £1,317 Cost saving £8,922 £6,852 £27,939
IGRA £90 £10,010 £13,015 £12,483 £41,907 £44,957 £89,114
LTBI £374.50 £924 £2,532 £4,968 £23,149 £19,128 £46,722
LTBI £1316.50 £10,758 £14,525 £6,943 £32,267 £39,171 £81,020
Active £3809.93 £11,503 £14,133 £11,788 £33,436 £34,635 £69,062
Active £15239.33 Cost saving Cost saving Cost saving £14,540 £14,412 £47,046
LTBI efﬁcacy 0·4 £15,521 £19,853 £15,938 £52,051 £55,086 £120,364
LTBI efﬁcacy 1 Cost saving Cost saving Cost saving £11,568 £11,530 £29,843
Uptake of testing 60% £5,225 £7,777 £5,832 £27,137 £27,894 £61,723
Uptake of testing 100% £5,225 £7,777 £5,832 £27,137 £27,894 £61,723
Uptake of LTBI treatment 
60% £13,213 £16,983 £3,343 £25,648 £38,966 £83,181
Uptake of LTBI treatment 
100% £2,906 £5,104 £6,554 £27,569 £24,680 £55,493
Sensitivity of IGRA 70% £10,728 £14,208 £11,263 £40,286 £42,088 £91,383
Sensitivity of IGRA 100% £3,587 £5,873 £4,202 £23,295 £23,812 £53,547
Indeterminate rate 10% £5,836 £8,446 £6,681 £29,023 £30,073 £65,219
Indeterminate rate 0% £4,910 £7,433 £5,394 £26,166 £26,772 £59,922
QALY loss active TB 0.271 £14,328 £21,803 £15,463 £80,561 £88,440 £242,470
QALY loss active TB 6.72 Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving
QALY loss latent TB 0.001 £4,968 £7,314 £5,640 £24,860 £24,854 £51,038
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At an incremental cost per QALY gained cost-effectiveness threshold of £20,000-
£30,000, and using data from 2000-2010, testing and treating latent tuberculosis in 
people with HIV (using ART in the majority of cases) appeared to be cost-effective 
with respect to no testing in a low TB incidence, high resource setting. [178] Of 
the four strategies compared, testing based on NICE criteria was the most cost-ef-
fective option using 2000-2005 data at a cost-effectiveness threshold of £20,000/
QALY and testing all clinic attendees at £30,000/QALY (Figure 3.3.5a). Between 
2005-2010, the BHIVA strategy was most likely cost-effective at a threshold of 
£20,000 and NICE at £30,000. Testing all clinic attendees became considerably 
less cost effective in this time period (Figure 3.3.5b). This change could have 
resulted from altering UK HIV demographics (e.g. as there were proportionally 
fewer HIV infected individuals in the UK from TB endemic countries) or from an 
increase in ART usage, which would reduce the risk of progression from LTBI to 
active TB. [54,213] For example – one third of our clinic population now have a 
blood CD4 cell count under 500 µL. If these changes are representative of other 
low TB incidence settings and continue, testing may become less cost effective 
in future, irrespective of the strategy selected. 
Of note, even with optimal implementation, our data indicate that these testing 
strategies would prevent only around one quarter of recorded cases of active 
tuberculosis. The majority of patients with HIV co-infection in the UK do not 
know their HIV status when they initially present with active TB disease and 
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are diagnosed with HIV subsequently. [54] These patients tend to access HIV 
care at a later stage in their illness, have a lower blood CD4 count and higher 
disease associated morbidity and hence treatment costs. [54] A possibly more 
effective strategy may involve community-based HIV testing, and then if posi-
tive, subsequent assessment for TB.
3.4.2 Limitations, criticisms and assumptions
This cost-effectiveness analysis is based on retrospective data and is not a 
contemporary, prospective study of LTBI preventive therapy versus placebo in 
people living with HIV with positive TST or IGRA. It did, however, reflect the 
cost-effectiveness of testing over a decade and showed that external factors may 
influence this relatively rapidly, and these factors should be acknowledged when 
modelling to influence guidance. Although a five-year outcome was used in this 
study to illustrate the changes over time, LTBI preventive therapy is likely to 
lead to benefit over a longer time period.
A number of assumptions were used. Costings were used for TB cases without 
HIV coinfection as there is little in the published literature for cases of TB/HIV 
coinfection. Previous studies have suggested an increased morbidity and mor-
tality, and more drug-interactions associated with TB/HIV coinfection. [68,216] 
If there were an increase in treatment cost and decrease in the quality of life 
associated with coinfection, systematic LTBI testing could be justified further. 
Also, HIV care in the UK already involves regular follow up, and testing and 
preventive treatment for other opportunistic infections (such as Pneumocystis 
pneumonia or toxoplasmosis) has become an intrinsic part of this. Similarly, 
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LTBI preventive treatment may be relatively easy to incorporate, requiring fewer 
resources than LTBI testing and treatment than other contexts such as amongst 
TB contacts or new entrants. Finally, the cost-effectiveness of preventing onward 
transmission using LTBI preventive therapy was not included here.   
The costs of hepatotoxicity related to preventive TB treatment and active TB 
treatment were not specifically determined, but the increased costs associated 
with this were included within the sensitivity analysis. In this model, an IGRA 
cost £60, the hospital list price for a TSpot.TB test. The actual costs for this assay 
may be less and could also fall if using the QuantiFERON Gold In-Tube, which 
tends to be less expensive. It is not clear if the two tests have equivalent sensi-
tivity or indeterminate result rates in this population. [163,167,217]
Again, due to lack of data in people with HIV, QALY reductions from TB cases 
without HIV coinfection were used. A recent study has shown a similar loss in 
quality of life measured by EQ-5D in those with active drug-sensitive TB with 
or without HIV coinfection in Thailand. [200] Our analysis has been from a clin-
ical perspective and has only used the potential costs and health status in those 
subjects tested. We have not included potential cases prevented in contacts and 
the monetary or quality of life costs associated with this. From a public health 
position, the appropriateness of a £20-30,000/QALY or £12-19,000/case averted 
ceiling could be questioned.
3.4.3 Implementation
Previous studies have reported difficulties in implementation of systematic 
LTBI testing in HIV, both at a clinic and patient level. In the Swiss Cohort Study, a 
programme to treat latent TB resulted in only 37% of HIV patients with a positive 
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TST receiving a full course of such therapy. In part this was due to physicians’ 
poor adherence to the recommendation. [76] In those that were given preventive 
treatment, however, there were no subsequent cases of active TB, a finding that 
has been mirrored in more recent studies from Western Europe. [77,174] Our 
assumptions of uptake and LTBI treatment completion are based on contempo-
rary studies from London;[77] however, by using results from a meta-analysis 
on TST positive HIV infected individuals, comparing LTBI treatment against 
placebo, we may have underestimated the efficacy of LTBI treatment in people 
with a positive IGRA (as modelled here) and hence the cost-effectiveness of 
testing. [71,77] As technologies to detect LTBI improve, the potential for a test 
with a better positive predictive value for the development of active TB would 
further reduce the costs and morbidity associated with LTBI treatment.
3.5 Conclusion
Retrospective data between 2000-2010 show that testing for tuberculosis infec-
tion in those with a known HIV diagnosis seems cost-effective using either NICE 
2011 or BHIVA strategies, both of which were published in 2011 and drew on 
data from 1996-2006. Using our clinic data from 2000-2005, the NICE strategy is 
simple, less likely to miss cases and cheaper to implement than universal test-
ing. This has reduced the cost effectiveness of testing. Checking for latent TB in 
known HIV infected persons cannot impact on the majority of cases of TB-HIV 
co-infection who are diagnosed with both conditions simultaneously. This argues 
for more population-based HIV testing, with subsequent TB risk assessment and 




CHAPTER 4: STUDY RESULTS
4.1 Introduction
4.1.1 Testing for TB disease and LTBI in HIV infected individuals
HIV is the single greatest risk factor for the development of active TB. Testing 
for both active and latent TB in people living with HIV has been recommended 
since this was first realised. [41,218] Guidelines in resource rich, low TB preva-
lence countries around the world differ, however. The United States Center for 
Disease Control (CDC) have very comprehensive advice that tests for active 
disease and latent infection, whereas the British HIV Association (BHIVA) guid-
ance tests for LTBI just in those at the highest risk of reactivation. [41,42] Over 
the past five years, the number of TB diagnoses in people with HIV has fallen in 
the UK annually, perhaps as a result of a change in UK HIV demographics and 
increasingly widespread use of antiretroviral therapy. [59,219]
4.1.2 Use of TST and IGRA
The British HIV Association (BHIVA) guidelines, published in 2011, were 
based on a large retrospective epidemiological cohort study from various UK 
HIV centres (UK CHIC) and the results of a national TB testing strategy, using the 
tuberculin skin test (TST), in HIV clinics in Switzerland. [31,220]  Since this study, 
Interferon-gamma release assays (IGRA) have been adopted more widely due to 
their relative convenience and increasing evidence base. Many groups have pub-
lished studies comparing these tests when investigating the prevalence of LTBI. 
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Some have used preventive therapy, where as some studied the outcomes in this 
group when left untreated. [146,165,171,174,175,220-222] Medium and long term 
follow-up data are relatively sparse, and it remains unclear whether IGRA pre-
dicts subsequent active TB in a manner to TST. [171,175,221,222] The prevalence 
of active TB disease and latent TB infection across European centres, however, 
have been surprisingly similar using either test. LTBI is detected in 13-24% of 
black Africans and in around 3% of white Western Europeans. [77,172,175,222] 
4.1.3 Rationale of testing strategies
Many of these studies start with an immunological test as a first step, then 
investigate only those with a positive result for active TB. Some individuals 
with a positive TST or IGRA were found to have active or clinically unapparent 
(subclinical) TB at the time of testing (so called prevalent TB). Since only those 
with a positive TST/IGRA were investigated for active disease, the prevalence 
subclinical TB in those that are TST/IGRA negative is unknown. Frequently these 
studies have investigated the impact of LTBI preventive therapy, and people 
with previously treated TB were therefore excluded. [77,175] 
Despite the number of studies of TB testing in HIV-infected adults in low TB 
prevalence areas, none of the guidelines have been compared for cost-effectiveness. 
4.1.4 Aim of the study
In this cross-sectional study, we sought to determine the prevalence of LTBI 
(with both TST and IGRA), subclinical and active TB; the uptake and yield of 
testing; quality of life data and costings, to determine the feasibility and cost-ef-
fectiveness of TB testing in a representative, contemporary UK HIV clinic. 
111
4.1.5 Hypotheses
1. There is a significant difference in the prevalence of TB infection between 
black Africans and those from low TB incidence countries attending a UK HIV 
clinic.  
2. Tuberculin skin testing provides no further information compared to single 
step blood Interferon Gamma Release Assay in the detection of M. tuberculosis 
infection in a UK HIV-infected clinic population.
3. Within this clinic population, asymptomatic HIV-infected individuals with 
normal chest radiographs have negative mycobacterial sputum microscopy and 
culture despite originating from high TB prevalence areas. 
4.1.6 Objectives
1. Determine the feasibility of systematic testing for M. tuberculosis infection 
in a UK HIV-infected population
2. To determine the prevalence of subclinical and active TB in a UK HIV clinic
3. To determine the sensitivity and specificity of systematic screening ques-
tionnaires for detecting cases of active TB outside of high TB incidence settings
4. To determine concordance between TST and blood TSpot.TB in latent TB 
infection
5. To identify risk factors for latent TB infection in the clinic population
6. To determine the sensitivity and specificity of Xpert MTB.RIF polymerase 
chain reaction (PCR) testing of sputum and induced sputum compared to myco-
bacterial microscopy and culture
7. To determine uptake of latent TB therapy (6 months isoniazid treatment)
8. To determine cost of latent TB treatment (including screening costs, clinic 
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time)
9. To determine quality of life and rate and severity of adverse events on latent 
TB treatment
Airways disease
10. To determine the underlying frequency of airways disease (using spirom-
etry) and of respiratory symptoms
4.2 Methods
4.2.1 Study design
1. Cross-sectional study to assess the prevalence of active, subclinical and latent 
tuberculosis in people living with HIV undergoing care at the Royal Free Hospital
2. Quality of life and subsequent economic analysis of systematic TB testing 
and latent tuberculosis treatment in this group 
3. Establishment of baseline measures for a cohort that can be followed over 
time while receiving long-term HIV care
4.2.2 Study population
Selection criteria were:
Ambulatory care patients at the Royal Free Hospital with HIV-1 or 2 positive 
antibody and over the age of 18, and: 
a new diagnosis of HIV during dates of recruitment, or 
in care and attending routine ambulatory HIV care clinics, selected by strat-
ified sampling. 
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Recruitment was carried out at the Ian Charleson Centre for HIV care at the 
Royal Free Hospital. Subjects were approached either before or after their routine 
appointments by their clinician or the researchers. Further details plus inclusion 
and exclusion criteria are listed in Chapter 2 (Methods), section 2.3.3.
All female participants under the age of 50 were asked to have urinary bHCG 
testing before frontal chest radiograph.
4.2.3 Data sources
Participants were asked to self-complete a questionnaire, including basic 
demographics, previous countries of residence, previous: education, occupation, 
history of TB exposure, smoking and drug use, other medical conditions and 
use of prescription medications other than antiretrovirals. A baseline quality of 
life score (EQ5D) was also requested. 
Antiretroviral use was taken from pharmacy records. 
Full blood count; creatinine and glucose measurements; plasma HIV viral load; 
nadir, previous and most recent blood CD4 cell counts were extracted from the 
pathology database. Previous CXR reports were taken from the radiology (PACS) 
system. HIV risk factors, nadir blood CD4 cell counts, viral loads at diagnosis 
and time from HIV diagnosis were extracted from the Royal Free HIV database.
At the time of enrolment subjects were asked to have:
• A frontal chest radiograph (CXR)
• Blood sampling for blood IGRA (TSpot.TB, Oxford Immunotec, Abingdon, 
Oxfordshire) with two lithium heparin tubes and other research blood 
tests for cytokine and RNA analysis (a further lithium heparin and two 
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3ml EDTA vials)
• Tuberculin skin testing (TST): 0.1ml purified protein derivative (Statens 
Serum Institute, Copenhagen, Denmark) was injected intradermally and 
instructions given on how to interpret the result in the case of non-reatten-
dance. Some participants agreed to sputum induction the same morning, 
some when they returned to have their TST measured 48-72 hours later
• Baseline spirometry, examination for BCG scar and limited cervical lymph 
node examination 
• Sputum induction, using 3.5% hypertonic saline was performed with repeat 
spirometry at 5 minutes for safety. Further details are in Methods Chapter 
2, Section 2.3.4
No routine bronchodilators were used before spirometry. If subjects had a 
history of bronchospasm, they were asked to pre-medicate with salbutamol. 
Participant results could be used in the analysis if they consented, provided 
a questionnaire and a blood IGRA or TST result was available. 
4.2.4 Definitions
Black Africans (BA) were defined as people born and raised in countries in 
subSaharan Africa (sSA), approximating to a national active TB disease incidence 
of >300/100,000. Middle incidence (MI) countries were defined as those outside 
of subSaharan Africa (including South America, South and East Asia and East-
ern Europe) approximating to countries with a TB incidence of 30-300/100,000. 
Low incidence (LI) included Western Europe, North America and Australia, 
approximating to a TB incidence <30/100,000.
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Active TB disease was defined as symptoms consistent with TB, radiographic 
changes and positive sputum microbiology for M. tuberculosis or a positive 
XpertTB.RIF. Subclinical TB was defined as positive sputum microbiology for 
M. tuberculosis or a positive XpertTB.RIF but without symptoms, with or without 
radiographic changes. Latent TB infection was defined as a positive tuberculin 
skin test (≥5mm) and/or positive blood IGRA in those without a prior history 
of treated TB and with an absence of symptoms or radiographic changes. 
4.2.5 Power calculation and statistics
The study was powered to show a difference in the prevalence of TB infection 
between black African (13% prevalence) and subjects from low TB incidence (LI) 
areas (3% prevalence), based on data by Kall et al. [77] The power calculation 
estimated 180 black African subjects and 120 patients from low TB incidence 
areas would have to be recruited, with a power of 80%, a 5% chance of a Type I 
error and allowing for a 20% drop out rate. To achieve this, the study pool would 
have to be enriched by recruiting only black African and subjects from middle 
TB incidence (MI) areas after enrolling 120 LI participants. This would involve 
only recruiting BA and MI participants after this point.
Statistics were performed using Excel 11 for Mac, Excel 10 for Windows (Mic-
rosoft) and SPSS 20.0 for Mac (IBM Systems). Demographics were compared 
using the Chi-Square test (proportions) and Mann-Whitney U tests (medians). 
Confidence intervals were calculated using an exact binomial distribution. 
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4.2.6 Ethics
The study was sponsored by University College London, approved for R&D 
by Royal Free/UCL Joint Research Office and Ethics approval was granted by 
the City and East Ethics Committee on the 16th November 2012. REC reference 
12/LO/1516; UCL protocol number 12/0212; ‘Study of systematic TB testing 
for active, sub-clinical and latent tuberculosis infection in a UK HIV-infected 
cohort’. Clinicaltrials.gov number was NCT02712671. There was no outside 
funding provided for the study.
The study was performed at the Royal Free Hospital, London.
All patient assessments were conducted on the hospital site.
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4.3 Results
4.3.1 Place, time period
The study was performed between 10th June 2013 and 6th September 2014 at 
the Ian Charleson Centre for HIV ambulatory care, Royal Free Hospital, London. 
As specified in the protocol, from June to September 2014, only black Africans 
and those from MI countries were approached.
Local TB incidence was 20 per 100,000 population in Camden (41.8/100,000 
London average and 13.9/100,000 in the UK) in 2013 and the HIV prevalence 
6.99 per 1000 population (1.5/1000 for the UK as a whole). [2,19,219,223,224]  
4.3.2 Recruitment
In total, 1205 outpatient attendees were identified from clinic lists to be 
approached, of which 222 did not attend or cancelled their appointment. A fur-
ther 300 patients were missed or left the clinic before being approached, and 683 
were approached to take part. Of these, 158 declined, 90 had contraindications 
to inclusion and 435 agreed. In total, 219 participants attended in the 14 months 
between June 2013 and September 2014. 
4.3.3 Demographics
Of those enrolled, 160 (73%) were male, median age was 46 years, 62 (28%) were 
black African, 31 (14%) from middle TB incidence (MI) countries and 126 (58%) 
from low TB incidence (LI) countries. Forty percent had a reported heterosexual 
HIV acquisition route, 2% injecting drug use (IDU) and 55% men who have sex 




























































































































































































































































































































who were eligible and also to the total Royal Free HIV cohort (Table 4.3.3).
4.3.3.1 ART status
Nine patients (4%) had a new diagnosis of HIV and 210 recruited by stratified 
selection from patients already attending the HIV clinic in established care. 
There were 202 participants (92%) taking antiretroviral treatment (ART), and 
the HIV viral load was ‘undetectable’ (<40 copies/ml) in 186 (85%). In those with 
an undetectable viral load, 51(27%) were black African, 26 (15%) from middle 
TB incidence (MI) countries and 109 (59%) from low incidence countries. The 
median age of this group was 46 years (IQR 41-53) and median blood CD4 count 
was 631 cells/µL (range 534-788). 
4.3.3.2 HIV viral load in participants
Thirty three subjects (15%) had a detectable HIV viral load. Apart from the 
nine patients (27%) with a new HIV diagnosis, a further three (9%) had only 
recently started antiretroviral therapy (ART) (within 6 months), eight (24%) still 
had not started ART, seven of whom had not met indications to start ART yet 
(ART naïve) at the time of the study.
Twelve subjects (36%) either had poor adherence or had elected to take a break 
from ART (none of these advised by a clinician). One patient (3%) had a break-
through viral load due to multi drug resistant HIV. Of these 33, 11 (33%) were 
black African, five (15%) from MI countries and 17 (51%) from LI countries. The 
median age of this group was 44 years (Interquartile range, IQR 35-50), median 
CD4 431 cells/µL (IQR 265-535; range 29-1260) and viral load 4851 copies/ml 
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Female 60 (27%) 229 (30%) 0.42 26%
Median age in years 
(IQR)
46 (41-52) 46 (41-53) 0.859 46 (40-52)
Black African 62 (28%) 213 (28%) 0.78 24.5%
From medium TB 
incidence country
31 (14%) 122 (16%) 18.2%
From low TB 
incidence country
126 (57.5%) 426 (56%) 57.3%
HIV transmission 
Heterosexual
89 (40%) 323 (42%) 0.81 39.7%
Injecting drug user 4 (2%) 12 (2%) 2%
Men who have sex 
with men
122 (55%) 402 (53%) 56%
Other 5 (2%) 24 (3%) 26 (1%)
On antiretroviral 
therapy
209 (95%) 698 (92%) 0.1 92.4%
HIV plasma load 
<50 copies/ml
183 (84%) 667 (88%) 0.05 84.8%
Median blood CD4 
cells/µL (IQR)
643 (449-780) 617 (447-718) 0.567 626 (458-819)
Number with blood 
CD4 <200 cells/µL
5 (2%) 34 (5%) 0.14 4.6%
Number with blood 
CD4 <500 cells/µL
63 (29%) 249 (33%) 0.22 30.6%
BCG vaccinated 179 (85%) Not measured Not measured
Previous TB 18 (8.4%) Unknown 8.8%
Self reported TB 
contact
48 (22%) Unknown Unknown
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(IQR 501–48,183; range 41-7.5 million).
4.3.4 Uptake of testing
4.3.4.1 IGRA 
Results were available for IGRA in 217/219 participants (99%). Two partici-
pants (1%) had an indeterminate first IGRA result. One (0.5%) result remained 
indeterminate on repeat testing. Two participants had no TSpot results, both 
of these failed to be processed in the time period required due to a failure of 
delivery on the courier’s part. One participant declined a repeat, whilst another 
agreed but this sample was delivered to the wrong place again. 
4.3.4.2 TST 
One hundred and sixty-two participants (74%) returned to the hospital to 
have their TST interpreted, 40 (18%) had been given a small plastic ruler and 
instructions on how to interpret their TST result and emailed or telephoned their 
result (read at 48-72 hours). Five (2%) refused to have TST testing and twelve 
participants (5%) did not return to have their TST measured. In all, 202 (92%) 
had TST results. 
4.3.4.3 CXR 




Two hundred and eight participants attended for sputum induction (11 did 
not re-attend), and samples were produced from 178 (85%; 27 subjects were 
unproductive). One participant’s sample leaked in transit. 
One hundred and sixty-one participants (90%) had a XpertTB.RIF result. One 
sample was inhibited and one PCR failed.
4.3.5 Yield of testing
4.3.5.1 IGRA
Of the 216 definitive IGRA results, 12 (6%) were positive. Four of the partic-
ipants with positive results had been treated previously for active TB. Of the 
remaining eight, six were black African and two from middle incidence countries. 
All but one of the 12 subjects also had a positive TST result (≥5mm). Three IGRA 
results (1.4%) were borderline and two (1%) indeterminate (see 4.3.7.6 and 4.3.7.7).
4.3.5.2 TST
Of the 202 TST results, 17 (8%) were positive (≥5mm) of which five (29%) had 
a self-reported history of previous active TB. In those with negative results, 174 
(86%) measured 0mm and 11 (5%) between 1 and 4mm. 
Two hundred and eleven had data relating to BCG status, of which 172 (82%) 
had either a BCG scar or self-reported previous BCG vaccination or both. Of 
these, 137 (80%) had a TST of 0mm, 11 (6%) were 1-4mm, 4 (2%) 5-9mm, 4 (2%) 
10-14mm and 5 (3%) participants had ≥15mm results.
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Figure 4.3.5.2a TST results
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Figure 4.3.5.2b Venn diagram of TST and BCG status 
4.3.5.3 CXR
One CXR was consistent with active TB (bihilar adenopathy), but on further 
investigation using endobronchial ultrasound and cytology, this was diagnosed as 
sarcoidosis. Mycobacterial culture was negative after 42 days. Another CXR was 
reported as possible active TB disease, but a CT scan of the chest was performed 
and reported as having changes consistent with old TB infection. Seventeen 
radiographs (8%) were consistent with possible previous TB (in which four had 
a self-reported history of previous TB), fifteen (7%) with other diagnoses and 




Not consistent with TB






(Later diagnosed as 
sarcoidosis on EBUS)
Consistent old TB
20 (2 IGRA pos)
Acute infection
4 (all IGRA neg)
Fibrosis/scarring 7 







Prominent hila 3 
Bronchial wall thickening 1 
Hyperinﬂated lungs 3 
Large heart 3 
Pericardial cyst 1 
Pleural plaques 1 
Resolving RLL pneumonia 1
Small amount consolidation 2
Bilateral upper lobe consolidation 
(new) 1 (later diagnosed as LIP)
Figure 4.3.5.3 Abnormal CXR results
4.3.5.4 Sputum induction
Of the 178 induced sputum samples produced, two (1%) subjects’ samples 
were culture positive for M. tuberculosis (neither with symptoms or signs of active 
TB and both culture positive at around 40 days). A third participant’s sputum 
cultured M. peregrinum (the patient had previously treated active TB, no history 
of chronic airway disease nor systemic symptoms; CXR showed a granuloma 
only). All XpertTB.RIF results were negative for all three patients’ samples.
126
4.3.6 Diagnoses of active and subclinical tuberculosis
Based on diagnostic criteria, there were no cases of incident active TB (0%; 
95% confidence intervals, CI 0%-1.67%), two cases of subclinical TB (0.9%; 95% 
CI 0.1-3.3%) and 14 cases of LTBI (6.4%; 95% CI 3.2-9.6%). There was a difference 
of 14.4% (CI 4-28%) between the incidence of total TB infection between high 
and low TB incidence countries (p=0.001).
 Table 4.3.6 Results
Prevalence
n=219
Percentage 95% Conﬁdence 
intervals
Active TB 0 0% 0% – 1.67%
Subclinical TB (total) 2/219 0.9% 0.11% – 3.26%
Black African 1/62 1.6% 0.04% – 8.66%
from Middle Incidence 
country 1/31 3.2% 0.08% – 16.7%
from Low Incidence country 0/126 0% 0% – 2.89%
Latent TB (total) 14/219 6.4% 3.16% – 9.64%
Black African 8/62 13% 4.63% – 21.37%
from Middle Incidence 
country 2/31 6.5% 0.8% – 21.4%
from Low Incidence country 4/126 3.2% 0.9% – 7.9%
Previous TB (total) 17/219 7.8% 4.25% – 11.35%
Black African 12/62 19.4% 9.56% – 29.24%
from Middle Incidence 
country 3/31 9.7% 2.0% – 25.8%
from Low Incidence country 2/126 1.6% 0.2% – 5.6%
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4.3.6.2 Descriptions of participants with subclinical tuberculosis
Two participants were found to have subclinical TB.
The first was a 45-year-old man, born in Ethiopia and diagnosed with HIV 
ten years previously, not yet treated with ART. His blood CD4 count was 359 
cells/µL. He worked, was a never-smoker, but had visited Ethiopian/Eritrean 
cafes socially in the UK, although denied doing so in the past six months. He 
had no symptoms of TB disease. His baseline CXR was normal.  His TST result 
was 0mm and TSpot negative (plate A 2 spots, B 0). Sputum was smear negative 
and XpertTB.RIF negative. Blood C-reactive protein (CRP) was <1 mmol/mL. 
At 40 days’ incubation his induced sputum grew M. tuberculosis and Variable 
Nucleotide Tandem Repeat (VNTR) testing revealed this to be a unique strain, 
making laboratory contamination extremely unlikely. 
Two subsequent sputum inductions, at six and 12 weeks after detection of the 
first organism, were both smear and culture negative after 42 days incubation. A 
CT scan of his chest/abdomen/pelvis to look for a site of disease was completely 
normal. Two further TSpot tests at three and six months were also negative. 
He was offered treatment for subclinical tuberculosis (with four drugs), but 
declined and preferred to stay under observation as he had just started ART as 
part of a clinical trial and would have required a medication switch in order to 
take a rifampicin. He has had no subsequent symptoms of active TB disease in 
the 36 months following this.
The second case was in a 28 year old Filipino man who had previously been 
treated for active TB ten years previously in the Philippines. A few weeks before 
enrolment he had a self-limiting cough. Both his TST and TSpot were positive 
(TST 18mm induration, TSpot A3, B24). His CXR showed established upper lobe 
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fibrosis consistent with old TB infection with some possible new subtle nodules. 
Blood CRP was <1 mmol/mL. 
At HIV diagnosis a year previously, he had had a CT scan that had shown 
chronic upper lobe TB changes. A bronchioalveolar lavage for mycobacterial 
culture at that time was negative after 42 days incubation. 
At the time of recruitment, he had been taking ART for 11 months. His most 
recent blood CD4 count was 331 cells/µl and HIV viral load <40 copies/mL. 
Both spontaneous and induced sputum were smear and XpertTB.RIF negative 
but both were mycobacterial culture positive at 41 days, with fully drug sensitive 
M. tuberculosis. This had a unique strain type. He was treated for subclinical TB 
with four drugs, which were fairly well tolerated (see Quality of life, Section 
4.3.11.1), and he made an uneventful recovery.
4.3.6.3 Sensitivity and specificity of symptoms for active and subclinical 
tuberculosis
Of the two cases of subclinical disease, one patient had no symptoms, the other 
had some recent self-limiting cough and sputum plus insomnia.
Due to the lack of no active cases, sensitivity and specificity of symptoms 
could not be calculated. 
4.3.6.4 Prevalence of subclinical tuberculosis by place of birth
The prevalence of subclinical TB (positive sputum culture of M. tuberculosis) 
was 1.6% (CI 0.04%-8.66%) in black Africans, 3.2% (0.08%-16.7%) in those from 
middle TB incidence countries and 0% (CI 0%-2.89%) in those from low TB 
incidence countries.
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4.3.6.5 Risk factors for active and subclinical tuberculosis
Due to the small numbers of cases of subclinical TB, no risk factors were sta-
tistically significant.
4.3.6.6 Use of XpertTB.RIF and time to sputum positivity
All 161 XpertTB.RIF results, including those from patients with subclinical 
disease were negative. The sputum from both individuals with subclinical dis-
ease had time to positive culture of >40 days. 
4.3.7 Diagnoses of LTBI 
4.3.7.1 TSpot and TST outcomes
Fourteen patients (7%) without a history of previous active TB infection had 
evidence of latent TB on TSpot or TST testing. Eight (57%) were black African, 
one Chinese, one white Eastern European, three white British (21%) and one 
black British. One subject had previously worked in healthcare. 
4.3.7.2 Prevalence of LTBI by place of birth
This gave a prevalence of latent TB (by positive TST or IGRA) of 13% (CI 5.7%-
23.9%) in black Africans, 6.5% (0.8%-21.4%) in those from middle TB incidence 
countries and 3.2% (CI 0.9%-7.9%) in those from low TB incidence countries. 
Consequently, the number needed to test for a single positive IGRA was 7.7 in 
black Africans, 15 in those from middle TB incidence countries and 31 for those 
from low TB incidence countries.
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4.3.7.3 Description of cases of LTBI
There were eight black African participants with LTBI. One had CXR changes 
consistent with old TB, was not on ART (blood CD4 712 cells/µL), and had neg-
ative mycobacterial culture from bronchoscopic lavage and induced sputum. 
All of the other black African participants had normal CXR and were taking 
ART with blood CD4 cell counts of >350 (80% over 500) cells/µL. Four (50%) 
had reported TB contact. One participant had already taken a course of LTBI 
preventive treatment after TB contact in Zambia. 
Of the eight Africans with LTBI, one was lost to follow up (history of severe 
depression, obesity, likely returned to his country of origin), three declined LTBI 
treatment, one stopped LTBI treatment due to side effects and three completed 
treatment. 
One patient, male, born in China, had a positive TSpot and TST of 7mm. His 
sister had recently been diagnosed with TB. He had a normal CXR and completed 
LTBI preventive treatment without averse events. Another, a Polish man, was 
taking methotrexate for rheumatoid arthritis. His CXR showed hilar adenopathy 
that spontaneously regressed and was negative on lymph node culture from 
EBUS. His case is discussed in the chest radiographic changes section.
The four patients from low incidence countries with LTBI were all from the 
UK. All had negative TSpots and three of four were BCG vaccinated at school 
age, the fourth unknown (although no BCG scar was seen). Two subjects had 
7mm TST responses (one BCG vaccinated, the other unknown), no TB risk fac-
tors, were taking ART and were adherent (CD4 cell counts were 1501 and 609 
cells/µL), and normal CXRs. Two other subjects (both BCG vaccinated) had 
larger reactions (14mm and 15mm) and both had worked in healthcare at some 















































































































































































































































































point. Both were adherent with ART and blood CD4 counts were 574 and 643 
cells/µL respectively and their CXRs normal. One had diabetes; both started 
and completed LTBI treatment. 
4.3.7.4 Risk factors for LTBI
Univariate analysis revealed that only TB incidence associated with the country 
of origin was associated with latent TB status. Those with a reported TB contact 
had a higher chance of latent TB infection (OR 1.51, CIs 0.452-5.101) but this was 
not significant (p=0.504).
4.3.7.5 Concordance between TST and TSpot
Excluding those with self-reported previous TB, seven subjects had positive 
and two had borderline positive TSpot tests. Of those with positive results, five 
had positive TST and one had no result. Six patients had a positive TST (≥5mm) 
and negative TSpot. All had previously had a BCG vaccination apart from one 
participant who was unsure (and had no visible scar).
Excluding borderline or indeterminate results, a kappa statistic of 0.569 (Stan-
dard Error 0.145), n= 178, p<0.0005, was calculated comparing those with both 
a TSpot result and a TST result  (see Table 4.3.7.5b). 
4.3.7.6 Change in diagnoses with differing TST cut off values
Were a positive TST redefined as ≥10mm, the number of subjects with latent 
TB infection fell to nine from 14. Three of those with positive IGRA and risk fac-
tors for TB infection (two with close TB contact, all three from medium or high 
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Table 4.3.7.4 Univariate analysis of risk factors for LTBI
Age (years); ART - antiretroviral therapy; BCG - self-reported history or scar associated 
with Bacille Calmette-Guerin vaccination; *HIV load undetectable signiﬁes <50 copies/ml; 
**Low TB - originates from low TB incidence country, Medium TB - orginates from medium 
TB incidence country.




Age <40 4 39 2.3 0.48 – 10.61 0.56
Age 40 – 50 7 82 1.9 0.47 – 7.55
Age >50 3 66 1
Female 6 47 2.2 0.74 – 6.77 0.15
On ART 13 164 1.8 0.23 – 14.6 0.57
HIV load 
undetectable 13 161 2.1 0.26 – 16.7 0.47
Low TB** 4 120 1 0.02
Medium TB** 2 26 2.3 0.40 – 13.3
Black African 8 41 5.9 1.78 – 20.5
History of 
smoking 6 100 0.7 0.22 – 1.95 0.44





Figure 4.3.7.5a Venn diagram of TST and TSpot
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TB-incidence countries) would then be TST negative, whilst two of those with 
negative IGRA would become TST negative (neither with any TB risk factors, 
one of whom was BCG vaccinated and the other not). 
The TST/TSpot kappa value would then drop to 0.310 (Standard error 0.179), 
p=0.013.
4.3.7.7 Indeterminate IGRA and results of repeat tests
Two participants had indeterminate TSpot results, both due to spot formation 
in the negative control. The repeat TSpot for Subject 88 was negative (ESAT-6 
and CFP-10 both zero spots, positive control >20). He had: no TB risk factors, 
a blood CD4 count of 1147 cells/µL (45%), undetectable HIV viral load, was a 
non-smoker, had a negative TST (no history of BCG) and normal chest X ray. 
Subject 125 had a repeat TSpot which was also indeterminate. He had no TB risk 
factors, a blood CD4 count of 541 cells/µL (24%), undetectable HIV viral load, 
nadir blood CD4 count of 239 cells/µL, negative TST, had been BCG vaccinated, 
was an ex-smoker and had previous PCP. 
Table 4.3.7.5b 2x2 table TST vs TSpot for those with latent TB infection




Positive 5 1 6
Negative 6 166 172
Total 11 167 178
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4.3.7.8 Borderline IGRA results
Three participants had borderline results. The first had a borderline negative 
result (5 spots on plate B) that on repeat six weeks later was negative; another 
had a borderline positive (7 spots on plate B) but was offered treatment for LTBI 
anyway as she had a positive TST (20mm) and came from a high TB incidence 
country. A third participant had a borderline positive result (6 spots on plate B) 
but a repeat showed a borderline negative result (5 spots on plate B). This sub-
ject had had a BCG in adolescence, had never smoked, previously worked as a 
physiotherapist, his blood CD4 count was 1028 cells/µL (nadir unavailable), his 
TST was 2mm and he was not started on LTBI preventive treatment.
4.3.8 Previous TB disease
4.3.8.1 Self reported previous TB disease
Seventeen subjects (7.8%) had a self-reported history of previous active TB. 
Of these, seven (41%) had TB treated in London – only three cases (18%) had 
been treated in the last ten years. Radiology was consistent with previous TB in 
eight cases (47%) (see Table 4.3.8.1). 
Five of the 17 (39%) with self reported previous TB had positive TSpots results. 
Four of these five also had positive TST (≥5mm) and one had declined a TST. 
4.3.8.2 Case descriptions 
One individual had subclinical (possibly recurrent) TB with radiographic 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































these, one had TB treated at the Royal Free London 10 years previously and his 
TST ulcerated with an induration of 30mm; one had been in the treated for TB 
and also imprisoned in the Democratic Republic of the Congo.
 Of the 11 with negative TSpots, six (54%) had radiographic changes consistent 
with old TB (as did one who had a negative TST, and no TSpot result). Only one 
of the patients with radiographic changes had a positive TST. 
 Twelve (71%) subjects were from high TB incidence countries, of which ten 
had negative TSpots (one missing); nine had TST indurations of <5mm, one 
subject declined TST and one had a positive TST (10mm).
One patient of the 17 isolated M. tuberculosis on sputum culture (and was 
treated for subclinical disease), whilst one other isolated M. peregrinum from 
induced sputum (with no nodules, cavities nor bronchiectasis on CXR, and the 
organism was not isolated again on subsequent sputum cultures). 
In cases of previous TB where both the TST and TSpot results were present 
(n=14), the kappa coefficient of agreement was 0.837 (Standard Error 0.155, 
p=0.005).
4.3.9 Uptake and completion of LTBI preventive treatment
In those with a diagnosis of LTBI, 50% (7/14) completed LTBI treatment. Four 
participants (29%) did not start treatment. 
4.3.9.2 Descriptions of patients offered LTBI preventive treatment
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Two participants, who were British, both male and with no TB risk factors, had 
marginally positive (7mm) TST results only and negative IGRA. One had had a 
history and evidence of a BCG vaccination, the second was unsure and no scar 
was seen. The other two participants were both female and from Nigeria. One 
lady was told the result but did not attend TB clinic or HIV appointments (even 
after follow up telephone calls). She had a positive IGRA and her TST measured 
7mm, blood CD4 cell count was 1197/µL and she had previous self-reported TB 
exposure. The second lady had a positive IGRA, 11mm TST, blood CD4 count 
of 728 cells/µL and despite a discussion, was not interested in taking LTBI pre-
ventive treatment. 
4.3.9.3 Adverse events on LTBI preventive treatment
Three of the participants who started LTBI preventive treatment had adverse 
events that impacted on their quality of life and that required a change or ces-
sation of treatment. Two had peripheral neuropathy on isoniazid, a third had a 
rash and low platelets on rifampicin. 
Of the seven that completed LTBI treatment, one patient had a short admission 
for a fever and malaise after 5 months isoniazid that may have been unrelated 
to LTBI treatment. Another developed peripheral neuropathy (despite the use of 
pyridoxine). He had been taking ART for many years. Also see Section 4.3.11.3.
4.3.10 Chest radiographic changes
4.3.10.1 CXRs consistent with active or previous TB
Thirty six subjects (16%) had an abnormal CXR. Three patients with CXR 
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consistent with active or previous TB disease also had positive IGRA or TST 
(patients 189, 174 and 107). 
4.3.10.2 Details of subjects with abnormal CXR
One participant had bihilar adenopathy (patient 189). He was a Polish man 
with no previous TB contact, although his wife was African. His mother had 
sarcoidosis. He had a blood CD4 count of 740 cells/µL and an undetectable 
HIV viral load. His IGRA was positive and TST 0mm. A subsequent CT showed 
bihilar adenopathy with no parenchymal changes. Cytopathology from a lymph 
node aspirate via endobronchial ultrasound showed granulomata. Mycobacterial 
culture of this node was negative at 42 days. The adenopathy reduced sponta-
neously without antituberculous medications, but he was subsequently treated 
with LTBI preventive therapy.
The second case was a 36 year old Angolan lady, diagnosed with HIV at prena-
tal testing and treated with ART only whilst pregnant. She had never had chest 
radiographs previously because she was diagnosed with HIV during pregnancy. 
Her blood CD4 count at the time of the study was 712 cells/µL. 
Her CXR at testing showed upper lobe fibrosis with opacification. Her CT chest 
suggested old TB changes. Both induced sputum and then a bronchioalveolar 
lavage were negative for mycobacterial culture at 42 days. She was treated initially 
with 3 months rifampicin/isoniazid but developed a rash and low platelets on 
rifampicin, and switched to isoniazid alone. She then started ART. 
Subject 107 was found to have subclinical TB and his clinical case was described 
earlier.
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Two other participants, (210 and 218) both had previous treated TB and radio-
graphic changes consistent with old TB but with negative TSTs (IGRA samples 
were lost by the courier). 
Three subjects had a history of previous TB and scarring, bronchiectasis and a 
previous lung lobectomy – presumed for active TB or subsequent bronchiectasis 
(Subjects 33, 76, 9 respectively).
Three other subjects had CXR reported as prominent hila. On review, these 
were thought to be vascular but in one case a thoracic CT scan showed fatty 
adenopathy. None of these participants had a history of TB exposure and all 
three had negative IGRA, TST and sputum culture.
Fourteen other subjects had other abnormal CXR consistent with old TB or TB 
exposure. These ranged from fibrosis and pleural thickening to multiple small 
nodules or small calcified granulomata (see Table 4.3.10.2).
4.3.10.3 CXR consistent with acute infection
Four subjects had CXRs consistent with acute infective changes. One subject 
had pneumonia as a first presentation of HIV (HIV viral load of 7.5 million 
copies/ml) which was also the time of recruitment to the study. This had already 
improved radiographically with antibiotics. Another had basal consolidation 
with a history of cough (already on co-amoxiclav) and another a small amount 
of consolidation with some back pain but no other symptoms. A fourth (a Ugan-
dan lady, on cotrimoxazole prophylaxis for PCP) had recently started ART and 
had bilateral upper lobe consolidation. Her sputum culture was negative for 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































on CT scan that improved with antiretrovirals. 
4.3.10.4 CXRs consistent with airways disease
Four subjects (1.8%) had CXR changes consistent with airways disease. One 
had possible bronchial wall thickening, three with hyper inflated lungs. Of the 
four, only one had an established asthma/COPD history and only one other 
had symptoms suggestive of airways disease. Symptoms and CXR changes are 
further discussed in the Airways Chapter 6, Section 6.3.7.
4.3.10.5 CXR changes felt unrelated to previous TB
Three subjects (1.4%) had an increased cardiothoracic ratio (cardiomegaly) 
and one (0.5%) had a pericardial cyst. Two of the subjects with cardiomegaly 
were black African and had a history of previous TB. 
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4.3.11 Quality of life changes and adverse events
4.3.11.1 Quality of life on active/subclinical TB treatment
There was relatively little loss in quality of life in the one patient treated for 
subclinical disease (Health utility of - 0.941 (CI 0.867-1), QALY loss of 0.06. Mostly 
this was in pain/discomfort and loss usual activities (likely not secondary to 
treatment).
In the second patient with subclinical disease (not on preventive treatment), 
there was no net change in quality of life utility values through the time being 
monitored.
4.3.11.2 Quality of life on LTBI preventive treatment
Of the 8 participants that took LTBI preventive treatment, five had three serial 
quality of life scores to use to calculate utilities. 
The median quality of life scores were 0.8286 (SD 0.11) when starting preventive 
treatment, 0.7496 (SD 0.073) at 2 months and 0.7686 (SD 0.154) at 4-6 months. 
This equated to a QALY loss of 0.0576.  
4.3.11.3 Adverse events on LTBI treatment
The participant taking four drugs for subclinical TB did not report any grade 
3 or 4 adverse events.
Of those taking latent TB preventive treatment, there were reports of grade 3 
events: in 2 cases joint pain, one case diarrhoea and feeling tired, one of tingling 
in the hand and feet. One participant reported new, grade 3 weakness, confusion 
and itch.  
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4.3.11.4 Adverse events after tuberculin skin testing
One patient with a known history of anxiety developed chest pain and breath-
lessness six hours after TST. There was no rash, wheeze, stridor or tongue 
swelling. He attended the emergency department at the Royal Free Hospital 
and his electrocardiogram (ECG) and troponin tests were normal. The symptoms 
settled and thought to be due to hyperventilation. Follow up ECGs and cardiac 
enzymes were normal.
One patient with previous tuberculosis developed a large ulcerated lesion on 
his forearm at the side of tuberculin skin testing. His IGRA was also strongly 
positive. He was unproductive at induced sputum and chest radiology was 
normal. He was treated with a steroid cream but has been left with a scar.
 4.3.11.5 Adverse events during sputum induction
Sputum induction seemed well tolerated, although formal satisfaction with 
the procedure was neither qualitatively or quantitatively assessed. One patient 
developed post-tussive vomiting during the procedure but elected to continue. 
Another patient complained of nausea and had to stop early. Eight subjects had 
a drop in FEV1 by 15% or greater, although in three of these, this was felt due 
to poor spirometry technique (corresponding also with a fall in FVC and rise 
in peak flow). Of the remaining five, three had a history of asthma and one had 
asthma symptoms and a history of smoking but no formal diagnosis. The fifth 
was a smoker with normal lung function, but with an FEV1 drop of 15%. These 
are further reviewed in the Airways Chapter 6 (Section 6.3.6.3).
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4.3.12 Costs associated with testing and treatment
4.3.12.1 Subclinical TB treatment and support
Including clinic appointments, two months pyrazinamide and ethambutol, 
six months of rifampicin and isoniazid and the blood tests required to monitor 
this, the treatment cost of the one participant with subclinical TB was £992.98 
and the cost of clinic appointments, a further CT chest and sputum inductions 
was £1,170. 
4.3.12.2 LTBI preventive treatment
Including the costs of fixed clinic appointments, ad hoc time with a doctor 
and nurse to discuss adverse events, drug costs for isonazid ± rifampicin and 
the blood tests required to monitor these, the total for the eight patients starting 
latent TB infection preventive treatment came to £16,927, or £2,116 per person.
4.3.13 Subsequent cases of active TB/HIV coinfection at the Royal Free Hospital
None of the patients that had taken part in the study has developed active TB 
since the study ended in September 2014. There have been four cases of active TB 
at the HIV clinic at the Royal Free Hospital, all in non-participants. One patient 




In this real-world cross-sectional study, we tested a group of patients consisting 
of those with newly diagnosed HIV and also those sustained in care. This study 
was novel in a low incidence TB area, in that it tested all selected HIV infected 
individuals for TB infection using chest radiographs and sputum culture irre-
spective of TST or IGRA result.
We found fewer than one in three subjects approached were willing to undergo 
all tests. In those that consented to all tests, three quarters returned for TST 
interpretation.
The prevalence of subclinical TB was 0.9% in all, and LTBI was 13% in black 
Africans, 6.5% and 3% in those from middle and low TB incidence countries 
respectively. This is similar to findings in other studies in Western Europe. [77,221] 
Neither of the two patients with subclinical TB in this study would have been 
detected in those using IGRA/TST as a first diagnostic step. 
The uptake for LTBI treatment was lower than expected. In those that com-
pleted treatment, this resulted in adverse events and fall in quality of life utility. 
4.4.2 Recruitment and demographics
Stratified sampling led to a cohort that were representative of the Royal Free 
cohort with similar proportions of black Africans, and people from middle and 
low TB incidence countries, and with similar results to that reported nationally. 
[219]Towards the end of the study, recruitment became more difficult as many 
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patients selected by stratified sampling had already being approached. It was 
not possible to recruit 300 patients in the time available but the numbers gained 
did demonstrate a significant difference between levels of TB infection in indi-
viduals from low and high TB incidence countries (p=0.001). Median CD4 cell 
count and proportion of patients on ART were higher than that seen in any other 
comparable European study so far published. [77,80,166, 171-175]
4.4.3 Uptake of testing
One third of subjects approached went on to take part in the study. Another 
third did not clearly decline taking part, but did not attend during the recruitment 
period. Comprehensive TB testing was perceived as time-consuming (involv-
ing up to three hours of patient time, over two visits) and uptake may have 
improved if only blood samples and CXRs been required. Some, predominantly 
black African, patients seemed unkeen to know about their TB infection status 
and were quick to decline testing when they were told about the study, perhaps 
a result of stigma associated with TB. Unfortunately the reason for refusal was 
not systematically recorded.
4.4.3.2 TST return rate
Three quarters of participants returned to have their TST result interpreted and 
a further fifth phoned or emailed the results. Many participants lived a distance 
from the clinic and with transport logistics and costs, an inability to complete 
the study in one morning was perhaps the biggest disincentive to reattend. In a 
study with similar methodology, 79/304 patients (26%) in a Norwegian setting 
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did not return for TST interpretation, whilst 43% did not attend in an Irish 
study. [80,166] Data from elsewhere are similar, with TST return rates of between 
19-40%. [146,164,202,225] In one study in an HIV clinic in the United States that 
investigated the use of incentives, the 35% return rate only improved to 61% at 
best with voucher incentives and education. [226] 
4.4.4 Results of investigations
4.4.4.1 TST results
The majority of TST results were unreactive (0mm), even in those with high 
CD4 counts and previous BCG vaccination. Very few subjects had blood CD4 
counts below 200 cells/µL and TSpot tests (which are reported to be more sen-
sitive than the QFT at low CD4 counts) were also negative,[174] inferring that 
these subjects are more likely to have true negative results rather than anergy, 
although testing for anergy was not performed specifically.
4.4.4.2 Indeterminate IGRA results
There were a low number (1%) of indeterminate TSpots. Other studies have 
shown higher rates than ours – 14% in a study in the USA and 7% in an Irish 
study, with the majority due to low CD4 cell count. [163,166] The higher median 
blood CD4 cell count in our study and drawing two LiHep bottles in order to 
increase the lymphocytes available for testing may have led to fewer indeter-
minate results.
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4.4.4.3 Yield of induced sputum 
In those that attended for sputum induction, samples were produced in 85%. 
This compares to a 60% yield with induced sputum in those that couldn’t cough 
in another study in London [77] We did not use quality control methods, such 
as microscopy for non-squamous cells or for pulmonary macrophages. 
4.4.5 Prevalence and diagnoses of subclinical and latent TB
4.4.5.1 Subclinical TB
We found two cases of subclinical TB in our cohort - one was in a black Afri-
can. In his case, strain typing by VNTR showed that there was no laboratory 
contamination or related strains. The subject had not travelled abroad for 2 years, 
but had mixed with Somali and Ethiopian people in the UK. His IGRA, TST 
and CXR were all negative for active or previous TB. If using an IGRA or TST 
based testing strategy, he would not have had a sputum induction performed. 
He elected not to have treatment for TB and has had no evidence of progression 
to active TB since. It is difficult to say if he would have progressed to TB disease 
had he not started ART. His two repeat IGRA were also negative, and so it is 
conceivable that he could have been recently exposed (despite no history) and 
was asymptomatically excreting the bacteria, as has been described in children. 
[117] There are no published cases of HIV/TB infection in the UK in asymptomatic 
patients with negative CXR and immunological investigations. Positive sputum 
cultures in asymptomatic individuals with HIV with normal CXRs have been 
documented in low and high TB incidence areas, but in the European studies, 
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either TST or IGRA were positive in all individuals tested. [77,222,227]
The second case was in a young Filipino gentleman with had very subtle 
radiographic changes on a background of old TB changes. His TST and IGRA 
were both positive, but given he had previous TB, he would not have been 
screened using either immunological method if they were used alone. He had a 
short history of cough that had resolved, but was still able to produce sputum 
spontaneously, which was mycobacterial culture positive for M. tuberculosis at 
42 days. Induced sputum was also culture positive at 42 days, both presumably 
had a low mycobacillary burden. 
The prevalence of subclinical TB was 2/219 (0.9%) for the cohort as a whole, 
or in 1/60 (1.7%) black Africans and 1/31 (3%) subjects from middle incidence 
countries. 
Since recruitment stopped 36 months ago, there have been no other cases of 
pulmonary TB in the Royal Free HIV clinic that would have been detected using 
CXR or sputum induction. Were there to be active or subclinical TB in 0.9% of 
those in clinic, we would have expected 23 cases of active TB in the entire clinic 
in the subsequent 9 months. Were there to have been other cases of subclinical TB 
in the 2331 patients that were not tested, assuming that most cases of subclinical 
TB will progress to active disease, we would have expected some of them to have 
presented with symptoms at this point. [61] The prevalence may, therefore, be 
closer to two cases of subclinical disease (one detectable by CXR, one detectable 
by induced sputum but not CXR) in a cohort of 2550 cases. The prevalence of 
subclinical disease in our cohort could be approximately 1/2551 (0.04%). 
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Kall et al. tested their entire HIV clinic cohort and describe three cases of sub-
clinical TB in 50 IGRA positive subjects, 242 black Africans or 502 HIV infected 
clinic attendees in total. One subject had CXR abnormalities (a nodule) and 
another had a normal CXR, but both had induced sputum that was positive at 
culture and both patients had a positive IGRA. [77] They had no subsequent cases 
of active TB in IGRA negative patients over the year following testing. Cases 
of ‘prevalent active TB’ (active disease found when screening in HIV clinics) 
were present in an Austrian study in eight of 830 patients (0.96%). [175] Seven 
had a positive IGRA, one a negative IGRA. In a Norwegian setting there were 
seven cases of ‘prevalent TB’ in 298 (2.3%), of which five were microbiologically 
confirmed. [222]
4.4.5.2 Latent TB
The prevalence of LTBI, as measured by either a positive TSpot or TST, was 
13% in black Africans, 6.5% in people from medium TB incidence countries (3% 
by TST or TSpot alone) and 3% in those from low TB incidence countries. These 
results are very similar to 13%, 10% and 3% respectively in the Danish and 
Homerton studies, although these were both measured by QFT only. [77,221] The 
Swiss study, using TST, found similar results with 15%, 8% and 3% respectively. 
[76] These studies of HIV-infected individuals from high TB incidence countries 
show a lower prevalence of LTBI compared studies of immigrants in primary 
care in the UK. [228,229] 
There were four individuals from low TB incidence countries diagnosed with 
LTBI. They were all from the UK and all had negative TSpots. Two subjects had 
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7mm TST responses (one BCG vaccinated, the other unknown), with no TB risk 
factors, were taking ART with CD4 cell counts of over 600. It could be that at 
least one of these was a false positive TST due to a BCG response.
4.4.5.3 Concordance between tests for LTBI
TST were all positive in those who had positive TSpots apart from one patient, 
(with bihilar adenopathy, taking methotrexate and had a family history of sar-
coidosis). Follow up has shown no subsequent TB or increase in adenopathy. 
His lack of TST response may be due to either sarcoid or use of methotrexate. 
[230,231]
In this study, there were more subjects with positive TST and negative TSpot 
than positive TSpot and negative TST. This is similar to a recent study in Norway 
(median blood CD4 cell count of 471 cells/µL) with more positive TST than IGRA. 
They demonstrated 80% agreement, kappa 0.52 between TSpot and TST, which 
was similar to that between TST and Quantiferon. Clark et al. in the UK had a 
similar numbers of discordant TST positive and TSpot results. [174] 
Other European and US studies, however, have demonstrated higher num-
bers of positive IGRA than TST. A German study (with median blood CD4 408 
cells/µL) had twice as many positive TSpots in subjects as positive TST. [167] In 
a Spanish setting there were three times more positive IGRA. [164] A US study 
(median CD4 335), reported more positive TSpots and negative TSTs with poor 
concordance (kappa = 0.16). Those with positive TST and negative TSpot were 
more likely to have been BCG vaccinated (OR 17.7). [163] This was not demon-
strated in the Norwegian study however. [80] More TSpots were also positive in 
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an Italian study (median blood CD4 461 cells/µL) and in a Spanish study (mean 
blood CD4 536 cells/µL). [232,233] 
In an African cohort, 5/9 TSpot positive subjects had positive TST (kappa 0.69). 
[234] This has been reviewed in a meta-analysis, were agreement was higher 
between the tests (89%) in high income countries than in lower (77%). There were 
higher numbers of TSpot positive, TST negative subjects, in direct comparison 
to this study. [162] with agreement of 80% (kappa=0.52) between the two tests.
4.4.5.4 Previous TB 
Sixty five percent of subjects with previously reported TB disease had nega-
tive TSpot results in this study. The majority of these were people from high TB 
prevalence countries.
This has been seen frequently in other studies where between QTF is negative 
in 62-90% and TSpot in 43-72% despite previous TB. [80,165,172,175,233]
4.4.6 LTBI preventive treatment
4.4.6.1 Uptake of LTBI preventive treatment
Fifty percent of subjects managed to complete LTBI preventive treatment. 
In those that did, there were notable number of adverse events (ranging from 
peripheral neuropathy at the most minor, to rash and low platelets). Two patients 
were unable to complete therapy because of these. There was, however, little 
hepatotoxicity.
The completion rates were similar to other studies in people with or without 
HIV. Amongst studies in individuals with HIV, only 48% started treatment and 
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75% of those completed in a Swiss study and 61% in Norway. [76,80] In older 
LTBI treatment studies, despite 86% starting, only 57% completed in a study in 
Spain and 56% stared and only 28% (16% total) completed in an Italian study. 
[78,202] In comparison, a study in Homerton, London had a 90% and 95% adher-
ence rate with LTBI treatment. [77]
Results may be even lower in the HIV-uninfected general population – a 
London study of TB contacts showed 54% completion rates [235] and around 
40% in the USA. [236]  In one Canadian study, fewer than 10% completed pre-
ventive treatment. [237]  
4.4.6.2 Quality of life during LTBI treatment
LTBI treatment seemed to be poorly tolerated in this group. The QALY deduc-
tion for LTBI (including treatment) from NICE is only 0.007 QALY. [43] Many 
other cost-effectiveness analyses have assumed this was zero, but do deduct 
for the low risk of hepatic toxicity due to isoniazid. [193] There are very few 
data on the quality of life associated with latent TB treatment in high income 
countries. It was hoped that this study may generate more data on quality of 
life and adverse events associated with latent TB treatment. To this end, quality 
of life data were recorded at each follow up appointment and adverse events 
were asked about systematically and proactively using standard chemotherapy 
adverse events forms (see Appendix). This may have led to a higher prevalence 
of adverse events than would have been expected. 
There are otherwise very few published studies for health utility scores for 
latent TB infection. [188,238,239] In a large study of South African gold-miners, 
isoniazid preventive therapy was very well tolerated, with adverse events in 
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only 1 in 200. [240] 
A systematic review of health related quality of life did find poorer quality 
of life in those treated for active TB compared to those with latent infection on 
treatment (although this was not quantified). [238] In our study, the numbers 
were small, and some of the patients that stopped preventive treatment were lost 
to follow up, or failed to submit quality of life data, but the one patient treated 
for subclinical disease had a lower reduction in quality of life than those that 
were treated for latent infection. 
4.4.7 Limitations of the study
Despite a pragmatic approach, we were unable to recruit as many participants 
as we would have wished, especially amongst those from high TB incidence 
countries.  A small number were too unwell, or missed appointments. Patients 
undergoing chemotherapy for solid organ or haematological malignancy, or 
those who had received solid organ transplants, who may have been at higher 
TB risk, but were either not well enough to be tested or were excluded (as the 
immunological results may have not have been reliable). Selection bias may 
have been introduced as individuals with HIV and chaotic lifestyles, who may 
be less adherent to ART may also have not attended clinic and therefore not 
been approached. These individuals may have a higher risk of TB exposure. 
Conversely, those with symptoms such as cough or chest pain, or who were 
concerned about TB contact in the past, may have been more willing to take 
part in the study. Despite this, the demographics of those enrolled were similar 
to those of the Royal Free cohort; as were the demographics of those who were 
eligible and those who had not taken part. The symptoms or specific reasons not 
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to enrol in the study were not systematically recorded in those that declined, so 
we cannot disprove selection bias due to this.
This cross-sectional study looked at new HIV diagnoses as well as those in 
established care. This approach was useful if we consider the cost-effectiveness 
of testing an entire clinic. There were low numbers of patients with new HIV 
diagnoses during the recruitment period, however, so establishing the cost-ef-
fectiveness of TB testing in individuals with new HIV diagnoses alone would 
have taken far longer, and a large study of treatment naïve individuals may give 
different results. In those with new HIV diagnoses, the blood CD4 cell counts 
may be lower, immunological and radiological tests may be less sensitive and 
the risk of developing TB higher. The very low numbers in this study make post-
hoc analysis difficult. Given most individuals with a new diagnosis of HIV will 
now start ART soon after, this risk may not be as significant.
There were no cases of symptomatic active TB at recruitment. This made the 
sensitivity of symptoms or radiology as a marker for active TB immeasurable. 
A reason for this could be the relatively short (16 month) recruitment period. 
The recruited cohort had a high median CD4 count – certainly higher than 
in other Western European and American studies. Although this reflects the 
immune status of a contemporary population with good uptake and adherence 
to ART. This may explain the higher numbers of patients with positive TSTs 
with discordant IGRA results. The use of TSpot rather than Quantiferon in this 
study may also have led to an increased discrepancy between tests, and use 
of Quantiferon (which has a higher rate of concordance with TST) cannot be 
directly compared.
Three participants (21%) were lost to follow up during LTBI preventive 
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treatment and this led to a lack of data surrounding quality of life results. As the 
subjects attended clinics at different times, the results are also not directly com-
parable. There were also fewer cases of active and subclinical TB than expected, 
and fewer participants with LTBI on treatment than expected and the small num-
bers make the results not significant enough to use in cost-effectiveness studies.
4.4.8 Conclusion
This cross-sectional study showed that extensive testing for TB in HIV subjects 
was achievable but time consuming, and that uptake was relatively low for all 
tests amongst clinic attendees when presented as part of a research study. Similar 
to other studies, many patients did not return for TST interpretation, despite 
fully consenting to the study. We found very similar numbers of patients with 
subclinical and latent TB infection compared to other European studies. Notably, 
we found that M. tuberculosis may be cultured from the sputum of asymptomatic 
HIV infected individuals with negative immunological tests and normal chest 
radiographs. In this case, the patient declined treatment and subsequent active 
TB disease did not develop. 
The uptake for LTBI preventive treatment was also similar to other studies, 
but there were adverse events than expected in those that did take treatment, 
but none related to hepatotoxicity. In contrast to studies in high TB-incidence 
areas, XpertTB.RIF added nothing to mycobacterial smear and culture when 
testing patients attending HIV clinics. The uptake and results of this study will 
be used to model different testing strategies in Chapter 5. 
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CHAPTER 5: COST EFFECTIVENESS OF TESTING FROM 
PROSPECTIVE STUDY
5.1 Introduction
International guidelines advise testing in HIV infected individuals to reduce 
the morbidity, mortality and transmission associated with active TB disease. 
[43,44,71,75,134,241] Each guideline recommends a different TB testing strategy – 
for example the most comprehensive, the US Centre for Communicable Disease 
Control (CDC) test for active disease and latent infection with a frontal chest 
radiograph (CXR) and an immunological test (TST or interferon gamma release 
assay - IGRA) in everyone at HIV diagnosis, plus sputum culture or yearly TST 
screening in some higher risk groups (see also Chapter 1, Section 1.5.6). [241] By 
comparison, the British HIV Association (BHIVA) target only those at the highest 
risk of reactivation of LTBI (based on place of birth, blood CD4 count and time 
on antiretroviral therapy, ART) and recommend testing using IGRA alone. [75] 
These guidelines have often been based on historical studies which contained 
populations with less ART uptake than is current practice. [19,52] This is impor-
tant as ART decreases the risk of TB reactivation by at least 65%. [59,89]  Also, 
although these investigated the prevalence of LTBI and active TB in low TB 
incidence areas such as the USA and Western Europe, none were specifically 
based on cost-effectiveness in an HIV infected cohort. [31,76]   
Using extensive assessments for active, subclinical and latent TB infection, we 
sought to determine the uptake and yield of TB testing in an adult UK HIV ambu-
latory care clinic. From this we calculated the most cost-effective management 
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strategy, based on the England and Wales National Institute for Health and Care 
Excellence (NICE) threshold of £20-30,000/QALY gained. [178]
5.2 Method
5.2.1 Study population and patient selection
Subjects were selected from those attending routine appointments at the Royal 
Free Hospital, London by stratified selection between June 2013 and September 
2014, unless they had a new diagnosis of HIV in the past four weeks, when all 
were approached. This and the study procedures are outlined in Chapters 2 
(Methods) and Chapter 4 (Prospective Study Results). 
5.2.2 Study procedures
 Symptom and medical questionnaires, quality of life scores, CXR, blood 
IGRA (T-Spot.TB), TST, and a single induced sputum were offered to all subjects 
and were usually performed over two visits 48-72 hours apart. HIV viral load 
and blood CD4 cell count were recorded from the pathology database. The pro-
cedures are further outlined in Chapter 2, Section 2.3.4.
Subjects were reimbursed for any travel costs to return for sputum induction 
and TST interpretation, but no other financial incentives were offered.
The study was approved by the London - City and East Ethics Committee - 
number 12/LO/1516, Clinicaltrials.gov number NCT02712671. There was no 
outside funding provided for the study.
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5.2.3 Case definitions
LTBI was defined as a TST result at 48-72 hours of ≥5mm (irrespective of BCG 
vaccination status), and/or a positive T-Spot.TB. [160,241,242] Active TB disease 
was defined as symptoms and radiographic changes consistent with tuberculo-
sis and positive sputum microscopy and culture for Mycobacterium tuberculosis. 
Subclinical TB was defined as positive sputum culture for M. tuberculosis with 
or without radiographic changes and in the absence of symptoms. Medium and 
low TB incidence countries were defined as those with a TB incidence of 30-300 
and <30/100,000 population respectively. [75,243]
5.2.4 Economic analysis – Model structure and assumptions
5.2.4.1 TB testing strategies
Participants were assessed using a symptom questionnaire, CXR, blood IGRA, 
TST, induced sputum for AFB smear, mycobacterial culture and Xpert MTB/
RIF testing. This information, along with participant characteristics (including 
place of birth, history of previous TB, time on ART, blood CD4 cell count) and 
uptake in the study, was used to undertake an economic analysis based on no 
testing and 29 predefined testing strategies (Table 5.2.4c). These reflected national 
guidelines or incremental combinations of readily available tests to increase the 
detection of TB infection. [43,44,75,134,241]
It was assumed: 
• subjects would only be tested once 
• those willing to attend HIV clinic for routine care would also agree to a 
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chest radiograph and blood IGRA 
• the return rate for TST interpretation reflected that seen in the observa-
tional study 
• LTBI preventive treatment would only be given to those who returned to 
have their TST measured 
• those with a previous history of TB disease would not be retested for LTBI 
with TST or IGRA 
• LTBI preventive treatment uptake would reflect that seen in the study and 
have an efficacy of 62% [71]
5.2.4.2 Baseline risk of TB
The probability of developing TB in a lifetime was considered to be 10% in 
those with a positive IGRA (irrespective of TST result), [173-175,211] 2% in those 
with a positive TST but negative IGRA, [211] and 0.02% in those with a negative 
TST and IGRA. [76] Using these, we estimated the expected total number of 
cases of active TB that would prospectively develop, had no LTBI testing and 
treatment occurred (see Figure 5.2.4.1b). The number of cases of TB prevented 
using various testing strategies were then compared against this. Proportions 
of patients from high, middle and lower TB incidence countries reflected UK 
HIV demographics. [19]
5.2.4.3 Utilities
















TST £16.14 £8.07 £32.28 4.12 15.37 1.05 Gamma [43]
IGRA £40.00 £23.00 £90.00 8.67 21.27 1.88 Gamma Local charges, [43]
CXR £50.00 £25.00 £100.00 12.76 15.37 3.25 Gamma Local costs
Sputum induction £100.00 £67.00 £150.00 16.84 35.28 2.83 Gamma Estimate, local costs
Sputum induction 
and TB PCR £160.00 £116.87 £200.00 22.01 52.86 3.03 Gamma
Estimate, local 
costs
LTBI £786.50 £374.50 £1,316.50 210.2 14 56.18 Gamma Local charges, [43,215]
Active TB £7,619.67 £3,809.84 £15,239.34 1943.79 15.37 495.86 Gamma [183]
Cost of subclinical 
disease £1655.32 £1234.92 £2075.72 210.2 62.01 26.69 Gamma Estimate, [183]
Proportion black 
African 25% 20% 30% 0.002 14938.78 45060.22 Beta [219]
Proportion middle 
incidence 13.9% 4% 24% 0.049 6.69 41.3 Beta Study
Subclinical disease in 
BA 0.17% 0% 0.41% 0.0012 2.09 1201.91 Beta Study, [77]
Subclinical disease in 
MI 0.09% 0% 0.18% 0.00087 1.11 1202.89 Beta Study, [77]
Subclinical disease in 
LI 0.04% 0% 0.1% 0.00057 0.48 1203.52 Beta Study, [77]
Uptake LTBI 50% 35% 65% 0.05 49.5 49.5 Beta Study
Efﬁcacy LTBI 62% 59% 65% 0.05 1473.74 903.26 Beta [71]
QALY loss LTBI 0.01 0 0.05 0.01 7.53 0 Gamma [43]
QALY loss active TB 0.68 0.35 1 0 16.72 0.04 Gamma [43]
QALY loss subclinical 
TB 0.2 0.01 0.3 0.17 7.31 0.03 Gamma Estimate
Progression rate with 
pos TST alone 2% 1% 4% 0.07 7.68 0 Gamma [144]
Progression rate with 
pos IGRA and TST 10% 3% 17% 0.01 7.84 0.01 Gamma [173-175]
Progression rate with 
neg TST 0.2% 0% 0.5% 0.04 3.84 0 Gamma [175,220]
Proportion old TB 7% 2.1% 12.6% 0.02 15.93 200.07 Beta Study
TST return rate for 
those having TSTs as 
well as IGRAs 
53% 30% 90% 0.03 116.07 102.93 Beta Study
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Costs of testing using TST and IGRA, latent TB treatment, and active TB treat-
ment were taken from local charges or published studies. [43,134,183]
Costs were measured from an English NHS perspective in £ Sterling. The time 
horizon was lifelong and costs and benefits discounted at 3.5% per year. [178]
A full list of assumptions and sources are presented in Table 5.2.4.1a.
5.2.5 Statistics
Sample group proportions were compared using the Chi-square and medians 
with the Mann-Whitney U test.
5.2.6 Cost effectiveness
Cost effectiveness was measured in terms of incremental cost/case detected 
and incremental cost/QALY gained. Each testing strategy was compared against 
no testing and against the last cost-effective (non-dominated) strategy ranked 
according to local cost. Cost effectiveness ratios were calculated as the difference 
in cost between the two strategies divided by the difference in outcome (either 
cases averted or QALYs gained).
5.2.6.2 Sensitivity analysis
Univariate and multivariate (best and worst case) deterministic sensitivity 
analyses were performed. We varied costs for TST, IGRA, CXR, sputum induc-
tion, latent, subclinical and active TB treatment. The rate of uptake of testing 
was varied to reflect patient acceptance for a second visit within 48 hours for 
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TST results, and uptake and efficacy of isoniazid prophylaxis. The quality of life 
parameters used were also varied (Table 5.2.4.1a).
A probabilistic sensitivity analysis using 10,000 Monte Carlo simulations was 
performed. From this, we calculated uncertainty ranges (UR) for each point esti-
mate and also cost effectiveness acceptability curves, showing which strategy 
was the most likely cost effective at different cost-effectiveness thresholds. 
5.3 Results
5.3.1 Uptake, and cases of active and subclinical TB
Between June 2013 and September 2014, 219 adult outpatients took part within 
the 14 months recruitment period (See Chapter 4, Figure 4.3.2). These patients 
were demographically similar to those approached; and were also representa-
tive of the total clinic population (Chapter 4, Table 4.3.3). Seventy-three percent 
(159/219) were male, 28% from subSaharan Africa and 57% from low TB inci-
dence countries, 95% were taking ART, of which 88% had an undetectable HIV 
load. Median CD4 cell count was 643 cells/µL.
The results of the study are described in Chapter 4. In all, 74% participants 
returned to have their TST result read whilst 19% telephoned or emailed their 
result after 48-72 hours. IGRA results were available for 99% and 98% had chest 
radiographs. Sputum induction was performed on 208 subjects and productive 
in 178 (86%). Of these, two were positive for M. tuberculosis on sputum culture. 
No samples had M. tuberculosis detected by Xpert MTB/RIF. 
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There were no incidental cases of symptomatic, active tuberculosis disease. 
Two patients (0.7%) were found to have subclinical TB, but only one had an 
abnormal CXR and positive IGRA and TST. 
Fourteen patients were diagnosed with LTBI – 13% in subSaharan Africans 
(8/62), and 6.5% (2/31) and 3% (4/126) respectively in those from middle and 
low TB incidence countries. Seven percent had a history of previous TB. 
Uptake of LTBI preventive treatment was 64% (9/14), 50 % (seven) fully com-
pleted treatment. Two stopped due to adverse effects and one lost to follow up 
despite multiple attempts to maintain contact. These data were used to model 
the cost-effectiveness of the testing strategies.
5.3.2 Cost effectiveness
It was estimated that over their lifetime, 92 of 10,000 people living with HIV 
(PLHIV) in care in England and Wales would develop active tuberculosis due 
to reactivation of latent infection in the absence of preventive treatment (Figure 
5.3.2). Thirty different testing strategies were then applied using the results 
obtained from the observational study. In the most targeted strategy (BHIVA), 
with an uptake rate for LTBI testing of 82%, TST return rate of 53%, completion 
and efficacy of chemoprophylaxis of 50% and 62% respectively, 2.28 cases of 
active TB would be prevented, costing an extra £48,658 compared to no testing, 
with a discounted cost/QALY of £37,952. The estimated costs, cases prevented 
and QALYs gained for each strategy in order of increasing expense are given in 
Table 5.3.2. Compared with no testing, only three strategies met the cost-effec-
tiveness criteria by NICE. A single TST in black Africans was the best value at 
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£23,429/QALY. Testing black Africans and those from MI countries with a TST 
cost £25,218/QALY and the strategy that prevented the most cases was testing 
all black Africans with a single IGRA (cost/QALY £28,971). All of these values 
had wide uncertainty ranges. Testing all BA and those from MI countries with a 
single IGRA cost just over the threshold at £32,410/QALY gained. Neither of the 
current UK HIV testing guidelines’ strategies were cost-effective from a health 
services perspective (Table 5.3.2). [75,134]  Compared to the previous most costly 
(non-dominated) intervention, only testing with a TST in black Africans had an 
incremental cost-effectiveness ratio of less than £30,000/QALY gained.
5.3.3 Sensitivity analysis
Univariate cost effectiveness analysis showed that: TST alone in all became 
most cost effective if TST cost below £4.98 (from £16.14), IGRA in BA and MI 
became cost-effective if the price of IGRA fell to £23 (from £40), or if the number 
completing LTBI preventive therapy increased to over 60%. If the average cost of 
an active case of TB rose to £15,239, then an IGRA and CXR in BA and MI, or a 
TST in all became most cost effective. If active TB cost ≤£3,810 to treat then none 
of the strategies were cost effective. As the uptake and efficacy of preventive 
therapy for LTBI increased, all strategies became more cost effective, though 
even with 100% uptake and completion, testing all attendees with IGRA alone 
never cost <£30,000/QALY. This strategy only became cost-effective if the pos-
itive IGRA progression rate was ≥ 16.5%.
Using a Monte Carlo analysis, a cost-effectiveness acceptability curve was 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































this range. Of the twelve that were, no testing was most likely cost effective up 
to £30,000; above which level testing using TST in BA became the strategy most 
likely to be cost effective. At £50,000/QALY, testing BA and middle incidence 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this cost-effectiveness analysis of real-world TB testing in a contemporary 
HIV clinic in a low HIV and TB incidence region, only three of thirty strategies had 
cost-effective point estimates. Compared with no testing, testing black Africans 
with a TST or IGRA was cost effective at under £30,000/QALY, as was testing 
both black Africans and people from middle TB incidence countries (approxi-
mating to all those from outside Western Europe or North America) with a TST. 
Using IGRA in these groups would be just above this threshold. When subjected 
to probabilistic sensitivity analysis, ‘No testing’ was most likely cost-effective 
up to  £30,000/QALY. 
Despite the low up-front costs, the efficiency of strategies involving TST was 
substantially reduced due to the number of people who did not return to have 
their TST interpreted. Routine sputum induction for mycobacterial culture also 
added significant cost for very little yield. Given the low TB bacillary burden in 
the patients with subclinical TB, routine sputum TB PCR testing also provided 
no further information. No strategies that used both a TST and IGRA, or CXR 
or sputum induction were cost-effective. This included all current national and 
international guidelines reviewed. [43,44,75,134,241]
5.4.2 Sensitivity analyses
If the cost of an IGRA fell, or its predictive value increased, the strategies were 
much better value. Testing also became better value if uptake of LTBI testing 
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and treatment increased, although even if both of these were 100%, testing all 
attendees was not cost-effective. 
5.4.3 Implementation
Whilst this model suggested that no testing is most cost effective using UK 
NICE criteria, other countries with low TB incidence may use different cost/QALY 
threshold criteria. [180] Similarly, our study models from an NHS perspective 
and, given the WHO aim of eliminating tuberculosis by 2050 to under one in a 
million cases per year, public health bodies may be willing to pay more in order 
to prevent disease in those at the highest risk of TB reactivation. [141,244,245]   
The selection of either TST or an IGRA as a preferred test may also depend 
on factors such as the availability of Purified Protein Derivative (PPD) for TST, 
or the advantage of not needing to recall for reading results in those having 
a blood IGRA. [246] Testing using an IGRA alone may be operationally more 
locally appropriate. 
5.4.5 Variables and need for more data
5.4.5.1 Uncertainty ranges
There were large uncertainty ranges around the final point estimates from the 
probabilistic analysis. This was in part due to a lack of contemporary data for 
HIV/TB treatment. The lower sample numbers led to large standard deviations 
and hence wide variables used in the probabilistic sensitivity analysis. There were 
also a large number of parameters that were varied, further increasing the ranges. 
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5.4.5.2 Predictive value of TST and IGRA
There are very few studies on the predictive value of a positive TST or IGRA 
in a contemporary HIV population using ART and calculating this more accu-
rately would take prolonged follow-up over years. We therefore had to estimate 
this from the few studies available in order to determine the number of cases 
of active TB that would be likely to occur, with or without LTBI treatment (also 
see Section 1.6.7). [173,175] 
Early reports indicated that active TB could occur in people with negative skin 
tests (possibly due to new TB exposure). [78,247] This was therefore included 
the model, though this may underestimate the effectiveness of testing, as more 
contemporary studies find zero or a very low risk of active TB in those with neg-
ative IGRA results or those with LTBI who take preventive therapy. [77,173,175]
5.4.5.3 Quality of life change and costs
In the study, the sample numbers with subclinical TB and LTBI, and those 
taking preventive treatment were too small to make a precise estimate of quality 
of life change. However, the adverse events associated with preventive treat-
ment were greater than would have been expected from estimates used in other 
cost-effectiveness models. In most previous cost-effectiveness models, LTBI 
treatment has not been associated with any loss in quality of life (except relat-
ing to hepatotoxicity). [192,193]  Where is accounted for, the only data are from 
Guo et al. where the QALY loss is estimated at 0.003, or from the study by Krui-
jshaar et al. in the UK, which NICE also use in their analysis, estimating this at 
0.007. [43,190,248-250]  These quality of life studies were also from the general 
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population, rather that people with HIV co-infection, where there may be more 
morbidity associated with preventive treatment. If so, this would make LTBI 
testing less cost-effective. 
Some TB quality of life studies have quoted a large drop in quality of life 
due to bronchiectasis or loss in lung function due to active TB disease. [195] We 
found respiratory symptoms were very common in the whole study cohort, but 
there were few sequelae of previous pulmonary TB. Again, the estimates used 
in the cost-effectiveness model were from NICE data for adults in the general 
population with active TB. [43] 
Along with a much larger study on quality of life data in people being treated 
for TB/HIV coinfection or LTBI, a more contemporary estimate of the cost of 
LTBI and active TB treatment would be would be useful in providing variables 
for cost-effectiveness in this modelling.
5.4.6 Other Limitations
Since ART use is now so widespread in higher resource countries, and is likely 
to increase with international guidelines (such as recommendations to treat soon 
after HIV diagnosis irrespective of blood CD4 count), there may be a further 
decline in the risk of TB disease due to reactivation – reducing the cost-effective-
ness of TB testing even more. [49,251]  This is consistent with the retrospective 
analysis in Chapter 3, where cost-effectiveness reduced as ART uptake increased. 
The study and model is appropriate for testing entire clinics of HIV infected 
individuals – both those with new HIV diagnoses and in established care. There 
were low numbers of individuals newly diagnosed with HIV in the study and 
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hence it is difficult to extrapolate to estimate the cost-effectiveness of testing 
just this group. Similarly, there were low numbers of injecting drug users and 
none in this study with subclinical TB or LTBI and so their risk could not be 
extrapolated, but the incidence of active TB disease is higher than the general 
population and it could be that they should be tested as much as individuals 
from high TB incidence countries. [252] 
The benefits of reducing TB transmission were also not included in this model 
– although, even if one case of active TB resulted in a single further case of active 
disease, testing all HIV clinic attendees was calculated to not be cost-effective. 
5.5 Conclusion
Even the most targeted testing for TB in a contemporary HIV clinic is only 
marginally cost effective at a £30,000/QALY threshold. Using more than one test 
was even more expensive. Pragmatically, either not testing routinely, or testing 
only those at the highest risk of reactivation of TB with a TST or IGRA alone 
may be the most cost-effective and convenient strategy. This is at odds with the 
majority of contemporary national guidelines.
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CHAPTER 6: RESPIRATORY SYMPTOMS AND AIRWAYS 
DISEASE
6.1 Introduction
6.1.1 History of lung disease in HIV
A series of patients with Pneumocystis pneumonia (PCP) led to the initial 
description of AIDS. [3] HIV infection is also a risk factor for Pneumococcal 
pneumonia [253,254] Since then, opportunistic lung infections have been recog-
nised as a cause of morbidity and mortality in people with HIV. 
As antiretroviral treatment has become more effective, respiratory infections 
have become less prevalent, but there is still an increased burden of chronic lung 
disease compared to the general population. These include chronic obstructive 
pulmonary disease (COPD) and bronchiectasis. [255,256] One pre-ART study 
showed HIV infection was associated with a low carbon monoxide transfer factor, 
but fairly well-preserved spirometry. [257]  Another, using high-resolution com-
puterised tomography (HRCT) scans of the lungs, found 37% of HIV-infected 
smokers had emphysema on CT. Previous pneumonia, PCP, injecting drug use 
and low blood CD4 count were implicated as risk factors for lung disease. [258] 
In these studies, as in many since, the prevalence of smoking was higher (63%) 
than the general population, and there was a history of previous respiratory 
infection in those with emphysema. [259] 
Since 1996, when ART became much more widespread, epidemiological data 
have shown a higher prevalence of COPD in HIV-infected versus non-infected 
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US veterans, although the association with lower CD4 and higher HIV viral 
load has become less consistent. [254,256,260,261] Three prospective studies 
have shown a prevalence of obstructive lung disease of 3.4-21% with a high 
frequency of respiratory symptoms. [258,262] In one study, ART was found to 
be a risk factor for airway obstruction (despite adjustment for age and smoking 
history). These were all from large US cross-sectional or cohort studies, however, 
where HIV demographics differ from the UK. Contrastingly, in the pulmonary 
substudy of START (a large, randomised control trial in 20 countries of early 
versus deferred treatment of HIV) there were similar rates of obstructive lung 
disease in both early and deferred ART groups. The follow-up time may have 
been too short to show a significant difference. [263]
6.1.2 Cause of chronic lung disease in HIV
These findings have led to a hypothesis that the aetiology of chronic lung 
disease in HIV may be due to a vicious circle of smoking and substance abuse 
damage (with malnutrition in some), defective immune responses and an increase 
in microbial colonisation with inflammatory cytokine and protease release. [11] 
The overwhelming epidemiological confounder, however, seems to be tobacco 
smoking. Smoking prevalence is higher in people living with HIV (up to three 
times that in the general population), although even when adjusting for this, the 
burden of lung disease remains high. [264,265] A Danish cohort study found that 
the number of years of premature death due to smoking was greater than that 
from HIV alone, provided patients were adherent with ART. [265]
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6.1.3 Diagnosis and aetiology of COPD
A diagnosis of COPD is made using obstructive spirometry in people with a 
risk factor (the greatest being smoking), but COPD only affects a fifth of smok-
ers. It may be that individuals that develop COPD have a modified response 
to smoker or noxious particles that causes more lung inflammation parenchy-
mal tissue disruption and have abnormal repair or defence mechanisms. [266] 
COPD tends to have an indolent onset, although symptoms such as exertional 
breathlessness, chronic cough, sputum production, winter bronchitis and wheeze 
are often present and may precede changes in lung function. More noticeable 
breathlessness and disability may only occur after substantial irreversible damage 
has occurred. [209] 
6.1.4 Respiratory symptoms
Compared to non-smokers, smokers with normal spirometry seem to have 
more respiratory symptoms, and it is speculated that these symptomatic patients 
may have a form of smoking related lung disease, an early predictor of COPD 
before measurable airways obstruction occurs. Alternatively the symptoms could 
be a marker of co-existent asthma. [267] These individuals also seem to have 
exacerbations, a feature of COPD. Smoking cessation and timely treatment of 
exacerbations could be useful interventions at this point.
6.1.5 Testing for COPD in primary care
There has been interest in testing smokers in order to detect COPD and inter-
vene before more noticeable disability occurs. Given the large populations and 
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resource associated with spirometry as a diagnostic test, pre-screening to find 
those at higher risk using questionnaires has been trialed. In a study in pri-
mary care in Leicester: age, breathlessness on exertion and wheeze identified 
COPD patients with a sensitivity of 77.4%-87.1%. [268] The COPD Diagnostic 
Questionnaire, another example, records smoking history, sputum production 
outside of viral infections, morning cough productive of sputum, and wheeze. 
[269,270] Screening for COPD in asymptomatic individuals, however, has not 
been shown to improve health outcomes and has been discouraged by the US 
Preventive Services Task Force. [271]
6.1.6 Sputum Microbiology
Despite smoking as a confounder, the presence of pathogenic bacteria, such 
as Haemophilus influenza, Streptococcus pneumoniae and Moraxella catarrhalis have 
been associated with exacerbations of COPD, and their presence correlates with 
markers of neutrophilic inflammation. [272] There are data to suggest that the 
bacterial load increases at exacerbation and the presence of these bacteria are 
associated with lung function decline in patients with COPD and bronchiectasis, 
and perhaps in exacerbating smokers with normal lung function. [273,274] The 
risk of pneumococcal pneumonia is also increased in both people with COPD 
or HIV infection. Pulmonary macrophages are central to airway innate immu-
nity and it there is evidence that in both conditions, dysfunctional apoptosis by 
macrophages could be the cause of impaired immunity, leading to colonisation. 
[274-276].  
Quantitative polymerase chain reaction (qPCR) is more sensitive than culture 
at detecting airway bacteria [273], and H. influenzae can exist intracellularly, 
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resulting in negative standard bacterial culture. QPCR  can also be analysed in 
a batch on frozen samples. 
6.1.7 Aims and objectives
Given the increased prevalence of COPD in HIV-infected individuals in 
epidemiological studies, we sought to determine the frequency of respiratory 
symptoms and airways disease using spirometry in an HIV-infected cohort in 
London with very high ART use, and identity their risk factors.
6.2 Methods
6.2.1 Setting and recruitment
A sample of subjects already undergoing care at the Ian Charleson Centre for 
HIV care at the Royal Free Hospital, plus all those with a new diagnosis of HIV 
were invited to take part in a TB-testing study. Selection method and criteria 
have been outlined in previous chapters (Chapter 2).
6.2.2 Study questions
In the study questionnaire (see Appendix 1.5, participants were asked about a 
history of asthma, bronchiectasis, inhaler use, smoking (tobacco and cannabis), 
injecting drug use, previous infection with Pneumocystis pneumonia (PCP), 
bacterial pneumonia and active tuberculosis disease. 
We enquired about: 
• recent and winter cough 
• sputum production 
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• history of wheeze 
• tight chest 
• breathlessness
A quality of life EQ5D score was included. Subjects were asked to self-report 
their height when filling in the questionnaire.
6.2.3 Pathology and radiology data
Blood tests including:
•  renal function
• recent and nadir blood CD4 cell count 
• recent HIV viral load
• hepatitis B and C serology
were taken from the hospital pathology database, and a frontal chest radio-
graph (CXR) performed. Any previous chest radiology reports were reviewed 
from the radiology database.
6.2.4 Spirometry and sputum induction
Spirometry and sputum induction methods are described in the methods 
chapter (2.3.4.5 and 2.3.4.6). Spirometry was performed before sputum induction 
then repeated 5 minutes after inhaling 3.5% saline. Where enough sputum was 
obtained at induction, samples were saved for research purposes. These samples 
were later thawed, the DNA extracted and tested using multiplex qPCR used 
for evidence of airway bacteria including Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, Legionella pneumophila, Chlamydia pneumoniae, 
Mycoplasma pneumoniae. This work was performed by Dr Camus Nimmo and 
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Sarah Thurston from the Department for Microbiology, University College 
London, Royal Free Campus. 
6.2.5 Statistical methods
Data were analysed using SPSS version 20 (IBM SPSS Statistics, USA) for Mac, 
Excel 10 for Windows and Excel 2011 for Mac (Microsoft, Seattle, USA). This is 
further detailed in the methods chapter (2.5).
Significance was calculated using the Mann Whitney U test for independent 
samples with a significance level at 0.05 for non parametric distributions, or the 
Pearson Chi-square test. Odds ratios were calculated using univariate analysis 
for variables relating to respiratory symptoms and smoking status and confi-
dence intervals calculated using the Pearson Chi-square test (or Fisher’s exact 
test if n<5). 
Forced expiratory volume in one second (FEV1) percent predicted, forced 
vital capacity (FVC) percent predicted and were calculated for each participant 
where a height had been recorded. European Respiratory Society equation and 
tables were used to calculated predicted FEV1 and FVC for an individual’s age 




The study was performed between 10th June 2013 and 6th September 2014 at the 
Ian Charleson Centre. Of the 1205 outpatients that were eligible, 219 participated. 
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Female (%) 51 (25%) 12 (10.8%) 39 (41.9%) <0.005
Age - years (IQR) 46 (41-53) 47 (12) 46 (13) 0.999 (MWU)
Median CD4 (IQR) 612 (457-789.5) 597 (336) 625 (277) 0.533 (MWU)
Number with VL <40 173 (83%) 88 (79.3%) 85 (91.4%) 0.016
On ART 201 (99%) 108 (98.2%) 93 (100%) 0.501
Indoor ﬁre exposure 47 (23%) 27 (24.3%) 20 (21.5%) 0.688
Still smoking 47/111 47 (42.3%) 0
Hx cannabis smoking 83 (40.7%) 70 (63.1%) 13 (14%) <0.005
History IDU 21 (10.3%) 16 (14.4%) 5 (5.4%) 0.106
HIV Risk Factor <0.005
Heterosexual 79 (38.7%) 29 (26.1%) 50 (53.8%)
IDU 4 (2%) 4 (3.6%) 0
MSM 116 (56.9%) 78 (70.3%) 38 (40.9%)
Vertical 2 (1%) 0 2 (2.2%)
Other 2 (1%) 0 2 (2.2%)
Place of birth/ethnicity <0.005
BA 54 (26.5%) 13 (11.7%) 41 (44.1%)
Middle TB incidence 29 (14.2%) 20 (18%) 9 (9.7%)
Low TB incidence 121 (59.3%) 78 (70.3%) 43 (46.2%)
Demographics are described in Chapter 4 (Figure 4.3.2). 
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Table 6.3.3: Demographics and differences between groups by smoking 
status (continued)
≥1 Respiratory 
symptom 121 (59.3%) 73 (65.8%) 48 (51.6%) 0.046
Winter cough 80 (39.2%) 45 (40.5%) 35 (37.6%) 0.373
Wheeze 53 (26%) 35 (31.5%) 18 (19.4%) 0.121
Tight chest 63 (30.9%) 38 (34.2%) 25 (26.9%) 0.348
Breathlessness 61 (29.9%) 38 (34.2%) 23 (24.7%) 0.077
Cough past 4 weeks 73 (35.8%) 44 (39.6%) 29 (31.2%) 0.209
Sputum past 4 weeks 65 (32.2%) 40 (36.7%) 25 (26.9%) 0.137
Abnormal CXR 37 (18.1%) 16 (14.4%) 21 (22.6%) 0.167
History of asthma 22/192 (11.5%) 12/103 (11.7%) 10/89 (11.2%) 0.928
History of 
bronchiectasis 6/188 (3.2%) 4/101 (4%) 2/87 (2.3%) 0.688
Obstructive spirometry 16 (7.8%) 13 (11.7%) 3 (3.2%) 0.025
Previous TB 15/202 (7.4%) 6/110 (5.5%) 9/92 (9.8%) 0.243
Previous PCP 24/189 (12.7%) 16/105 (15.2%) 8/84 (9.5%) 0.277
Previous bacterial 
pneumonia 34/188 (18.1%) 22/107 (20.6%) 12/81 (14.8%) 0.311
Hepatitis B coinfection 59/194 (30.4%) 30/105 (28.6%) 29/89 (32.6%) 0.545







6.3.2 Uptake and symptoms
Both symptoms and spirometry were available for 204 subjects. Five (2.2%) 
participants did not fill in the questionnaire, and ten (4.5%) did not perform 
spirometry. 
Of the 204, 135 (63%) had a height available in order to calculate the predicted 
FEV1 %.
Of the questionnaire responses, 121 participants (59%) had at least one 
respiratory symptom, five (2.6%) had three and 20 (9.8%) had four symptoms. 
Eighty-three individuals (41%) denied having any symptoms at all.
6.3.3 Smoking status
Of 204 participants with questionnaire responses, 93 (46%) were never smokers 
and 47 (23%) current smokers and 64 (31%) ex-smokers. 
Symptom Percentage Number
Tight chest 31% 69/207
Wheeze 26% 60/209
Winter cough 39% 85/213
Breathlessness 30% 67/212
Tight chest and wheeze 20% 42/207
Wheeze and breathless 16% 34/207
Tight chest, wheeze and breathless 11% 23/207
Breathlessness alone 3% 6/212
Table 6.3.4a Respiratory symptoms
Table 6.3.4b Odds Ratios for respiratory symptoms








OR 95% CI p
Age
<40 26 (62%) 16 (38%) 1.20 0.55-2.61 0.90
40-50 53 (60%) 36 (40%) 1.09 0.58-2.04
50+ 42 (58%) 31 (42%) 1.00*
Ever smoker 73 (65.8%) 38 (34.2%) 1.80 1.02-3.17 0.046
Current smoker 39/47 (83%) 8/47 (17%) 4.42 1.78-11.0 0.001
Cannabis ever 
smoker
56 (67.5%) 27 (32.5%) 1.94 1.10-3.48 0.026
Biofuel exposure 31 (66%) 16 (34%) 1.51 0.76-2.99 0.235
Female 28 (54.9%) 23 (45.1%) 0.79 0.41-1.49 0.459
History of asthma 18 (81%) 4 (18.2%) 3.55 1.15-10.94 0.02
History of 
bronchiectasis
5 (83.3%) 1 (16.7%) 3.59 0.41-31.30 0.219
On ART 120 (59.7%) 81 (40.3%) 0.68 0.04-10.95 0.781
Undetectable VL 100 (57.8%) 73 (42.2%) 0.65 0.29-1.47 0.300
From low TB 
incidence country
76 (62.8%) 45 (37.2%) 1.16 0.60-2.24 0.209
Medium TB 
incidence country
13 (44.8%) 16 (55.2%) 0.56 0.23-1.39
High TB incidence 
country
32 (59.3%) 22 (40.7%) 1.00*
History IDU 15 (71.4%) 6 (28.6%) 1.85 0.69-4.99 0.218
Previous TB 9 (60%) 6 (40%) 1.02 0.35-3.00 0.961
Previous PCP 14 (58.3%) 10 (41.7%) 0.93 0.39-2.23 0.876
Previous bacterial 
pneumonia
24 (70.6%) 10 (29.4%) 1.75 0.78-3.92 0.168
Abnormal CXR 24 (64.9%) 13 (35.1%) 1.35 0.64-2.83 0.431
* - reference value. Confidence intervals and p values are calculated using the likelihood ratio 
Chi square test or Fishers exact test if n <5. 
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Smokers were more likely to be male (p<0.005) and to have a detectable plasma 
HIV viral load (>40 copies/ml) (p=0.016). Seventy-four percent of men who have 
sex with men (MSM) were smokers or ex-smokers, whereas only 24% of black 
Africans had ever smoked. Smokers were more likely to have more than one 
respiratory symptom (p=0.046) and have obstructive spirometry (p=0.025), but 
apart from these factors, the smokers and non-smokers had similar frequencies 
of symptoms, history of asthma, TB, PCP, pneumonia or bronchiectasis, and also 
to have an abnormal CXR. 
6.3.4 Respiratory symptoms
The frequency of respiratory symptoms was 59% (121/204) in all, 66% in 
smokers and 52% in non-smokers.
The frequency of symptoms are listed below.
The most common symptom was winter cough (39%), although 11% had three 
symptoms and 3% complained of breathlessness alone.
Of those with self-reported tight chest and breathlessness, only three had 
obstructive spirometry. 
Respiratory symptoms were more frequent in current rather than ex-smok-
ers (OR 4.3, CI 1.74-10.6, p=0.002), but ex-smokers were no more likely to have 
symptoms than never smokers (OR 1.06, CI 0.56-2.0, p=0.82). 
6.3.5 History of asthma
Twenty-three participants (11%) had a self-reported history of asthma. Four-
teen (61%) had been diagnosed before the age of 30 years and 15 (79% of those 
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Table 6.3.6.2: Table of odds ratios for those with and without obstructive 
spirometry
that answered) had inhalers. Three participants used inhaled corticosteroids 
and long acting beta agonist combined, one salbutamol alone, eleven did not 
specifically identify their inhaler. 
Nineteen of the self-reported asthmatics (83%) reported airways disease symp-
toms. Six (26%) were current smokers and seven (30%) were ex-smokers. Seven 
of 13 (54%) had a greater than 20 pack year smoking history. Three subjects had 
injected drugs. 








OR 95% CI p
Age
<40 2 (5%) 40 (95%) 1.00* - 0.02
40-50 6 (7%) 83 (93%) 1.45 0.28-7.48
50+ 8 (11%) 65 (89%) 2.46 0.50- 12.18
Ever smoker 13 (12%) 98 (88%) 3.98 1.10-14.42 0.03
Current smoker 5 (11%) 42 (89%) 0.79 0.24-2.59 0.70
Cannabis ever smoker 11 (13%) 72 (87%) 3.39 1.13-10.17 0.02
Biofuel exposure 6 (13%) 41 (87%) 2.65 0.87-8.08 0.10
Female 3 (6%) 48 (94%) 0.67 0.18-2.46 0.55
History of asthma 4 (18%) 18 (82%) 2.93 0.85-10.03 0.09
History of 
bronchiectasis
3 (50%) 3 (50%) 13.0 2.38-70.93 0.009
202
Table 6.3.6.2: Table of odds ratios for those with and without obstructive 
spirometry (continued)
* reference
Not on ART 1 (50%) 1 (50%) 12.4 0.74-208.3 0.15
Undetectable VL 11 (6%) 162 (94%) 0.35 0.11-1.10 0.07
From low TB incidence 
country
10 (8%) 111 (92%) 1.00* - 0.96
Medium TB incidence 
country
2 (7%) 27 (93%) 0.82 0.17-3.97
High TB incidence 
country
4 (7%) 50 (93%) 0.89 0.27-2.97
History IDU 2 (10%) 19 (90%) 1.26 0.27-5.95 0.68
Previous TB 3 (20%) 12 (80%) 3.35 0.84-13.37 0.10
Previous PCP 2 (8%) 22 (92%) 1.16 0.24-5.53 0.69
Previous bacterial 
pneumonia
5 (15%) 29 (85%) 2.48 0.79-7.8 0.15
Abnormal CXR 5 (13%) 32 (86%) 2.20 0.72-6.77 0.18
≥1 respiratory symptom 14 (12%) 107 (88%) 5.30 1.17-23.97 0.02
Cough in past 4 weeks 10 (14%) 63 (86%) 3.31 1.15-9.51 0.02
Sputum in past 4 
weeks
8 (12%) 57 (88%) 2.26 0.81-6.33 0.11
Tight chest 10 (16%) 53 (84%) 4.25 1.47-12.26 0.01
Wheeze 7 (13%) 46 (87%) 2.35 0.83-6.67 0.14
Breathlessness 6 (10%) 55 (90%) 1.59 0.54-4.68 0.39








OR 95% CI p
* - r ference value. Confidence intervals and p values are calculated using the likelihood 
ratio Chi square test or Fishers exact test if n <5. 
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obstructive lung function.  
Of the other respondents in the study, 181 did not report a previous diagnosis 
of asthma, but despite this, 62 (53%) had symptoms of airways disease, of whom 
10 (8.5%) also had obstructive spirometry.
6.3.6 Spirometry
Sixty five percent (142/219) of participants performed spirometry and had 
also recorded their height (to calculate FEV1 % predicted). Sixty-four (29%) had 
spirometric values but no height, and 13 (6%) did not attend for sputum induc-
tion nor performed spirometry.
Thirteen of 206 (6%) had obstructive spirometry initially and one (0.5%) devel-
oped obstructive spirometry after five minutes inhaling nebulised 3.5% hypertonic 
saline.
6.3.6.2 Risk factors for obstructive lung disease
Ex-smokers were more likely to have obstructive lung function than never 
smokers (OR 4.3, CI 1.1-16.8, p=0.04), but current smokers no more likely than 
ex-smokers (OR 1.2, CI 0.37-3.93, p=0.76). Ever use of cannabis had an OR of 3.4 
(p=0.022).  Self reported asthmatics, those with a tight chest and those with a 
cough over the past four weeks were also more likely to have obstructive lung 
function. Those with a self-reported history of bronchiectasis had an even higher 
risk (OR=13.0, p=0.009). 
The sensitivity of one respiratory symptom for obstructive spirometry was 
87.5%, specificity was 46%, positive predictive value was 11.6% and negative 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.6.3 Characteristics of participants with obstructive lung function
After excluding those with a history of asthma or bronchiectasis, 102/181 (56%) 
subjects had at least one symptom, and 10 (5.5%, CIs 2.2-8.9%) had obstructive 
spirometry. Of these, 10 (see Table 6.3.6.3), eight had documented heights avail-
able of which four had an FEV1 <80% predicted and four had an FEV1 of 50-80% 
predicted. All but one subject had at least one respiratory symptom, wheeze was 
reported in three, and winter cough in four. None had a history of injecting drug 
use, but 80% had smoked at some point. 
Four subjects had a history of smoking, wheeze and an FEV1 of 50-80% pre-
dicted. One had a 510ml drop in FEV1 after 3.5% saline. There were two African 
participants with obstructive lung function, both of whom were non-smokers 
(although one with biomass exposure, the other with previous TB) but they had 
not supplied their heights and so FEV1 predicted could not be calculated. 
The remaining four subjects had mild obstruction (FEV1 80-100% predicted), of 
which one was African with a very short smoking history, another an African with 
a heavy smoking history. Two were British with substantial smoking histories. 
6.3.7 Chest radiographs
Chest radiographs were available on 214 (98%). Five participants did not 
return for CXR. Normal and abnormal radiographs are discussed further in the 
Chapter on the prospective study results (Chapter 4, section 4.3.10). 
Six participants had radiographic features of airways disease. One had left 
lower lobe bronchiectasis, two had possible bronchial wall thickening (207,174), 
three had hyperinflated lungs. 
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The subject with bronchiectasis had cough, but no obstructive lung function.
A subject whose radiograph was reported as having bronchial wall thicken-
ing had a self-reported history of asthma using inhalers, was an ex-smoker and 
had normal spirometry. He reported no respiratory symptoms.  The second had 
radiological signs of previous TB infection (described further in Results Chapter 
4), but no airway symptoms and normal spirometry.
Of the three participants with hyperinflated lungs: one subject had obstructive 
spirometry; another had never smoked, had no respiratory symptoms, no his-
tory of asthma and had an FEV1 of 115% predicted; a third had never smoked, 
reported no airways symptoms but had noted a recent cough. He had an FEV1 
of 95% predicted. 
Of those participants with obstructive spirometry, one subject had left apical 
scarring and volume loss, another had left upper lobe fibrosis consistent with 
old TB and a third had hyperinflated lung fields.
Ever-smokers were no more likely to have an abnormal chest radiograph than 
never-smokers (OR 1.8, CI 0.86-3.6, p=0.13), and ex-smokers as likely as current 
smokers (OR 1.43, CI 0.5-4.2), p=0.50).
6.3.8 Old TB or PCP
Of the 15 participants with self-reported previous active TB disease, two had 
a self-reported history of asthma, five had abnormal CXR (one with bronchiec-
tasis), three had obstructive spirometry. Nine (60%) had one or more respiratory 
symptoms.  
Twenty-four patients reported previous PCP, of which four (17%) had asthma 
(three of whom diagnosed in childhood), 14 (58%) had respiratory symptoms 
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Female 11 (21%) 46 (27%) 0.14
Age years (median, IQR) 47 (40-52) 46 (41-53) 0.50
UK born 21 (40%) 69 (41%) 0.86
and two (8%) had obstructive spirometry.
6.3.9 Quality of life
Those patients with at least one airway symptom had a median quality of life 
score of 71/100, (IQR 60-80) and those without of 88/100 (IQR 75-95, p=0.00).
Those with obstructive spirometry had a median quality of life of score 80 
(IQR 66.5-90) and those without 80 also (IQR 60-90, p=0.943).
6.3.10 Sputum culture and qPCR
Fifty-three patients also provided sputum for research purposes. This group 
was demographically similar to the entire cohort (see Table 6.3.10). Median CD4 
cell count was 643 cells/µL and 84% had an undetectable blood HIV viral load. 
They were more likely to have reported a history of winter cough (p=0.01) or a 
cough in the previous week (p=0.04). 
The sputum had DNA extracted and multiplex quantitative PCR performed 







Black African 14 (27%) 47 (28%) 0.95
White British 31 (59%) 95 (57%)
Ever smoker 24 (46%) 89 (54%) 0.29
Current smoker 14/24 (58%) 34/89 (38%) 0.12
Smoking pack years (median, 
IQR)
15 (5-30) 10 (5-25) 0.62
Injecting drug use ever 3 (6%) 18 (11%) 0.45
Smoked cannabis ever 21 (40%) 64 (39%) 0.82
Any respiratory symptom 40 (77%) 92 (56%) 0.007
Recent cough 27 (52%) 51 (31%) 0.007
Recent sputum 24 (46%) 46 (29%) 0.02
Wheeze 21 (40%) 39 (24%) 0.03
Tight chest 23 (44%) 46 (29%) 0.10
Breathless 17 (33%) 50 (31%) 0.83
Winter cough 32 (62%) 53 (33%) 0.00
Asthma 7 (14%) 18 (12%) 0.71
Bronchiectasis 2 (3.8%) 4 (2.7%) 0.68
Obstructive lung function 6 (11.5%) 10 (6.6%) 0.25
FEV1 % predicted (median, 
IQR)
90% 98% 0.12
Previous TB 5 (9.6%) 12 (7.2%) 0.61
Prev PCP 8 (15%) 19 (13%) 0.90
Previous bacterial pneumonia 8 (15%) 26 (17%) 0.87
On ART 52 (100%) 161 (97%) 0.26
Recent CD4 (median, IQR) 709 (436-806) 606 (461-778) 0.777
On Septrin 1 (2%) 7 (4.3%) 0.32
Table 6.3.10b Demographics of those with or without sputum bacteria
No bacteria Bacteria p
n 29 23
Female 7 (24%) 4 (17%) 0.46
Age (median, IQR) 45 (39-50) 47 (43-53) 0.84
UK born 12 (41%) 9 (39%) 0.87
Black African 9 (31%) 5 (22%) 0.73
White British 16 (55%) 15 (65%)
Ever smoker 9 (31%) 15 (63%) 0.01
Current smoker 3 (33%) 11 (79%) 0.07
Smoking pack years (median, IQR) 5 (5-30) 15 (6-30) 0.85
Injecting drug use ever 0 (0%) 3 (14%) 0.04
Smoked cannabis ever 10 (36%) 11 (48%) 0.38
Any respiratory symptom 20 (69%) 20 (87%) 0.13
Recent cough 16 (55%) 11 (48%) 0.60
Recent sputum 11 (38%) 13 (57%) 0.18
Wheeze 10 (35%) 11 (48%) 0.33
Tight chest 11 (38%) 12 (52%) 0.30
Breathless 8 (28%) 9 (39%) 0.38
Winter cough 17 (59%) 15 (65%) 0.63
Asthma 5 (18%) 2 (9%) 0.34
Bronchiectasis 1 (3%) 1 (4%) 0.87
Obstructive lung function 3 (10%) 3 (13%) 0.76
FEV1 % predicted (median, IQR) 95 (81-104) 88 (82-104) 0.70
Previous TB 3 (10%) 2 (8.7%) 0.84
Previous PCP 2 (7%) 4 (17%) 0.28
Previous bacterial pneumonia 5 (19%) 3 (13%) 0.56
On ART 29 (100%) 23 (100%) NA
Recent CD4 (median, IQR) 712 (451-805) 707 (433-801) 0.92
On Septrin 1 (3%) 0 (0%) 0.37
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In 16/52 (31%) Streptococcus pneumoniae was isolated, Haemophilus influenza in 
10/53 (19%) and Moraxella catarrhalis in 1/53 (1.9%).
The participants with bacteria detectable in their sputum were more likely to 
be smokers, or to have injected drugs (Table 6.3.10b). Those with a winter cough 
were more likely to have a higher total bacterial load (p=0.04). In those with S. 
pneumoniae detected, those who were breathless had a higher S. pneumoniae load 
(p=0.01)
6.4 Discussion
The absence of respiratory symptoms was moderately useful in ruling out 
obstructive spirometry in this group. 
6.4.1 Summary of findings
There was a high prevalence of respiratory symptoms in this group (59.3% 
complained of one or more symptom), and this was even more frequent in 
smokers (65.8%). George et al. described symptoms in 31.5% of an HIV infected 
cohort in Southern California, whilst Diaz et al. found each symptom was pres-
ent in around 40% HIV infected participants compared to 7-20% HIV negative 
controls. [258,259] Our figure is similar to that seen in HIV-negative individuals 
with COPD, where macrophage dysfunction is thought to play a role in lower 
airway bacterial colonisation and lead to lung damage. [266,273]
Despite the high prevalence of symptoms, there was relatively little obstruc-
tive lung disease (7.8%), although significantly more in smokers (11.7%) than in 
non-smokers (3.2%), especially when participants with asthma were excluded. 
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There are few published studies of respiratory symptom prevalence and air-
ways diseases in cohorts of European HIV patients. Our cohort had a median age 
of 46 years, 24% were current smokers (similar to the prevalence in the general 
UK population) and 31% were ex-smokers.  [278]
6.4.2 Obstructive lung function
Ten participants had obstructive lung function (from those without a self-re-
ported history of asthma or bronchiectasis). Three of these were African and also 
never smokers/very light smokers. Participants with more than one respiratory 
symptom were more likely to have obstructive lung disease (OR 5.3), especially 
those who reported tight-chestedness. One participant had changes consistent 
with previous TB on chest radiograph and this may be consistent with residual 
bronchiectasis or small airways disease. Of the others, one subject had a signif-
icant drop in FEV1 after five minutes nebulised 3.5% saline which could be a 
feature of previously undiagnosed asthma. 
Twenty-seven percent of subjects in one published United States cohort had 
obstructive spirometry, although their median age was 50 years, 68% were current 
smokers, and 44% had a history of injecting drug use. [256] A number needed to 
test was 5 in this study to detect abnormal spirometry irrespective of respiratory 
symptoms. In our cohort, this would be 18.
6.4.3 Chest radiographs
There were few subjects with abnormalities on chest radiograph in this cohort, 




Despite seemingly good immune function in this cohort, respiratory symptoms 
are common and bacteria frequently detected in the samples. Nearly half had 
qPCR evidence of chronic bacterial colonisation (predominantly in smokers), a 
similar frequency to that seen in stable state COPD – although with lower bac-
terial loads than seen in the COPD cohort. [273] This HIV cohort also had high 
rates of Streptococcus pneumoniae (in contrast to patients with COPD who are 
more likely to have Haemophilus influenzae), but H. influenzae and M. catarrhalis 
were also found. [279]
It is difficult to ascertain if the increased frequency of bacterial isolation is a 
cause or consequence of symptoms, although total bacterial load was associated 
with winter cough and history of breathlessness. These 52 participants with 
sputum samples available for analysis were more likely to be smokers and have 
a cough, so there may be a selection bias to those that were more productive.
Despite there being a similar prevalence of airways disease in the bacteria and 
non-bacteria groups, could airway bacteria be a marker of smokers who may go 
on to develop COPD in this cohort? 
Unfortunately, there were no matched HIV negative controls to compare with 
this group, although one study has shown that the health HIV lung microbiome 
does not seem to differ to that in non-HIV controls. [280]
6.4.5 Limitations
This cohort, although recruited using stratified selection, may have been self-se-
lecting as part of a tuberculosis testing study. It is conceivable that they had a 
higher frequency of respiratory symptoms than an entire clinic cohort, as these 
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symptoms may have motivated them to take part in the study. Unfortunately, 
we could not record respiratory symptoms in those who had declined or not 
attended. In order to limit the time burden on participants less, a systematic 
respiratory questionnaire such as the St Georges Respiratory Questionnaire was 
not included. The EQ5D may be too insensitive to ascertain loss of quality of life 
due to respiratory disease alone.
A relatively large number of participants did not self-reported their height – we 
feel most overlooked this. Our spirometry data therefore was less complete and 
formal anthropomorphics would have been a valuable part of the study protocol. 
Many of our participants had not performed spirometry before and there was 
an appreciable learning effect, with some participants increasing their FEV1 by 
over 500mls over four attempts. Using a hand held spirometer, our results may 
not have been as reliable as those in a lung function laboratory. We also did not 
perform carbon monoxide transfer factor (due to logistics and resources involved 
with testing), which may have better characterised lung damage.
With respect to bacterial testing on sputum, only those who could produce a 
larger volume of sputum could have a qPCR assay performed. Although those 
producing sputum were no more likely to have symptoms or obstructive spi-
rometry, the high frequency of airway bacteria could be confounded by this. 
Finally, there was no HIV-negative control group in which to compare fre-
quency of symptoms, lung function or presence of sputum bacteria. Also, this 
was a single cross-sectional study – serial measurements may give more insight 
into FEV1 decline in HIV-infected symptomatic smokers. 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS
7.1 Summary
This is the first study of systematic, extensive testing of an HIV infected contem-
porary population for active, subclinical and latent TB with a cost-effectiveness 
analysis in a low TB incidence area. Retrospective modelling showed decreasing 
cost-effectiveness of testing for latent TB infection with time over the past 15 
years – testing in all with blood CD4 <500 cells/µL with an IGRA (NICE 2011 
guidance) was cost-effective up to 2005, then more targeted testing in those at 
the highest risk (BHIVA 2011) up to 2010. Modelling using prospective data 
shows that even the most targeted testing for LTBI in those at the highest risk 
of reactivation is only just cost-effective from an NHS perspective in a contem-
porary HIV infected population. It also shows that neither testing all attendees 
nor using more than one test was cost-effective, contradicting nearly all of the 
current national or regional LTBI testing guidance.
One participant in the study had a positive sputum culture for M. tuberculosis, 
but with no symptoms or radiological or immunological evidence of TB disease. 
Previous cases from other low TB settings have been presented in the literature 
but all have had positive immunological tests. 
 The prevalence of subclinical TB and LTBI in this study was very similar to 
other recent estimates in Western Europe as was the uptake of LTBI treatment – 
perhaps many clinic patients were not convinced that this was beneficial, which 
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also reflects the views of clinicians in many centres. [201] 
This study found a high number of adverse events with LTBI preventive 
treatment, although these were sought pro-actively, there are more than are 
usually described when estimating the quality of life utility for LTBI. This has 
implications for future cost-effectiveness models. 
There was a high frequency of respiratory symptoms amongst the whole cohort, 
even higher in smokers, although the prevalence of obstructive spirometry was 
much lower. In those who produced adequate sputum samples, nearly 50% 
had molecular evidence of bacterial colonisation. This was also more common 
in smokers. 
The participants in the study will continue to serve as part of a cohort to help 
calculate the predictive value of TST and IGRA over the next 15-20 years. 
7.2 Application of the work
Although two cases of subclinical tuberculosis were detected in this cohort, the 
low frequency of active disease implies that more comprehensive testing than just 
using immunological tests for latent TB infection in this context (asymptomatic 
patients in HIV clinics in low TB prevalence areas) is not economically viable.   
As the risk of reactivation is a reflection of TB prevalence, it could be suggested 
that guidelines should also test injecting drug users (who have a high incidence 
of active TB disease) as well as those from high TB incidence countries. [281] The 
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work from this study has already influenced the British HIV Association draft 
guidelines for testing people living with HIV for latent TB infection, who will 
suggest testing using a single immune-based test in only those from subSaharan 
Africa, TB contacts or in those that inject drugs. 
7.3 Future directions
Although modelling is cited as always wrong but sometimes useful, the analysis 
has highlighted certain areas with little data. There are very few studies into the 
quality of life of patients with both HIV (on ART) and LTBI or active TB disease. 
Even the suitability of the questionnaires used are controversial. [189,248] Nor 
are there up to date costs of treatment for these groups. There are also few data 
on the predictive value of TST or IGRA in HIV infected individuals who adhere 
to ART. The available information will improve as more studies report their long-
term outcomes, newer immunological or even RNA transcriptomic tests that 
identify those at highest risk of reactivation are developed, and better-tolerated, 
shorter LTBI treatments become available. [282] All of these interventions may 
make testing for TB in this group more cost-effective in the future. 
There still seems to be a need to convince both patients and clinicians that TB 
prevention is worth implementing. The number of patients in this study with 
new HIV diagnoses was too low to make a prediction of the effectiveness of 
LTBI testing in this group, but their risk of reactivation is higher. A larger study 
using just immunological tests, with more costing and quality of life data and 
higher recruitment amongst individuals with new HIV diagnoses, may resolve 
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this. In anticipation of that, some centres are only testing those with new HIV 
diagnoses and TB contacts, whilst some national guidelines already suggest only 
testing only those from the highest incidence countries and those with chaotic 
lifestyles (such as injecting drug users). [283] 
Up to now, the majority of diagnoses of active TB in people with HIV have been 
made before the HIV status of the patient is known. Perhaps HIV prevention, 
increasing HIV testing and prompt treatment with ART will have consequences 
to prevent active TB, and this, again, could be modelled to assess its impact.
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Background
Despite effective antituberculosis medication, the number of cases of (active) 
tuberculosis (TB) disease worldwide has continued to increase over time 
(1). The main driver of this is HIV infection. People living with HIV have a 
20-40 times higher risk of developing TB disease compared to individuals 
without HIV (2,3). This results from the immune dysregulation associated 
with HIV infection, and has a number of consequences: 1. An increased 
risk of developing active TB disease soon after exposure to Mycobacterium 
tuberculosis (Mtb), 2. An increased risk of progression of latent TB infection 
(LTBI) to TB disease, 3. A worse overall outcome (4). 
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The majority of cases of TB result from inhalation of Mtb, usually from contact 
with another person. It is thought that around seventy percent of those 
exposed clear the infection and have no evidence of ongoing infection. Up to 
five percent of those exposed develop active TB disease, often characterised 
by weight loss, fever, night sweats and other localising symptoms such as 
cough, within 2 years of exposure. The remainder, who may have a short, 
self-limiting illness, remain infected, and have latent infection. This can be 
defined as a clinical state, where an individual is well and their Mtb infection 
is controlled by their immune response. For often unknown reasons, in 
approximately 5-15% of those without HIV, LTBI can progress to active 
tuberculosis during the person’s lifetime (4-6). 
In the UK and other low TB incidence areas, reactivation of LTBI is thought to 
be the cause of the majority of active TB disease. In those with HIV infection, 
the risk of reactivation is estimated to be much higher at 5-14% per year (2,7). 
More recently, a state between active and latent TB, with detectable Mtb in 
sputum but no symptoms or chest radiographic (CXR) abnormalities, has 
been described in high TB prevalence countries. This is now referred to as 
subclinical disease (8-10). 
LTBI almost certainly encompasses a spectrum, from near sterilisation of 
the infecting microbe to low level/paucibacillary infection with replicating 
bacteria. This is usually diagnosed with positive markers of cellular immunity 
– classically the tuberculin skin test (TST) and more recently the Interferon 
Gamma Release Assay (IGRA) – e.g. the T-Spot.TB and QuantiFERON-
TB Gold tests. Inevitably, with such immune based tests, their accuracy 
is less certain in the context of HIV co-infection. As systemic immunity 
declines (reflected in falling blood CD4 count), skin tests are less reactive 
in people with Mtb infection, whilst IGRAs maybe indeterminate (defined 
as a QuantiFERON-TB Gold mitogen nil result of <0.5 IU/ml, a T-Spot.TB 
positive control of <20 spots in the context of a negative sample result or nil 
control >10 spots). Within the same subjects, there is up to 30% discordance 
between TST and either IGRA, and also discordance between the Quantiferon 
and TSpot.TB tests (11-13). 
Given the natural history of tuberculosis infection, much work has focused on 
treating asymptomatic LTBI to prevent active disease. This is important as 
globally, it is estimated that a third of the world’s population may have LTBI. 
The use of preventive therapy (with antituberculous agents, e.g. 6 months 
of isoniazid treatment) in high TB prevalence countries has been shown to 
result in reduced risk of reactivation by up to 60%, with an effect lasting up to 
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4 years (14,15). Antiretroviral therapy (ART) for HIV also decreases the risk of 
active TB disease (by up to as much as 80% in low and high TB prevalence 
areas) (16-18).  Hence, the use of combination of isoniazid preventative 
treatment (IPT) and ART is an attractive option, although the drugs can have 
significant interactions and lead to severe adverse events. However, in high 
TB prevalence areas (especially in countries also with high HIV prevalence, 
such as those in sub-Saharan Africa) the benefit to risk ratio is clearly in 
favour of treatment (19,20). In low TB prevalence areas, for example, the UK, 
this is less certain. There is a need for guidance. 
In England and Wales, NICE guidelines suggest using IGRA testing alone or 
TST and IGRA together in patients with a blood CD4 count of 200-500 cells/
µL and both IGRA and TST with blood CD4 <200 cells/µL (21). The British HIV 
Association (BHIVA) use data from a European cohort to calculate the risk of 
progression to active TB and test depending on country of origin, CD4 count 
and use of ART using IGRA alone (Table 1) (22). Testing is only performed 
in those where the risk of progression to active TB is higher than the risk of 
serious liver toxicity from preventive treatment. If the IGRA is positive, the 
individuals are recommended treatment (23,24). Both sets of guidance make 
an implicit assumption that the majority of cases of active TB are as a result of 
reactivation of latent disease. 







Blood CD4 count Any <500 cells/µl <500 cells/µl
Duration of ART use < 24 months < 24 months < 6 months
NICE guidance is often underpinned by economic evaluation, typically 
using cost-utility analyses expressed in terms of Quality Adjusted Life Years 
(QALYs). The EQ-5D is a standardised, generic quality of life questionnaire 
used to calculate loss of QALYs and has been a widely used instrument for 
NICE appraisals including the assessment of asthma interventions and drug 
treatments in rheumatoid arthritis. Previous estimations of QALY change in 
LTBI (on preventive treatment) and active TB disease vary considerably and 
there are no empirical data to support QALY differences in those with active or 
latent TB and HIV co-infection (25-27).
Exclusion of active TB is required before starting latent TB treatment. To do 
this, the World Health Organisation (WHO) and others advocate symptom 
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screening questionnaires (28,29). This is to prevent both inadequate 
treatment of active disease with the smaller number of drugs and shorter 
duration of treatment used to treat LTBI, and hence to avoid drug resistance. 
The questionnaires ask about cough, sweats, fever, fatigue and loss of 
appetite. In high TB prevalence areas, when used without CXR or sputum 
analysis, these still appear to miss 3-16% of cases with active or subclinical 
disease (29,30). In low prevalence areas, their utility has not been assessed. 
Diagnosis of active TB depends upon identification of the organism. 
Pulmonary tuberculosis occurs in at least 50% of individuals and therefore 
sputum analysis with microscopy (AFB smear) and culture has been used 
as the mainstay of TB diagnosis for over fifty years. However, microscopy 
has a low sensitivity (even lower in HIV infection) and culture results can 
take several weeks to become positive. There is an urgent need to develop 
new techniques that can improve detection compared to microscopy and 
decrease the time to diagnosis when compared to standard culture. These 
include nucleic acid amplification of specific gene regions in the mycobacterial 
genome e.g. polymerase chain reaction (PCR) and transcriptome, e.g. 
detection of 16S ribosomal RNA (16S rRNA). In a study from South Africa, 
Xpert.TB PCR testing detected up to 60% of culture-proven TB cases in 
HIV infected subjects, compared to 5% that were smear positive (30). 16S 
rRNA analysis has been used to identify Mtb and other non-tuberculous 
mycobacteria and, importantly, to quantify bacterial load (31,32).
ART improves life expectancy in those infected with HIV, and as these 
individuals age, pulmonary diseases that affect the general population 
become more prevalent. In particular, as rates of smoking are higher in people 
with HIV, the prevalence of non-infective respiratory conditions such COPD 
or lung cancer will increase (33,34). The synergistic impact of smoking (both 
cigarettes and other drugs), plus recurrent pulmonary infections, creates a 
milieu within the lung that predisposes the individual to significant long term 
risk of further pulmonary disease. This can include reactivation of pulmonary 
tuberculosis (35). 
Given the undoubted beneficial effect of ART in HIV, and the high levels of 
access to good quality care in the UK, plus lack of UK data, there is an urgent 
need to evaluate the role of assessments for tuberculosis (latent, subclinical 
and active) in UK HIV infected individuals at risk of TB who also are likely to 
receive sustained ART. 
Hypotheses
1. Systematic testing for Mtb infection (with IGRA) is feasible and cost-
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effective in a UK HIV population. 
2. Tuberculin skin testing provides no further information compared to single 
step blood Interferon Gamma Release Assay in the detection of Mtb 
infection in a UK HIV infected clinic population.
3. Within our clinic population, asymptomatic HIV infected individuals with 
normal chest radiographs have negative mycobacterial sputum microscopy 
and culture despite originating from high TB prevalence areas. 
Aim
We propose to investigate the frequency of TB sensitisation (by TST and 
IGRA), abnormal radiology (by chest radiograph) and mycobacterial smear/
culture positivity (by spontaneous and induced sputum) in a cohort of HIV 
infected individuals in a London centre with an incidence of TB of >40 per 
100 000. These data will allow us to understand the role of testing for TB 
using IGRA, TST, chest radiograph and sputum analysis in people in a low 
incidence setting. This population can then be followed to determine the short 
and longer term risks of reactivation with or without concomitant antiretroviral 
therapy.
Primary objectives
To determine the feasibility, yield and cost-effectiveness of systematic testing 
for M. tuberculosis infection in UK HIV infected individuals.
Secondary objectives
For all subjects:
1. To determine the prevalence of subclinical and active TB in a UK HIV 
infected clinic
2. To determine the sensitivity and specificity of systematic screening 
questionnaires for detecting cases of active TB outside of high TB 
prevalence settings
3. To determine concordance between TST and blood T-Spot.TB in latent TB 
infection
4. To identify risk factors for latent TB infection in the clinic population
5. To determine the underlying frequency of airways disease (using 
spirometry) and of respiratory symptoms
6. To determine the sensitivity and specificity of Xpert MTB/RIF PCR testing 
of sputum and induced sputum compared to mycobacterial microscopy and 
culture
7. To compare the Molecular Bacterial Load (MBL) assay, based on 16S 
rRNA, and other available molecular assays, with Xpert MTB/RIF for 
detection of Mtb
8. To determine quality of life scores (EQ-5D) for those with HIV infection, with 
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and without latent TB infection and/or undergoing treatment
On those with evidence of LTBI:
9. To determine uptake of latent TB therapy (6 months isoniazid treatment)
10. To determine cost of latent TB treatment (including screening costs, clinic 
time)
11. To determine quality of life and rate and severity of adverse events on 
latent TB treatment
12. To determine rate and time until active TB in those with LTBI on or off ART 
and/or isoniazid prophylaxis
In all patients (over 20 year follow up):
13. To determine the rate of incident active TB
14. To determine the time until progression to active TB with in patients with 




1. Cross sectional study of the prevalence of active, subclinical and latent 
tuberculosis in people living with HIV undergoing care at the Royal Free 
Hospital. 
2. Quality of life and economic analysis of systematic TB testing and latent 
tuberculosis treatment in this group 
3. Establishment of baseline measures for a cohort that can be followed over 
time whilst receiving long term HIV care.
Study numbers
300 HIV infected adults will be recruited from the Ian Charleson Centre, Royal 
Free Hospital, London. 
A control group will be formed from the other patients not approached for 
testing but that attend the Ian Charleson Centre, Royal Free Hospital, London 
during the period of recruitment. Retrospective diagnoses of tuberculosis can 
be identified using previously obtained ethical approval for the HIV cohort as a 
whole.
The study is powered to identify a difference between all TB (latent infection 
and active disease) between subjects from sub-Saharan Africa and low TB 
prevalence areas (such as the UK) with 80% power, allowing a 5% Type I 
error.
Selection criteria
All patients with a new diagnosis of HIV will be approached, plus stratified 
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sampling of existing patients undergoing care (by approaching 3 patients 
in each HIV clinic, 1st, 4th and 7th on each clinic list on Mondays, Tuesdays, 
Wednesdays and Fridays) in order to recruit 180 subjects originating 
from sub-Saharan Africa and 120 from lower TB prevalence areas. After 
recruitment of 100 subjects, certain clinics (for example, with a predominance 
of African patients) will be selected in order to enrich the cohort. Due to 
a delay of 48-72 hours being required between Mantoux skin testing and 
reading, we will not be able to recruit on a Thursday. 
Data will be collected on patients already known to the service and 
prospectively on those newly diagnosed with HIV infection and consist of:
• a record of baseline characteristics (including country of birth, time in UK, 
blood CD4 lymphocyte subset count at diagnosis),
• a symptom questionnaire (based on WHO and Cain questionnaires (29)),
• EQ-5D quality of life scores, respiratory symptoms,
• history of previous BCG,
• blood T-Spot.TB testing,
• PA chest radiograph, 
• tuberculin skin testing,
• spontaneous sputum analysis where possible,
• spirometry according to international guidelines,
• sputum induction for mycobacterial smear and culture, Xpert MTB/RIF and 
16S rRNA testing.
In subjects with evidence of LTBI:
• EQ-5D in all and adverse event questionnaires for subjects prescribed LTBI 
treatment,
• Comprehensive costings and resources used by subjects whilst receiving 
LTBI treatment. 
Recruitment and informed consent
Patients will be approached by their usual clinical care team during routine 
appointments. All patients with a new diagnosis of HIV will be approached 
by their nominated consultant. Those already undergoing care will be 
identified by the researchers or Ian Charleson Centre nurses as the 1st, 4th 
or 7th patient in a clinic from clinic lists only – without access to the medical 
history. The patient’s regular doctor will then approach the patient during 
routine consultation if he/she fits inclusion criteria. Patients will be given an 
information sheet and any questions can be answered by the researchers. 
Written informed consent will be obtained at this point. 
Participants can be reimbursed for reasonable transportation costs for visits 
that do not form part of their routine treatment/healthcare.
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Storage of sputum and blood samples
Sputum samples will be tested in the Department for Clinical Microbiology, 
Royal Free Hospital. Any leftover sputum sample will be stored in the 
Department for Clinical Microbiology and identifiable by study number only. 
Blood samples: Blood samples for T.Spot.TB tests will be sent by secure 
courier to Oxford Immunotec laboratories on the day of sampling. 3 further 
blood samples (2xEDTA, 1xLiHep) will be stored in the Department for Clinical 
Microbiology, Royal Free Hospital. Plasma or human cells from these may 
be sent to the University of Southampton and University College London for 
further analysis after recruitment finishes. They will be identifiable by study 
number only.   
Inclusion Criteria
Able to give informed consent
Over the age of 18
HIV infected, with confirmed positive HIV antibody status
Exclusion Criteria
Diagnosis of active TB or undergoing treatment for active or latent TB
Inability to produce sputum by coughing (e.g. recent rib fracture, chest pain, 
pneumothorax)
Pregnancy
Use of steroids (equivalent to 15mg prednisolone for ≥4 weeks) or any other 
immunosuppressive drugs (e.g. azathioprine)
Active solid organ or haematological malignancy (excluding Kaposi’s 
sarcoma)
Previous hypersensitivity to purified protein derivative (PPD) 
Extensive eczema
Study Procedures
Questionnaire (see Appendix B)
Subjects will be asked to complete a questionnaire including age, place of 
birth, previous time living abroad (if appreciable), symptoms (including cough, 
haemoptysis, fever, weight loss), smoking history, previous BCG vaccination 
for tuberculosis (with examination for BCG scar). Clinical and medication 
data will be added to this from subjects’ medical records (including suspected 
route of infection with HIV, time of diagnosis with HIV, previous antiretroviral 
treatments, blood CD4 counts and HIV viral load).
Chest radiograph
Subjects will be asked to have a departmental posterior-anterior radiograph 
268
(unless performed in last 4 weeks). If found to be abnormal (e.g. parenchymal 
lesion or pleural effusion), further testing may be necessary (see abnormal 
chest radiograph below) as part of routine care.
Women of childbearing age will have urine beta-hCG measured before 
undertaking this.
Sputum analysis
Any subjects with a productive cough will be asked to produce one sputum 
sample for mycobacterial microscopy and culture, Xpert MTB/RIF and MBL 
16S rRNA testing in a negative pressure area. 
Sputum induction
Sputum induction will be performed in a negative pressure closed unit within a 
side room. The procedure will be explained to the participants prior to sputum 
induction. Salbutamol 100 two puffs via metered dose inhaler and spacer will 
be given to prevent bronchospasm in those with underlying airways disease. 
Spirometric (FEV1, FVC) and peak flow measurements will be performed as a 
precaution in order to identify airways disease before starting the procedure 
using a hand held spirometer and again 5 minutes after commencing the 
salbutamol nebuliser. 40mls 4% hypertonic saline will be nebulised over 
20 minutes, re-measuring FEV1 after 5 minutes, followed by active cycle of 
breathing to augment airway clearance. The procedure will be terminated 
if the subject complains of chest tightness, breathlessness or intense 
cough. Oxygen and nebulised salbutamol will be available if necessary for 
treatment of bronchospasm. All sputum will be expectorated into one pot 
and analysed for mycobacterial microscopy and culture, Xpert MTB/RIF and 
16S rRNA testing. Sputum may be analysed for whole genome sequencing 
of the bacterial genome or sent to University College London and University 
of Southampton laboratories for further analysis of candidate biomarker 
molecules. 1 paired plasma (EDTA) samples will be taken (at the same time 
as T-Spot testing) for blood/sputum marker comparison.
If subjects have symptoms suggestive of active tuberculosis or a chest 
radiograph suggestive of active tuberculosis then tuberculin skin testing may 
be deferred. 
TST (Tuberculin skin testing)
Intradermal administration of 2 TU=0.1ml purified protein derivative (SSI) 
with a (28 gauge) insulin needle on the upper third of the forearm (palm up) 
to form a wheal 6-10mm in diameter. Time and date of injection, lot number 
of solution and location of injection site will be documented and the subject 
advised to avoid pressure or bandage at the injection site. The diameter of the 
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lesion will be measured at follow up 48-72 hours later by the investigators. A 
lesion measuring 5mm or above will be considered a positive result. 
T-Spot.TB testing
2 x 6ml lithium heparin tubes of whole blood, drawn simultaneously with 
routine clinic blood testing, will be sent to Oxford Diagnostic Laboratories 
using the DX same-day courier service in a robust, blood transport container 
for T-Spot.TB Testing. Samples will be identified by study number only. A 
difference of ≥6 spots between either CFP10 or ESAT6 antigen panels and 
the nil control panel will be considered a positive result, <6 spots a negative 
result. Where the difference between the higher of both panels and nil control 
is 5,6, or 7 spots, the result will be considered borderline. A positive control 
of <20 spots in the context of a negative sample or nil control >10 spots will 
be considered indeterminate. Borderline and indeterminate results will be 
recorded and a blood sample retested two weeks later.
Blood samples:
1 EDTA and 1 LiHep blood samples will be taken at the same time as T-Spot.
TB testing and will be stored for possible future tests of immune function 
(including for the detection of biomarkers, microRNA and cell phenotyping 
associated with active and latent TB). Written consent will be obtained for 
these blood samples and they will only be used in ethically approved future 
studies. 
Subjects with a positive result to tuberculin skin testing or T-Spot.TB testing 
will be referred to TB/HIV clinic for discussion of the results and consideration 
of LTBI treatment with 6 months of isoniazid. Costs and resources used during 
treatment will be calculated for each subject. Those undergoing treatment will 
have clinic follow up with assessment of adverse events using a standardised 
questionnaire and quality of life scores using EQ-5D. Those with LTBI and not 
undergoing treatment will also be asked to complete the EQ-5D questionnaire 
for comparison. (In this group, this can also be done by telephone).
Study measures
Questionnaire results:
Chest radiology – categorised as either:
(i) normal
(ii) abnormal suggestive of previous exposure but not active TB 
infection
(iii) abnormal suggestive of active TB infection
(iv)  abnormal not suggestive of active TB infection
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T-Spot.TB results (negative, equivocal, indeterminate, positive)
TST reaction size (defined as a reaction after 48-72 hours of intradermal 
injection of PPD of 0mm, 1-4mm, 5-10mm, 10-15mm, >15mm) 
Spirometry (FEV1, FVC and ratio) before and 5 minutes in to sputum 
induction.
Sputum quality and mycobacterial smear and culture status, and result of 
Xpert MTB/RIF and 16S rRNA testing for M. tuberculosis
Induced sputum quality and mycobacterial smear and culture status, and 
result of Xpert MTB/RIF and 16S rRNA testing for M. tuberculosis
Sputum stored for inflammatory and immunological markers
Follow up phase: 
Uptake of latent TB treatment in those offered it
Completion rate of latent TB treatment in those offered it
Time to (incident) active TB over following 20 years 
Quality of life: 
Cost of resources and clinic appointment time related to latent TB treatment 
(including with TB nurses and Ian Charleson staff)
Adverse event rate whilst on latent TB treatment (see Appendix F)
Quality of life scores on those with and without LTBI and those on treatment 
for LTBI (using Euro-QoL/EQ-5D)
Time to active TB in those with and without latent TB treatment
Ethics and R&D
This study will not be commenced until approval from the local Ethics 
Committee and Hospital R&D department. The Ethics Committee will be 
informed of all subsequent study protocol amendments.
Prior to participation in the study, informed consent will be obtained from each 
patient. This consent must be retained as part of the study records.
Collaboration with external sites
All recruitment will take place within University College London (Royal Free 
Hospital Campus).
Transfer of tissues: Sputum samples and EDTA blood samples will be sent to 
the University of Southampton. All tissues will be labelled with study number 
only (pseudoanonymised). 2xLiHep blood samples will be transferred to 
Oxford Immunotec diagnostic laboratory for central T.Spot.TB testing using 
the specialist DX courier service. These will be identified by study number 
only.
Transfer of funds: Oxford Immunotec will be funded for commercial T.Spot.TB 
testing. There will be no other transfer of funds to external sites.
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Transfer of data: Data on background risk of tuberculosis and immune status 
associated with blood and tissue samples will be transferred to the University 
of Southampton. All data will be pseudoanonymised.
Statistical analysis
Analysis will be performed using parametric and non-parametric measures in 
association with the Department of Infection and Population Studies, UCL.
Economic analysis
Economic Analysis will be performed with the UCL Department of Health 
Economics at the Centre for Applied Health Research. 
Data and Quality Management
Data will be stored on a secure database. Participants will be followed through 
their clinical care pathway for up to 20 years. This will have as an endpoint 
of follow up: development of active TB. If participants no longer attend the 
Royal Free Hospital, other sources such as the Health Protection Agency or 
London TB Register may be contacted to look for newly diagnosed cases of 
active tuberculosis disease. This will be performed with patient anonymity and 
confidentiality, and within data protection requirements.
Data will be pseudoanonymised at data entry and files kept in an encrypted 
form on computers at the Royal Free Hospital and University College London 
(Royal Free Campus).
Patient details will not be sent to outside centres apart from those performing 
diagnostic tests (i.e. T-Spot.TB testing, which is performed at an external 
laboratory), in which case only hospital number and date of birth will be sent.
Data management will be subject to regular 3 monthly review by one study 
investigator to ensure records are complete and storage secure.
Explicit consent will be taken before subject’s participation in the study is 
disclosed to their general practitioners. 
Appendix A
In the event of an abnormal chest radiograph:
A medical history and examination will be undertaken. If there are no 
concerning features, no further action will be taken. Subjects will undergo 
investigations as part of routine care, as if they would were they presenting to 
hospital via their General Practitioner.
If the chest radiograph is suggestive of active TB, subjects will remain in the 
study for quality of life evaluations whilst on treatment and would undergo 
mycobacterial sputum microscopy and culture. Treatment of active TB and 
subsequent further radiological investigations would occur as routine care.
If there are any other abnormalities found, a medical history and examination 
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will be performed, the subject’s General Practitioner will be notified (with 
patient consent) and the subject will have further investigations as part 
of routine care and not as part of this study. No data from subsequent 










Latent/active TB treatment adverse event symptom questionnaire and 
checklist
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Tel: 020 7794 0500
         
Date:
INFORMATION ABOUT THE RESEARCH
Testing for Tuberculosis in a UK HIV Infected Population
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish.
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.
Why have I been invited?
We have asked people living with HIV to take part in this study. It is to see if there are 
things about you (your gender, where you were born, a skin test result) that make you 
more likely to develop tuberculosis (TB) in the future. 
What is the purpose of the study?
Many people are exposed to the bacteria that causes TB without knowing it. Most of 
these people won’t get TB and the bacteria are completely removed from the body. 
In some people, a small amount of TB remains. Of these people who have a small 
amount of bacteria remaining, a few will go on to develop TB sometime in their life. 
The chance of this happening is higher in people with HIV, but lowered to a certain 
extent on effective HIV antiretroviral medication and also prevented by 6 months 
of an antibiotic called isoniazid (although we are not sure by how much in the UK). 
We don’t know who will develop TB later in life and who won’t, but there are some 
factors that increase the risk.  
In TB high prevalence areas, such as Southern Africa, up to a third of patients 
with HIV but who are well are found to have TB in their sputum when they start 
antiretrovirals, but no one has looked for this systematically in the UK. We would 
like to look for this in sputum, which is produced either by deep coughing, or helped 
by breathing in a sterile mist of salty water. This sputum will be sent for TB testing 
including microscopy (looking for the TB bacteria under a microscope) and with a 
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PCR test (looking for the TB bacteria’s DNA). 
Do I have to take part?
It is up to you whether or not to take part.  If you decide to do so, you will be given 
this information sheet to keep and be asked to sign a consent form.  If you decide to 
take part you are free to withdraw at any time, without giving a reason.  Whether you 
take part or not will not affect your healthcare or treatment in any way.
What will happen to me if I take part?
The study only involves 2 visits. The first can be today and will take at most a couple 
of hours. The second is 2-3 days later and will only take a few minutes. 
On the first visit, we will ask you to fill in a questionnaire. This covers things like 
your place of birth, time you’ve lived in areas that have a high TB rate and other 
questions that relate to your risk of exposure to TB. The risk of TB goes up in people 
who have been in prison or who have taken injectable drugs, so we’ve asked these 
questions in the questionnaire, although we appreciate they are sensitive. We would 
then like you to have a chest x-ray, some blood tests (including a T-Spot test) and 
a Mantoux test (which is a small injection on the forearm into the skin) to test for 
previous exposure to TB. We would also ask you to produce a sputum sample (using 
a water nebuliser) in which we will look for the TB bacteria. If positive, you will be 
told about the test results by us. If we find that you have been exposed to TB, you will 
see a doctor in clinic who will explain the advantages and disadvantages of having 
any treatment to stop TB causing you disease. All of your other treatments will remain 
the same during the study. It will be your decision as to whether or not you want to 
take the treatment. We will ask you some questions about how you feel each time you 
come to clinic, or if more convenient, over the telephone. If we find that your chest x 
ray is not completely normal, then you will be told this and we will explain what has 
caused the abnormality and do any necessary further tests. 
What are the possible benefits of taking part?
As an individual, you may not benefit directly from the research carried out. If we do 
detect tuberculosis in your sputum, then catching this early may mean that you do not 
become as unwell as you might, had it been left, and you will be offered treatment. If 
we detect latent TB (previous exposure but no symptoms) with the skin or blood test 
then you will be offered treatment to stop you developing symptoms. The risks and 
benefits of this will be explained to you when it is offered and it is completely your 
own choice. Research from these types of studies will help us improve diagnosis of 
tuberculosis in the future and increase our understanding of how tuberculosis infection 
causes disease. If you wish, you can be informed of the tests performed. You can 
be reimbursed for travel expenses to visits additional to routine care. Please submit 
a claim to the researchers (Dr Santino Capocci or Research Nurse Janey Sewell) 
enclosing receipts. 
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What are the possible disadvantages and risks of taking part?
We do not envisage any significant risk to you if you decide to participate in this 
study.  Sputum induction can make you cough but it is very unlikely to cause any 
harm.  Anyone with a history of asthma or obstructive airways disease will be given 
2 puffs of a salbutamol inhaler, which opens up the airways. This will prevent any 
wheeze when the salt water nebuliser is being breathed in. 
The skin test may cause some discomfort on your skin. A chest x ray is required 
as part of the study and has negligible radiation risk, equivalent to a few days 
background radiation. A new x ray is not necessary if you have had a chest x ray 
within the last 4 weeks. We will ask any women under the age of 50 taking part to 
have a pregnancy test before a chest x ray as a precaution.
What will happen to the results of the research study?
Results generated from your tests will form part of a larger data set including results 
from other participants.  The final results may be published in scientific journals or 
presented at conferences Please let us know if you would like to be informed of the 
outcome of this research. These results will be anonymous, so that people outside 
of the research group cannot identify you. If you wish, you will be informed of the 
results of your skin test, blood tests, x ray and sputum tests. 
Will any additional information be collected?
To enable us to accurately interpret the results, we would like to collect information 
about your treatment details and progress including the results from your blood tests.
One of the aims of the study is to find out who gets tuberculosis in the future. Over 
the next 5-20 years we would like to check if you have been diagnosed with TB. If 
you are still treated at the Royal Free Hospital, we would like to recheck your records 
here; if not, then we may need to check via the TB database at the Health Protection 
Agency, which records this data. Just as now, all information gathered then will be 
kept securely at the Royal Free Hospital and be kept strictly confidential.
What will happen to my samples?
As part of the study, one blood test will be sent to a central laboratory in Oxford for a 
T.Spot.TB test, looking for previous exposure to tuberculosis. This will be transported 
by secure courier and no identifiable data will be used on the sample bottle or form.  
This and most of the other samples will be destroyed after analysis. However a 
small amount of the sample will have a chemical added that preserves any bacterial 
genetic information present. This will be stored in a freezer in a secure site at the 
Department of Microbiology at the Royal Free Hospital. This will be identified by a 
sample number only. This may be stored indefinitely. A very small amount of sputum 
and blood may be sent to the University of Southampton and to University College 
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London, where there are researchers that have a special interest in TB and HIV. These 
samples may be tested for biomarkers (chemicals secreted by human cells) that are 
associated with tuberculosis, or human cells may be extracted and tested to see why 
and how TB affects the cells in the lungs. All the research using these samples will 
be approved by an ethics committee and samples will not be identifiable. The data 
associated with the samples will also not contain any identifiable information. This 
extra analysis is very helpful for us, but is optional and you can still take part in the 
study without these samples being used in future research.
Who will have access to information about me?
All data collected will be held on a database at the Royal Free Hospital.  Only the 
doctors, nurses and research personnel involved in running this study will have access 
to it. All information collected about you during the course of the research will be 
kept strictly confidential, and any information about you that leaves the hospital 
will have your name and address removed so that you cannot be recognised. Any 
samples sent to University College London, the University of Southampton or Oxford 
Immunotec (for the IGRA blood test) will be identified only by a sample number 
(referred to as pseudoanonymised). Staff outside of the Ian Charleson Centre and the 
research group will not be able to access any personal information about you.
We will ask you if you would like the results of the TB tests we perform. We will 
specifically ask you if you would like your GP to be informed about your participation 
in the study. You will be able to see the GP letter before agreeing to this. You can still 
take part in the study without your GP being aware. We will also ask if you are happy 
for your GP to see the results of your TB tests.
Who is organising and funding the research?
The study is being organised by medical doctors from University College London 
who also work at the Ian Charleson Centre. It is funded by the HIV Department at the 
Royal Free Hospital.
Who has reviewed the study?
All research in the NHS is looked at by the independent group of people, called an 
Ethics Committee, to protect your safety, rights, wellbeing and dignity. The London 
City and East Research Ethics Committee, the Research and Development Office and 
a Senior Respiratory Consultant, Dr John Hurst, from University College London, 
have reviewed the study.
What if I have any other concerns or wish to seek independent advice about the 
study?
If you have any complaints about the way the investigator has carried out the study 
please contact the Patient Advocacy Liaison Service at the Royal Free Hospital; 
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telephone number 0207 472 6447.
What if there is a problem?
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (0207 794 0500 extension 
31148).
If you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated by members of staff you may have experienced due 
to your participation in the research, National Health Service or UCL complaints 
mechanisms are available to you. Please ask your research doctor if you would like 
more information on this. 
In the unlikely event that you are harmed by taking part in this study, compensation 
may be available. 
If you suspect that the harm is the result of the Sponsor’s (University College London) 
or the hospital’s negligence then you may be able to claim compensation.  After 
discussing with your research doctor, please make the claim in writing to Dr Marc 
Lipman who is the Chief Investigator for the research and is based at the Royal Free 
Hospital. The Chief Investigator will then pass the claim to the Sponsor’s Insurers, via 
the Sponsor’s office. You may have to bear the costs of the legal action initially, and 
you should consult a lawyer about this.
Contacts for further information:
If you require any further information regarding the study at any stage, or in the event 
of an emergency please contact the following doctor or nurse:
Dr Santino Capocci    0207 794 0500 extension 31148 or 35151  Royal Free 
Hospital site
Research Nurse Janey Sewell    0207 794 0500 extension 34673 Royal Free 
Hospital site
Dr Marc Lipman      0207 317 7560      Royal Free 
Hospital site
Thank you for taking the time to read this information sheet.






Tel: 020 7794 0500
Date:                                               
Consent Form





The participant should complete this sheet him/herself.              
Please initial box.
1. I confirm that I have read and understood all the information 
contained in the information sheet above (Version 2, dated 26th 
October 2012). I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. By completing and returning this form, I consent that the personal 
information I provide will only be used for the purposes of this project 
and not transferred to an organisation outside of the Royal Free 
Hospital/UCL. The information will be treated as strictly confidential 
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and handled in accordance with the provisions of the Data Protection 
Act 1998.         
 
4. I give permission for blood results and certain data from my medical 
records to be used in the study and stored in a database kept at the Ian 
Charleson Centre at the Royal Free Hospital. I give permission for 
my Royal Free Medical records to be consulted again in the future to 
look for any diagnoses of tuberculosis.      
        
5. I give permission for my blood and sputum samples to be stored 
in the Centre for Clinical Microbiology at the Royal Free Hospital 
and my blood sample to be sent to Oxford Immunotec (for latent TB 
blood testing).         
          
6. I agree to take part in the Testing for tuberculosis in a UK HIV 
Infected Population study.   
Optional: These parts are voluntary and you can still take part in 
the study without them:
7. I give permission for data about me and any leftover sample to be 
stored and used for future ethically approved studies. You will not be 
identifiable from this data or stored sample.      
       
8. I agree to pseudo-anonymised samples of my sputum and blood 
to be sent for analysis within other departments in UCL and to the 
University of Southampton.      
9. I agree to being informed of the results of my TB tests (blood IGRA 
test, tuberculin skin test, x ray result and induced sputum results) as 
clinically needed.
10. I agree to my GP being informed of my participation in the study 
(This is voluntary and you can still take part in the study without 
your GP being informed).     
11. I agree to my GP being informed of the results of my TB tests 
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